



- 1. Patentcopy
- 2. Brief Write Up
- 3. Test Reports For Patient Suffering From Leukemia
- 4. Test Reports (HBA1C Before & After Use Of The Device)
- 5. Test Reports For Patient Suffering From High Cholesterol (Lipid)
- 6. Test Reports For Patient Suffering From Diabetes (Type 2)
- 7. Communications with Test labs and Patients





The Hypothesis:

The universe is all about energy. No matter whether you call the energy chi, prana, electrons, or some other name. the universe is about the interactions of energy.

In general it is observed that frequencies can repair damaged tissues and cells within body. This is the primary basis for the therapeutic use of this technology, stimulating tissues at a cellular level. Electrical pulse and frequencies passing through our whole body will have a positive charge to our trillions of cells.

Basic cell functions and the effect of Electromagnetic frequencies:

Our skins, bones, and organs are composed of tiny cells. The membrane of a healthy cell has both positive and negative charges that are required for the exchange of potassium, sodium, and calcium ions. When cells become distressed from disease. trauma or toxins, they lose their ability to function efficiently. Medi Magic restores the positive and negative charges in the cell, enabling it to perform its natural function while speeding tissue recovery.

Everyone's body responds differently to electro pulse waves and different frequencies target specific tissue types. Medi Magic emits a unique series of Pulsed Electro Fields at precise frequencies targeted on four key tissue types resulting in increased circulation. reduced inflammation, improved mobility, and relieved pain.

All cells need energy to function through the increased motion of ions and electrolytes magnetic cells help cells increase their energy or "charge".

Electro field also affects the charge of the cell membrane, which allows membrane channels to open up.

Resting cells are negatively charged on the inside, while the outside of the cell is more positively charged. The flow of charges across the cell membrane is what generates electrical currents.

When a cell is stimulated, it allows positive charges to enter the cell through open ion channels. The inside of the cell then becomes more positively charged, which triggers further electrical currents that can turn into electrical pulses, called action potentials. Our bodies use certain patterns of action potentials to initiate the correct movements, thoughts and behaviours.

A disruption in electrical currents can lead to illness. e Medica Electro Field therapy can restore the disruption of the electrical current to its normal state, therefore. helping restore the cell. (Source)

Electric and magnetic fields (EMFs) are invisible areas of energy, often referred to as radiation, that are associated with the use of electrical power and various forms of natural



and man-made lighting. EMFs are typically characterized by wavelength or frequency into one of two radioactive categories:

- Non-ionizing: low-level radiation which is generally perceived as harmless to humans
- Ionizing: high-level radiation which has the potential for cellular and DNA damage

Along with the increased **voltage**, the **body** also needs the raw materials (proper nutrition) to **heal**. If your **body** does not have the energy storehouse necessary to produce **healing**, the **voltage in the** cells lessens, and when that happens, the **body** will become diseased

These channels are like doors and windows of a house. By opening cell channels, nutrients are better able to enter the cell and waste is more easily eliminated from the cell. This helps to rebalance and restore optimum cell function. If you restore enough cells, they will all work efficiently. Cells of the same type come together to make tissues and those tissues come together to make organs. So, by restoring or maintaining cellular function, allowing the entire body to function better. We all know that body ages over time. Maintaining the function of every individual cell at an optimal level every day is an important part of slowing aging.

Can e Medica therapy protect me from future illnesses?

Magnetic fields protect against cell injury by improving circulation, energy and repair process. Magnetic fields balance cells, tissues and bodily functions at very fundamental levels. A key to understanding Energetic Medicine is to understand that each cell is designed to run at a specific voltage and a specific frequency. Generally speaking, disease is caused when cells have too little voltage and are running at too low a frequency.

To operate correctly, cells must have both the proper voltage and the proper frequency. Chronic illness is almost always characterized by low voltage and a decrease in the frequency of the affected organ. Restoration of health must involve correcting both the voltage and the frequency of each cell and providing the nutrition necessary to make good new cells.





संचालनालय, वैद्यकीय शिक्षण आणि संशोधन, मुंबई



शासकीय दंत महाविद्यालय व रु^{रणा}लय इमारत चौथा मजला, सेंट जॉर्जेस् रुग्णालय आवार, पी. डीमेलो रोड, फोर्ट, मुंबई - ४०००० दुरध्वनी:+९१-२२-२२६२०३६१-६५/२२६५२२५१/५७/५९. संकेतस्थळ: http://www.med-edu.in & http://www.dmer.org

क्र.संवैशिवसं/संकीर्ण/eMedica/इलेक्टॉनिक मेडिकल गॅजेट/ /४-अ/२०२१, दिनांक १५ /१९/२०२१ कार्यालयीन आदेश

विषय : The innovative Wellness product_eMedica.

संदर्भ : सीईओ, रोहेरा हेल्थकेअर ॲन्ड टेक्नॉलॉजी प्रा.लि, पुणे यांचे पत्र दिनांक १२/१०/२०२१

प्रस्तुत विषयी संदर्भीय पत्रान्वये सीईओ, रोहेरा हेल्थकेअर ॲन्ड टेक्नॉलॉजी प्रा.लि., पुणे यांनी "eMedica" या उत्पादनाचे शासकीय रुग्णालयामध्ये ट्रायल करण्यास परवानगी मिळणेबाबत विनंती केली आहे.

उक्त प्रस्तावामध्ये पुढील बाबी नमुद करण्यात आल्या आहेत.

9. "eMedica" या उपकरणाची उपयुक्तता

Improves Immunity, Support to reduce Heart blockages, Support to control Diabetes, Support to fight different viral infection, Support to control Hypothyroidism, Improves Blood Circulation, Increase Oxygen saturation, Balance the pH level, Control Cholesterol levels, Control Blood Pressure, Support to control Parkinson°s & Paralysis, Prevent Cancer & Metastasis, Support to detox liver and kidney, Support to control Uric acid levels (Gout), Support to reduce lung diseases and Fibrosis of lungs. No side effects, Non invasive, Family device.

- २. उक्त उपकरणास अन्न व औषध प्रशासनाची मान्यता मिळण्याकरीता संबंधित कंपनीमार्फत प्रस्ताव सादर करण्यात आलेला आहे.
- 3. eMedica या उपकरणास NABL Approved, CE, ROSH, ISO Certified असे विविध नामांकीत प्रमाणपत्रे प्राप्त झाली असल्याचे प्रस्तावात नमुद केले आहे.

रोहेरा हेल्थकेअर ॲन्ड टेक्नॉलॉजी प्रा.लि., पुणे यांनी eMedica या इलेक्टॉनिक मेडिकल गॅजेट उपकरणाच्या उपयोगासंदर्भात अधोरेखित केलेल्या उक्त बाबींच्या पडताळणीसह पुढील नमुद मुद्यांबाबत देखिल स्पष्टता होणे आवश्यक आहे.

- सदरचे उपकरण रुग्णोपचाराच्या दृष्टिने उपयुक्त आहे का ? असल्यास प्रचलित उपचार पध्दतीच्या तुलनेत किती प्रमाणात फायदेशिर आहे ?
- शासकीय रुग्णालयात सदर उपकरणाचा वापर करणे शक्य आहे किंवा कसे ?

(कृ.मा.प.)

यासर्व बाबींचा उहापोह करुन सदर उपकरणाचे आयुर्मान, उपयोग सुलभता इत्यादींच्या परिक्षणात्मक अभ्यासांती अहवाल प्राप्त होणे आवश्यक आहे.

यास्तव eMedica या उत्पादनाचे सर्वांगीन चाचणीअंती अहवाल सादर करण्याकरीता पुढील प्रमाणे तज्ञ समिती गठित करण्यात येत आहे.

- १) डॉ. विद्या नगार, प्राध्यापक (तदर्थ), औषधवैद्यकशास्त्र, ग्रॅं.शा.वै.म., मुंबई
- २) डॉ. गिता शेठ, सहयोगी प्राध्यापक, नेफ्रोलॉजी, ग्रॅ.शा.वै.म., मुंबई
- ३) डॉ. तेजल वधान (सुरळकर), सहयोगी प्राध्यापक, कामा व अल्ब्लेस रुग्णालय, मुंबई

उपरोक्त समितीने eMedica या **इलेक्टॉनिक मेडिकल गॅजेट** उपकरणाचे परिक्षण करुन स्वयंस्पष्ट अहवाल १० दिवसांत संचालनालयास सादर करावा.

संचालक,

वैद्यकीय शिक्षण व संशोधन, मुंबई

प्रति,

9) डॉ. विद्या नगार, प्राध्यापक (तदर्थ), औषधवैद्यकशास्त्र, ग्रॅ.शा.वै.म., मुंबई

२) डॉ. गिता शेठ, सहयोगी प्राध्यापक, नेफ्रोलॉजी, ग्रॅ.शा.वै.म., मुंबई

३) डॉ. तेजल वधान (सुरळकर), सहयोगी प्राध्यापक, कामा व अल्ब्लेस रुग्णालय, मुंबई

प्रत : सीईओ, रोहेरा हेल्थकेअर ॲन्ड टेक्नॉलॉजी प्रा.लि, पुणे यांना कळविण्यात येते की, eMedica या उपकरणाचे उक्त समितीसमोर सादरीकरण करावे. तसेच तपासणी/प्रात्यक्षिकाकरीता उपकरणी उपलब्ध करुन द्यावे

प्रत: माहितीस्तव.

- १) अधिष्ठाता, ग्रॅन्ट शासकीय वैद्यकीय महाविद्यालय, मुंबई
- २) अधिक्षक, कामा व अल्ब्लेस रुग्णालय, मुंबई



@ www.emedica.in

शासकीय होम्योपैथिक चिकित्सा महाविद्यालय एवं चिकित्सालय आयुष परिसर कलियासोत डेम के किनारे एम.ए.सी.टी हिल्स, भोपाल क0/चिकि /21/648-49 भोपाल, दिनांकः 16/11/2021

प्रति

जी.वी हेल्थकेयर वेलिंगटन बिजनेस पार्क-01 अंधेरी ईस्ट मरोल मुबंई महाराष्ट्रा-400059

विषय: - इ-मेडिका उपकरण के डेमोसट्रेशन के संबंध मे। संदर्भ:- आपके ईमेल दिनांक 16/11/2021 के संदर्भ मे।

-00-

उपरोक्त संदर्भित ईमेल के अनुकम मे लेख है, शासकीय होम्योपैथिक चिकित्सा महाविद्यालय से सम्बद्ध चिकित्सालय आयुष परिसर, भोपाल में इ-मेडिका डेमोसट्रेशन 1 माह के लिए रोगियो हेतु कराये जाके देखना उचित होगा ।

Syamos

डॉ०सुनीता तोमर अधीक्षक शासकीय होम्यापैथिक चिकित्सा महाविद्यालय एवं चिक्तिसालय,भोपाल

पु०क0/चिकि /21/

भोपाल, दिनाकः

C33

1. प्रधानाचार्य एवं सीईओ महोदय० शासकीय होम्योपैथिक चिकित्सा महाविद्यलाय एवं चिकित्सालय,भोपाल ।

> अधीक्षक शासकीय होम्यापैथिक चिकित्सा महाविद्यालय एवं चिक्तिसालय,भोपाल















Maharashtra Government Health Department

Medical Superintendent, Regional Referral Services Hospital, (Daffrin Hospital Campus), Shrikrushana Peth, Amravati-444601

Ph.No. 0721-2970161, 0721-2970167. Outward no./RRSH,Amt./MOU /

3844 /2022

Date. $99/\frac{2022}{}$

Email: msrrshamt@gmail.com

To,
Rohera Healthcare & Technologies Pvt Ltd
E-Medica
Pune.

In Regional Referral Services Hospital, Amravati the installation & inauguration of E-Medica device was done in the month of February 2022, since that time patients were enrolled of different diseases as per instructions given by experts of E-Medica.

Total of 132 Covid confirmed cases were enrolled & studied for their improvement in health during this study period. About 60 minutes sessions were given on respective described mode of E-Medica device & parameters like SPO2, Pulse, Temperature, Blood pressure were noted for three different settings.

A total 110 already diagnosed hypertensive patients & 153 diagnosed type II Diabetes mellitus patients were enrolled in study to see the effect of device to minimize blood pressure & blood sugar respectively.

Individual values of baseline (i.e. before use of device) & also values after the use of device on day one, day two & day three were noted in Microsoft excel. Mean and standard deviation were calculated & 't' test were applied using open epi software. After applying 't' test of significance, 'p' value less than 0.05 at 95% confidence interval was considered statistically significant.

From the study conducted in this hospital it was concluded that, use of E-Medica device in covid-19 positive patients is a potent adjuvant to reduce the body temperature, pulse rate & improve the oxygen saturation levels in very short continuance of its utility. Also E-Medica device can be adjuvant to decrease the blood pressure & Blood sugar level in diagnosed hypertensive & diabetic patients.

Above results are due to following reasons as stated in Information Brochure given by the manufacturer of E-Medica-

"After applying eMedica device on the specific program (as pre-programmed & fed in the device), with specified frequency, voltage & current, it will Enhance the Cell charge of the organ. This process Improves the function of the Organ, Reduces Blood-Fat, Reduces the chances of Cardiac Arrest, Improves the Blood Circulation. When a mild current is exposed to virus or bacteria it would destroy the Virus & Bacteria in the body. In diabetic patients eMedica device transmits specific Voltages and Frequency with the specific electric charge into the human body. As this 3-dimensional technology passed through the blood stream, it enhances the charge of the β-cell in the pancreas, which in-turn improves the function of the organ helping it to produce more insulin. As a specific combination of Voltages-Frequency-Current is passed through the blood stream, it burns the fat/deposit/plaque from the blood vessel. This allows the

insulin generated from the $(\beta$ -cell) pancreas to penetrate into the blood cells. As the natural insulin (produced by β -cell) reached the blood stream it immediately balances the Blood Sugar Level. Hence controlling Diabetes." (Reference- www.emedica.in, Rohera Healthcare & Technology Private Limited ROHERA INC.)

This present pilot study was conducted on a limited sample size, which proved the efficacy on covid positive & hypertensive patients. Currently the study is being in process in large number of groups to see its results on Diabetic & hypertensive Patients. The long term effect of e- medica is conducted on Diabetic patients to understand better blood sugar control over a long term use. As soon we achieve our desired sample size, we will publish its results.

Detailed results of this study with mean with standard deviation & P value are enclosed with this.

1. Dr. M. R. Mendhe - OSD, RRSH, Amravati.

2. Dr. G. Khobragade - MO, RRSH, Amravati.

3. Dr. Ravi Bushan - Nodal Officer RRSH-Covid, Amravati

4. Dr. V. S. Pawar – MO, RRSH, Amravati.

5. Dr. V. S. Dhande- MO, TBH, Amravati.

6. Dr. Shyam Gawande- MO, RRSH, Amravati

Medical Superintendent RRSH, Amravati

Medical Superintendent
Regional Referral Services Hospital
AMRAVAT1.

COVID-19

Table No.1: Effect of Emedica device on temperature in covid 19 positive patients (n=132)

DAY	TEMPARATURE (P Value	
	BEFORE	AFTER	(t test)
DAY 1	99.99 <u>+</u> 0.98	97.20 ± 0.88	<0.0000001
DAY 2	99.56 <u>+</u> 0.64	97.25 <u>+</u> 0.94	<0.0000001
DAY 3	99.56 <u>+</u> 0.51	97.61 <u>+</u> 0.76	<0.0000001

Table No.2: Effect of Emedica device on oxygen saturation in covid 19 positive patients

DAY	SPO2 (Mean	P Value	
	BEFORE	AFTER	(t test)
DAY 1	93.12 ± 1.52	96.15 <u>+</u> 1.19	<0.0000001
DAY 2	94.94 <u>+</u> 2.68	97.06 <u>+</u> 1.64	<0.0000001
DAY 3	94.78 ± 2.24	97.48 <u>+</u> 1.30	<0.0000001

Table No.3: Effect of Emedica device on pulse rate in covid 19 positive patients

DAY	PULSE (Mean	P Value	
	BEFORE	AFTER	(t test)
DAY 1	92.09 <u>+</u> 5.76	84.28 <u>+</u> 12.51	<0.000001
DAY 2	94.68 <u>+</u> 4.91	89.27 <u>+</u> 7.42	<0.000001
DAY 3	96.12 <u>+</u> 4.48	90.53 ± 5.73	<0.000001

Total 132 covid positive patients were enrolled in research to study the effect of Emedica device on improvement in health status of patients. It was found that mean temperature of covid positive patients get decreases, after a session of 60 minutes duration in a day, also it was found that mean temperature of patients were decreases subsequently on day 2 & 3 after its use and the difference was statistically significant. (P < 0.05).

Similarly, one of the crucial parameter in covid patients i.e. oxygen saturation shows drastic increase in SPO2 & the difference was statistically significant. (P<0.05)

Mean pulse was also reduced subsequently after the use of Emedica device, & difference was also statistically significant.

Thus, it can be concluded that, use of Emedica devise in covid 19 positive patients can be a potent adjuvant to reduce the body temperature, pulse rate & improve the oxygen saturation in very short continuance of its utility.

BLOOD PRESSURE

Table No.4: Effect of Emedica device on systolic blood pressure in diagnosed case of hypertension (n=110)

DAY	SYSTOLIC BI	P Value	
	(Mear	(t test)	
	BEFORE		
DAY 1	147.73 <u>+</u> 15.63	125.93 <u>+</u> 16.45	<0.0000001
DAY 2	139.70 ± 11.55	131.5 ± 13.52	0.000002496
DAY 3	143.30 ± 9.12	133.94 <u>+</u> 9.73	<0.0000001

Table No.5: Effect of Emedica device on diastolic blood pressure in diagnosed case of hypertension

DAY	DIASTOLIC B	P Value	
	(Mear	(t test)	
	BEFORE	AFTER	
DAY 1	90.21 ± 9.87	88.85 ± 13.70	0.3992
DAY 2	84.71 <u>+</u> 8.00	74.77 <u>+</u> 6.89	<0.0000001
DAY 3	86.72 <u>+</u> 7.86	82.68 ± 7.70	0.0001547

Total 110 diagnosed cases of Hypertension were studied to see the effect of Emedica device on its effect on lowering blood pressure. It was found that both systolic and diastolic blood pressure get decreases after the use of Emedica device. Also the difference was statistically significant. (P < 0.05)

RANDOM BLOOD SUGAR

Table No.6: Effect of Emedica device on random blood sugar in diagnosed case of diabetes mellitus. (n=153)

DAY	RANDOM BLOOD SUC	P Value	
	BEFORE	AFTER	(t test)
DAY 1	197.16 <u>+</u> 20.00	136.84 <u>+</u> 16.92	<0.0000001
DAY 2	185.19 ± 19.75	135.17 ± 16.23	<0.0000001
DAY 3	172.90 <u>+</u> 21.55	126.56 ± 15.58	<0.0000001

Total 153 diagnosed cases of Diabetes mellitus type 2 were studied for the effect of Emedica device on blood sugar level & it was found that after a session of Emedica device random blood glucose level get decreases and the difference was statistically significant. (P < 0.05)





B-32/1/2, MIDC, Ranjanggon, Pune, Maharashtra info@hiphysix.com, infohplindia@gmail.com Phone: 02138 - 232901, 232902, 232903

> CIN: U74120DL2009PTC194754 Mobile 1: +91 7768005400 Mobile 2: +91 7768005411

Mobile 3: +91 7768005422

Page No. 1 of 10

SRF No.: 21040014

TEST REPORT

TEST REPORT AS PER :- IS 13450 (Part 1)/ IEC 60601-1

Name & Address of Customer:

Office No A3/A4/A5 Royal Arcade,

Pune Satara Road, Near Shankar Maharaj

e-Medica

Math, Pune - 411043

ULR No.: TC510021000000450F

Discipline: Electrical

Group: Safety Testing Facility

Test Report No: HPLI/Test/2104001401

Date of Issue: 04/05/2021

Customer Ref. & Date: 09/04/2021

Date of Sample Receipt:

Start of Test Date:

End of Test Date:

09/04/2021

09/04/2021

30/04/2021

PART A -PARTICULARS OF THE SAMPLE SUBMITTED

Sample description	e-Medica (Wellness Device)		
Grade/ variety/ type/ class/ size etc.	e-Medica (Wellness Device)		
Declared values, if any	e-Medica (Wellness Device):- Input Rating: 19.0Vdc, 1.0A		
	AC/DC Adapter: - Input Rating: 100-240Vac, 50/60Hz,0.3A		
	Output Rating: 19.0Vdc,1.0A		
Code no., BIS seal and IO's sign. if any	Nil		
Batch no., date of manufacture and	Model No. e-Medica (Wellness Device)		
Brand name	Brand Name: e-Medica		
Quantity	01		
Condition of the sample	Good		
Reference specification (s)	IS 13450 (Part 1)/ IEC 60601-1		
	(Tests have been carried out as per customer request)		
Environmental conditions	Temperature (25±5)°C & Relative humidity<70%		

Statement of Conformity	N/A
Decision Rule	N/A

PART B - SUPPLEMENTARY INFORMATION

- a) Deviations from the test methods as per relevant specification/ work instructions, if any:
- b) Details of the drawings, graphs, tables, sketches or photographs as referred in the test report, if any: ANNEXURE A attached

c) Testing procedure according to work instruction: HPLI03/Test-Medical/WI-01 to 07

d) The Management System is maintained in accordance with IS/ISO/IEC 17025:2017 and testing Standards/ Instruments are traceable to National/ International Standards.

Notes: i) This report is not to be reproduced wholly or in part without our special permission in writing.

ii) This report refers only to the particular sample detailed above.

iii) The results reported in this certificate are valid at the time of and under the stipulated conditions of measurement.

ested by

Checked by

HI PHYSIX LABORATORY INDIA PVT. Approved by

Format No.- HPLI 04 F3 www.hiphysix.com

Registered Office: B-9/51, Sector-18, Rohini, Delhi - 110089.





B-32/1/2, MIDC, Ranjangaon, Pune, Maharashtra info@hiphysix.com, infohplindia@gmail.com Phone: 02138 - 232901, 232902, 232903

CIN: U74120DL2009PTC194754

Mobile 1: +91 7768005400 Mobile 2: +91 7768005411 Mobile 3: +91 7768005422

ULR No.: TC510021000000450F Test Report No.: HPLI/Test/2104001401

TEST RESULT

PART C

Sr.	TESTS WITH CLAUSE	CDEC	SIEIED DEOLIDEMENTS	IS 13450 (Part 1)/IEC 60601-
No.	REFERENCE	SPEC	CIFIED REQUIREMENTS	RESULTS
1.	Power Input Test (Cl.4.11 of IS 13450 (Part 1) /IEC 60601-1)	i)	Steady-state measured input of ME Equipment or ME System at rated voltage and at operating settings indicated in instructions for use did not exceed marked rating by more than 10%	See appended Table 4.11
		ii)	-Measurements on ME Equipment or ME System marked with one or more rated voltage ranges made at both upper and lower limits of the range	See appended Table 4.11
2.	Humidity Preconditioning Treatment (Cl.5.7 of IS 13450 (Part 1) /IEC 60601-1)		ME Equipment or parts there of affected by climatic conditions were set up completely, or partially, with covers detached and subjected to a humidity preconditioning prior to tests of Clauses 8.7.4 and 8.8.3	Before the test of 8.7.4 & 8.8.3, the humidity preconditioning is performance
			ME Equipment heated to a temperature between T and T + 4 °C for at least 4 h and placed in a humidity chamber with a relative humidity of 93 % \pm 3 % and an ambient within 2 °C of T in the range of + 20 °C to + 32 °C for 48 h	25 degree C 93 %RH
3.	Leakage Currents And Patient Auxiliary Currents (Cl.8.7 of IS 13450 (Part 1) /IEC 60601-1)	8.7.1	a) Electrical isolation providing protection against electric shock limits currents to values in 8.7.3	See appended Table 8.7
			b) Specified values of Earth leakage, Touch, Patient Leakage, and Patient Auxiliary Currents applied in combination of conditions in appended Table 8.7	See appended Table 8.7
		8.7.2	Allowable values specified in 8.7.3 applied under Single Fault Conditions of 8.1 b), except	See appended Table 8.7
			Where insulation used in conjunction with a Protective Earth Connection, insulation short circuited only under conditions in 8.6.4 b)	See appended Table 8.7
			The only single Fault Condition for Earth Leakage current was interruption of one supply conductor at a time	See appended Table 8.7
			- Leakage currents and patient auxiliary current not measured in single fault condition of short circuiting of one constituent part of double insulation	See appended Table 8.7
			Single fault conditions not applied at same time as special test conditions of maximum mains voltage on applied parts and non- protectively earthed parts of enclosure	See appended Table 8.7

Tested by

Checked by Page 02 of 10 HI PHYSIX LABORATORY INDIA PVT. LTD.

Approved by

www.hiphysix.com Registered Office: B-9/51, Sector-18, Rohini, Delhi - 110089.





B-32/1/2, MIDC, Ranjangaon, Pune, Maharashtra info@hiphysix.com, infohplindia@gmail.com Phone: 02138 - 232901, 232902, 232903

CIN: U74120DL2009PTC194754 Mobile 1: +91 7768005400 Mobile 2: +91 7768005411 Mobile 3: +91 7768005422

ULR No.: TC510021000000450F

	T		Test Re	port No.: HPLI/Test/210400140 IS 13450 (Part 1)/IEC 60601-
Sr. No.	TESTS WITH CLAUSE REFERENCE	SPEC	CIFIED REQUIREMENTS	RESULTS
		8.7.3	measured based on, and are relative to currents in Fig 12 a), or by a device measuring frequency contents of currents as in Fig 12 b:	See appended Table 8.7
			b) allowable values of patient leakage and auxiliary currents are according to tables 3 & 4, and values of a.c. are relative to currents having a frequency not less than 0.1Hz:	See appended Table 8.7
			c) Touch current did not exceed 100 μA in normal condition and 500 μA in single fault condition	See appended Table 8.7
			d) Earth Leakage Current did not exceed 5 mA in normal condition and 10 mA in single fault condition	See appended Table 8.7
			Higher values of Earth Leakage Current permitted for Permanently Installed ME Equipment connected to a supply circuit supplying only this ME Equipment according to local regulations or IEC 60364-7-710:	See appended Table 8.7
			e) Leakage Currents, regardless of waveform and frequency, did not exceed 10 mA r.m.s. in normal or in single fault condition (measured with a non-frequency-weighted device:)	See appended Table 8.7
		8.7.4	Leakage and Patient Auxiliary Currents measurements:	See appended Table 8.7
4.	Temperature Rise Test (Excessive temperatures in ME Equipment) (Cl.11.1 of IS 13450 (Part 1) /IEC 60601-1)	11.1.1	Temperatures on ME Equipment parts did not exceed values in Tables 22 and 23 operating in worst-case normal use at maximum rated ambient operating temperature T	See appended Table 11.1.1
	71EC 00001-1)		Surfaces of test corner did not exceed 90 °C	Satisfactory
		11.1.2	Applied parts (hot or cold intended to supply heat to a patient comply	(See appended Table 11.1.1) Applied part not supply heat to patient
		11.1.2.2	Applied parts not intended to supply heat to a patient complies with the limits of table 24 in both normal condition and single fault condition	Complies (See appended Table 11.1.1)
			Applied parts surface temperature exceeds 41°C disclosed in the instruction manual:	Not exceed 41°C
			Applied parts surface temperature of equal to or less than 41°C	See appended Table 11.1.1
5.	Interruption of Power Supply (Cl.11.8 of IS 13450 (Part 1) /IEC 60601-1)		Interruption and restoration of power supply did not result in a hazardous situation, except interruption of its intended function	Unit operation normally after Interrupted and restored (Equipment state: Loaded, operating mode)

Tested by

Page 03 of 10

Checked by





B-32/1/2, MIDC, Ranjangaon, Pune, Maharashtra info@hiphysix.com, infohplindia@gmail.com Phone: 02138 - 232901, 232902, 232903

> CIN: U74120DL2009PTC194754 Mobile 1: +91 7768005400 Mobile 2: +91 7768005411

Mobile 3: +91 7768005422

ULR No.: TC510021000000450F

			Test Rep	port No.: HPLI/Test/2104001401
Sr.	TESTS WITH CLAUSE	SDECI	EIED DEOLUDEMENTO	IS 13450 (Part 1)/IEC 60601-
No.		SPECI	FIED REQUIREMENTS	RESULTS
6.	Abnormal operation & Single Fault Condition (Cl.13 of IS 13450 (Part 1) /IEC 60601-1)	13.1.1	None of hazardous situations in 13.1.2-13.1.4, inclusive, occurred when single fault conditions applied, one at a time, as in 4.7 and 13.2	Satisfactory
	/IEC 00001-1)	13.1.2	Emission of flames, molten metal, poisonous or ignitable substance in hazardous quantities did not occur	No fire, emission of molten metal or ignition of substances was noted during the tests.
			Temperatures of applied parts did not exceed allowable values in table 24 when measured as in 11.1.3	Complies (See appended Table 11.1.1)
			Temperatures of ME equipment parts that are not applied parts likely to be touched did not exceed values in table 23 when measured and adjusted as in 11.1.3	See appended Table 11.1.1
			Limits for leakage current in single fault condition based on 8.7.3 did not exceed	Complies (See appended Table 8.7)
			Voltage limits for accessible parts including applied parts in 8.4.2 did not exceed	Complies (See appended Table 8.7)
		13.2.1	During application of single fault conditions in 13.2.2 -13.2.13, inclusive, normal conditions in 8.1 a) applied in least favourable combination	Considered.
		13.2.2 to 13.2.12	ME Equipment complied with 13.2.2 -13.2.12	See appended Table 13.2
		13.2.13	ME Equipment remained safe after tests of 13.2.13.2 to 13.2.13.4 (inclusive), and cooling down to within 3°C of the temperature in the test environment	See appended Table 13.2
			For insulation of thermoplastic materials relied upon as a means of protection (see 8.8), the ball pressure test specified in 8.8.4.1 a) performed at a temperature 25 °C higher than temperature of insulation measured during tests of 13.2.13.2 to 13.2.13.4 (inclusive).	Ball-pressure test for nonmetallic enclosure has been carried out at 75°C & found Satisfactory (See appended Table 8.8.4.1)
7.	Drop test (C1.15.3.4 of IS 13450 (Part 1) /IEC 60601-1)	15.3.4.2	Sample of portable ME Equipment, accessories and portable part with safe working load lifted to a height as in table 29 above a 50 ± 5 mm thick hardwood board lying flat on a concrete floor or rigid base, dropped 3 times from each orientation in normal use (cm)	There was no damage to the interior or exterior of the tested sample which caused exposure to live parts or increased risk of electric shock
PAR	T D:			The same and the s

Remarks: 1. The observations given in part A of the cover page of the test report are taken from the marking on the sample and specification given by the customer. 2. All the test covered in this test reports are performed as per Customer request.

HI PHYSIX LABORATORY INDIA PVT. LTD.

Tested by

Checked by Page 04 of 10 Approved by

awatade





B-32/1/2, MIDC, Ranjangaon, Pune, Maharashtra info@hiphysix.com, infohplindia@gmail.com

Phone: 02138 - 232901, 232902, 232903 CIN: U74120DL2009PTC194754

> Mobile 1: +91 7768005400 Mobile 2: +91 7768005411 Mobile 3: +91 7768005422

ANNEXURE A

ULR No.: TC510021000000450F Test Report No.: HPLI/Test/2104001401

IS 13/50 (Part 1)/IEC 60601 1

8.10	TABLE: List Of Cr	itical Components	A Company of the Comp		Part 1)/IEC 6060
Object/part or Description	Manufacturer/ Trademark	Type/Model	Technical data	Standard (Edition/ year)	Mark(s) of Conformity ¹)
AC/ DC Adapter	Magnetics	LT19-SEM-7450	Input:100-240Vac ,50/60Hz,0.3A Output: 19Vdc, 1.0A		Tested with appliance
Interconnecting Cable	R R Kabel Limited	Various	PVC 1100V	IS 694	CN/L. 3934068
LCD Display	Shenzhen Jing Handa Electronics. Ltd	JHD204A	5.0V, 1.2mA	IS13450(Part 1)/ IEC60601-1	Tested with appliance
Varistor	TDK Electronics GmbH & Co OG	S14 series	30Vrms,38Vdc	IEC 61051-1 IEC 61051-2 IEC 61051-2-2	VDE 40027582
Plastic Enclosure	Various	Various	71	UL94	UL

An asterisk indicates a mark which assures the agreed level of surveillance. See Licenses and Certificates of Conformity for verification.

4.11 TABLE: Power Input					
Operating Conditions / Ratings	Voltage (V)	Frequen cy (Hz)	Current (A)	Power (W or VA)	Power factor (cos φ)
Test on Model e-Medica				<u> </u>	
For AC/DC Adapter: (Shyam Electronics Magnetics, Type LT19-SEM-7450)	-			TO CO	
Max. normal loaded / 1.0 A	90Vac	50	0.318	22.59	
Max. normal loaded / 1.0 A	90Vac	60	0.320	22.60	
Max. normal loaded / 10 A	100Vac	50	0.306	22.45	
Max. normal loaded / 1.0 A	100Vac	60	0.309	22.48	
Max. normal loaded / 1.0 A	240Vac	50	0.196	22.38	
Max. normal loaded /1.0 A	240Vac	60	0.199	22.40	
Max. normal loaded / 1.0 A	264Vac	50	0.194	22.34	
Max. normal loaded /1.0 A	264Vac	60	0.197	22.35	
Max. normal loaded	19Vdc		0.556	10.56	

Tested by

Checked by





B-32/1/2, MIDC, Ranjangaon, Pune, Maharashtra info@hiphysix.com, infohplindia@gmail.com Phone: 02138 - 232901, 232902, 232903

CIN: U74120DL2009PTC194754

Mobile 1: +91 7768005400 Mobile 2: +91 7768005411 Mobile 3: +91 7768005422

ULR No.: TC510021000000450F Test Report No.: HPLI/Test/2104001401 IS 13450 (Part 1)/JEC 60601

8.7 TABLE: Leakage	e current			Management of the Course of th
Type of leakage current and test condition (including single fault		Supply frequency (Hz)	Measured max.value (µA)	Remarks
Fig. 13 - Earth Leakage (ER)	-	-	-	Maximum allowed values:
Before Humidity Condition:				5 mA NC; 10 mA SFC
200.				
ER, NC	264	60	152.3	S1 = 1, S5 = 1
ER, NC	264	60	157.9	S1 = 1, S5 = 0
ER, SFC (Neutral Open),	264	60	197.5	S1 = 0, S5 = 1
ER, SFC (Neutral Open)	264	60	199.1	S1 = 0, S5 = 0
After Humidity Condition:				
ER, NC	264	60	153.8	S1 = 1, S5 = 1
ER, NC	264	60	157.7	S1 = 1, S5 = 0
ER, SFC (Neutral Open),	264	60	198.4	S1 = 0, S5 = 1
ER, SFC (Neutral Open)	264	60	199.5	-
with non frequency-weighted		100	199.3	S1 = 0, S5 = 0
Before Humidity Condition:				Maximum allowed values: 10 mA for NC & SF
ER, NC		4	**************************************	
ER, NC	264	60	160.1	S1 = 1, S5 = 1
ER, SFC (Neutral Open),	264	60	163.8	S1 = 1, S5 = 0
ER, SFC (Neutral Open)	264 264	60	201.6	S1 = 0, S5 = 1
After Humidity Condition:	204	00	205.7	S1 = 0, S5 = 0
ER, NC	264	60	160.8	S1 = 1, S5 = 1
ER, NC	264			
ER, SFC (Neutral Open),	264		164.2	S1 = 1, S5 = 0
ER, SFC (Neutral Open)	264		201.5	S1 = 0, S5 = 1
Fig. 14 - Touch Current (TC)	204	60	205.4	S1 = 0, S5 = 0
	-		-	Maximum allowed values: 100 μA NC; 500 μA SFC
AD between Earth and AC/DC A	dapter Plast	ice Enclosure	e surface (cov	vered with metal foil)
Sefore Humidity Condition:				
C, NC	264	60	7.6	S1 = 1, S5 = 1, S7 = 1
C, NC	264	60	5.8	S1 = 1, S5 = 0, S7 = 1
C, SFC (Neutral Open)	264		9.1	S1 = 0, S5 = 1, S7 = 1
C, SFC (Neutral Open)	264			S1 = 0, S5 = 0, S7 = 1
C, SFC (Ground Open)	264	60 8	3.3	S1 = 1, S5 = 1, S7 = 0
C, SFC (Ground Open)	264	60	17.7	S1 = 1, S5 = 0, S7 = 0

fested by

Page 06 of 10

Checked by





B-32/1/2, MIDC, Ranjangaon, Pune, Maharashtra info@hiphysix.com, infohplindia@gmail.com

Phone: 02138 - 232901, 232902, 232903 CIN: U74120DL2009PTC194754

> Mobile 1: +91 7768005400 Mobile 2: +91 7768005411 Mobile 3: +91 7768005422

ULR No.: TC510021000000450F Test Report No.: HPLI/Test/2104001401

Type Of Leakage Current And Test Condition (Including Single Faults)	Supply Voltage (V)	Supply Frequency (Hz)	Measured Max. Value (Ma)	IS 13450 (Part 1)/IEC 60601. Remarks
After Humidity Condition:				
TC, NC	264	60	8.3	S1 = 1, S5 = 1, S7 = 1
TC, NC	264	60	6.1	S1 = 1, S5 = 0, S7 = 1
TC, SFC (Neutral Open)	264	60	9.5	S1 = 0, S5 = 1, S7 = 1
TC, SFC (Neutral Open)	264	60	9.8	S1 = 0, S5 = 0, S7 = 1
TC, SFC (Ground Open)	264	60	8.8	S1 = 1, S5 = 1, S7 = 0
TC, SFC (Ground Open)	264	60	19.1	S1 = 1, S5 = 0, S7 = 0
Fig.15 - Patient Leakage Current (P) MD between surface of footprint o earth)	-	-	-	Maximum allowed values: Type B or BF AP: 10 μA NC; 50 μA SFC (d.c. current); 100 μA NC; 500 μA SFC (a.c.) Type CF AP: 10 μA NC; 50 μA SFC (d.c. or a.c. current)
P, NC	264	60	ac<1	S1 = 1, S5 = N
P, NC	264	60	ac<1	S1 = 1, S5 = R
P, SFC	264	60	ac 1.29 µA	S1 = 0, S5 = N
P,SFC	264	60	ac 1 32 IIA	S1 - 0 $S5 - D$
Fig. 16 - Patient leakage current w. (PM) (MD between External voltage)	ith mains or ge & surface	n the F-type	applied parts nt)	Maximum allowed values: Type B: N/A , Type BF AP: 5000 μA Type CF AP: 50 μA
P, NC	264	60		S1 = 1, S5 = N
P, NC	264		- TOTAL 175	S1 = 1, S5 = R
P, SFC				S1 = 0, S5 = N
P,SFC				S1 = 0, S5 = R
Supplementary information:				5. 0,55 K

- Note 1: For Earth Leakage Current see 8.7.3 d) and 8.7.4.5;
- Note 2: For Touch Current see 8.7.3 c) and 8.7.4.6;
- Note 3: For Patient Leakage Current See 8.7.3.b) and 8.7.4.7
- Note 4: Total Patient Leakage Current values are only relative to equipment with multiple Applied Parts of the same type.
- See 8.7.4.7 h). The individual applied parts complied with the Patient Leakage Current values.

Note 5: In addition to conditions indicated in the Table, tests conducted at operating temperature and after humidity preconditioning of 5.7, equipment energized in stand-by condition and fully operating, max rated supply frequency, at 110 % of the max rated mains voltage

ı	ER -	Earth	leakage	current

- TC Touch current
- P Patient leakage current
- PA Patient auxiliary current
- TP Total Patient current
- PM Patient leakage current with mains on the applied parts
- MD Measuring device

- A After humidity conditioning
- B Before humidity conditioning
- 1 Switch closed or set to normal polarity
- 0 Switch open or set to reversed polarity
- NC Normal condition
- SFC Single fault condition

Checked by

Page 07 of 10





B-32/1/2, MIDC, Ranjangaon, Pune, Maharashtra info@hiphysix.com, infohplindia@gmail.com

Phone: 02138 - 232901, 232902, 232903 CIN: U74120DL2009PTC194754

Mobile 1: +91 7768005400 Mobile 2: +91 7768005411 Mobile 3: +91 7768005422

ULR No.: TC510021000000450F Test Report No.: HPLI/Test/2104001401

IS 13450 (Part 1)/IEC 60601-1

8.8.4.1	TABLE: Resistance to heat - Ball pressure test of thermoplastic parts							
	Allowed impression diameter (mm):		=<2 mm		-			
	Force (N):	20						
Part/material			Test temperature Impression diam		ion diameter (mm)			
Plastic End	closure		75		0.8			
Supplemen	ntary information:							
The results	were less 2 mm. Cracks were visible to the naked	ł eye.						

11.1.1	TABLE: Excessive temperatures in ME Equipment						
Model N		See below		T			
Test aml	bient (°C):	25.6				19.59	NA PA
Test supply voltage/frequency (V/Hz)(4):		90V/50Hz			***************************************		
Sr.No	Thermocouple location(3)		Max allows temperature ¹ from Table 2 23 or 24 or R file for AP(5 (°C)) 22, RM	_ I control and the control an	measured ature(2),	Remarks
1	PCB		105		31.4		35.8
2	Plastics Enclosure		60	60 30.9		0.9	35.3
3	LCD Display		60 2		7.9	32.3	
4	LCD Display PCB		105		2	7.4	31.8
5	Applied part		41			6.8	31.2
6	Adapter Enclosure	0.100	60			5.8	40.2
7	Internal wire		105		28		33.1
8	Metal		56			1.3	35.7
9	Test Corner		90			5.9	30.3
10	Ambient					5.6	Shift Tma 30

Supplementary information: ¹⁾When thermocouples used to determine temperature of windings, limits of Table 22 reduced by 10 °C.

Tested by

Page 08 of 10

Checked by





B-32/1/2, MIDC, Ranjangaon, Pune, Maharashtra info@hiphysix.com, infohplindia@gmail.com

Phone: 02138 - 232901, 232902, 232903

CIN: U74120DL2009PTC194754 Mobile 1: +91 7768005400

Mobile 2: +91 7768005411 Mobile 3: +91 7768005422

ULR No.: TC510021000000450F Test Report No.: HPLI/Test/2104001401

IS 13450 (Part 1)/IEC 60601-1

13.2	TABLE: Single Fault Conditions		
Clause No.	Description of Single Fault Condition	Results observed	Hazardous Situation (Yes/No)
13.2.2	Electrical Single Fault Conditions per Clause 8.1:	-	-
	Output shorted (AC/DC Adapter)	Unit switched off. No hazard. No defect.	No
	Output overload	Output current: 1.48A max. Maximum temperature of the enclosure: 46.8°C at 25.5°C ambient temperature.	No
		No hazard. No defect.	

Supplementary information:

- The measured temperatures did not exceed those allowable. See Table 11 for Temperatures obtained during the indicated Abnormal Operation tests.

- There was no flame, extensive smoke or melted metal.

Tosted by

Page 09 of 10

Checked by





B-32/1/2, MIDC, Ranjangaon, Pune, Maharashtra info@hiphysix.com, infohplindia@gmail.com

Phone: 02138 - 232901, 232902, 232903 CIN: U74120DL2009PTC194754

> Mobile 1: +91 7768005400 Mobile 2: +91 7768005411 Mobile 3: +91 7768005422


ULR No.: TC510021000000450F Test Report No.:HPLI/Test/2104001401

IS 13450 (Part 1)/IEC 60601-1

Photograph of EUT



External View



Internal View



AC/DC Adapter

AC-DC POWER ADAPTER

Model: LT19-SEM-7450
INPUT: 100VAC-240VAC 50/60Hz 0.3A
OUTPUT: 19 = 1A
CAUTION
For use with Industrial Technology Equipment

ATTENTION:
VILLESIR AVEG DU MATERIELINFORMATIQUE SEULEMENT

VILESIR AVEG DU MATERIELINFORMATIQUE SEULEMENT

> 1E CAUCION

PARA USE CONEQUIPOS DE YECHOLOGIA DE LA INFORMACION

e Med

Trademark

Copy of Marking Plate of AC/DC Adapter

Checked by

Page No. 10 of 10

HI PHYSIX LABORATORY INDIA PVT. LTD.

Approved by

Or. W. N. Awatade (General Manager Electronics Division)

***** END OF THE TEST REPORT *****



Presents -



CERTIFICATE OF RECOGNITION

Healthcare Innovation Award – Corporates

AWARDED TO



Rohera Inc.(E Medica)

THIS AWARD IS TO RECOGNISE & HONOUR YOUR EXEMPLARY WORK IN THE FIELD OF HEALTHCARE, HELD ON 28TH JULY 2021

An Initiative of

Innoserv

www.innoserv.group

Mr. Rahul Jain

Rahul Jain

MD, InnoServ Group Director, ADMH



Certificate of Compliance

RoHS Directive (2011/65/EU) of the European Parliament and of the Council on the restriction of use of certain Hazardous Substances in Electrical and Electronic Equipments

Certificate No. ROHS-SAPP-20-0700155

Manufacture

Name : SWATANTRA POWER PRIVATE LIMITED

Address : 201, MANISH PLAZA, OPP BHARAMA MAJESTIC, N.I.B.M RD, KONDHWA KHURD,

PUNE-411048, MAHARASHTRA, INDIA

FACTORY ADDRESS: GATE NO. 37, KHED SHIVAPUR-SASWAD ROAD, OFF PUNE SATARA

HIGHWAY, KASURDI KHEDIBADI, TAL. BHOR, PUNE 412205, MAHARASHTRA, INDA

Product : "MANUFACTURER OF ELECTRONIC MEDICAL DEVICE E-MEDICA"

This is to state that the above mentioned products is in compliance with RoHS Directive (20/95/EC)of the European Parliament and Commission Decision 2005/618/EC on the restriction of use of certain Hazardous Substances [Lead (Pb), Mercury (Hg), Cadmium (Cd), Hexavalent Chromium (Cr6+), Polybrominated biphenyls (PBBs) and Polybrominated Diphenyl ethers (PBDEs)] in Electrical and Electronic Equipments.

Statement:

This certificate declares that the product type/model described above complies with the mentioned above European Standard(s).

Remarks:

This certificate of complies is based on the evaluation of a sample of the above mentioned products. It does not imply and assessment of the mass-production of the product. This certificate holder may use this certificate in connection with the test certification body should be informed (revision of technical file)for any modification or alterations made to the aforementioned product type(s), including design and manufacture and/or extension to the existing scope of application.

The certificate is valid for three years if the company applies the technical construction file which has been stored IMC office. This certificate includes declaration of manufacturer.

Certificate remains property of IMC to whom it must be returned upon request. The certificate validity is conditioned by positive results or surveillance audits.

Validity of this certificate can be verified at www.gaafs.us

Date of Certification

1st Surveillance Due

2nd Surveillance Due

Certificate Expiry (Subject to the company maintaining its system

To the required standard)

Certification



06th JUNE 2020

05th JUNE 2021

05th JUNE 2022 05th JUNE 2023



Authorized Signatory



Certificate of Registration

This is to certify that

SWATANTRA POWER PRIVATE LIMITED

201, MANISH PLAZA, OPP. BHARAMA MAJESTIC, N.I.B.M RD, KONDHWA KHURD, PUNE-411048, MAHARASHTRA, INDIA FACTORY ADDRESS: GATE NO. 37, KHED SHIVAPUR-SASWAD ROAD, OFF PUNE SATARA HIGHWAY, KASURDI KHEDIBADI, TAL. BHOR, PUNE 412205, MAHARASHTRA, INDIA

has been independently assessed by QVA and is compliant with the requirement of the standard

ISO 13485:2016

Quality Management SystemFor Medical Devices

For the following scope of activities

"MANUFACTURER OF ELECTRONIC DEVICE TO MEDICAL DEVICE E-MEDICA"

Certificate Number: QMS-SAPP-20-0700156

Verify this certificate visit at www.gaafs.us

Date of Certification 07^{TH} April 2020Issuance Date 07^{TH} April 20201st Surveillance Due 06^{TH} April 20212nd Surveillance Due 06^{TH} April 2022Re-Certificate Due 06^{TH} April 2023













Certificate of Compliance

We hereby declare that the technical file of product complied with the requirement of directives 2006/95/EC on LVD

Manufacture

Name : SWATANTRA POWER PRIVATE LIMITED

Address : 201, MANISH PLAZA, OPP BHARAMA MAJESTIC, N.I.B.M RD, KONDHWA KHURD,

PUNE-411048, MAHARASHTRA, INDIA

FACTORY ADDRESS: GATE NO. 37, KHED SHIVAPUR-SASWAD ROAD, OFF PUNE SATARA HIGHWAY, KASURDI KHEDIBADI, TAL. BHOR, PUNE 412205, MAHARASHTRA, INDIA

Product : "ELECTRONIC DEVICE TO MEDICAL DEVICE E-MEDICA"

Complies with the requirements applicable to it

The Certification body has performed an audit of the above product quality system covering the design, manufacture and final inspection of the certified product. The quality system has been assessed, approved and is subject to continuous surveillance according to the directives 2006/95/EC on LVD

This certificate is issued under the following conditions:

It applies only to the quality system maintained in the manufacture of above referenced models and it does not substitute the design or type-examination procedures, if requested.

- The certificate remains valid until the manufacturing conditions or the quality systems are changed.
- 2. The certificate validity is conditioned by positive results or surveillance audits.
- 3. After fulfilling the relevant EU legislation, the manufacturer shall affix to each device, of the above referenced models.
- 4. The CE mark as shown above can be used, under the responsibility of the manufacturer, after completion of an EC Declaration of conformity and compliance with all relevant EC Directives. The statement is based on a single evaluation of one sample of above mentioned product. It does not imply an assessment of the whole production.

Certificate No. CE-SAPP-20-0700154

Certificate can be verified at www.gaafs.us

Date of Certification 07TH JULY 2020

1st Surveillance Due 06TH JULY 2021

2nd Surveillance Due 06TH JULY 2022

Certificate Expiry (Subject to the company maintaining its system 06TH JULY 2023


To the required standard)




Authorized Signatory



(E





TO WHOM SO EVER IT MAY CONCERN

I Dr. Mohan Kumar V have been introduced to eMedica and found the concept quite interesting and since it has all the certification in place I decided to use eMedica on my patients.

On 10th of April 2022 | started using eMedica on my patient Mrs. Saraswathi Her right side of the body is paralyzed. She was unable to move her right side at all.

To test the device (after making sure the device has no side effect) I made her use the device regularly for the paralytic program daily 4 hours from 10th April 2022 to 30th of April 2022.

After using for only 20 days, to my surprise I found excellent results. She can move & lift her right hand. I suggest her to continue the same for few more months to get back to normal.

I highly recommend the device for Paralysis.

The Revive A Holistic Neuropsychlatric Care
(A Unit of CMD Hospital)
9, Beside Hebbal Lake, Near V-Lead,
Hebbal Ring Road, Mysore-570016

- m therevivehospital@gmail.com
- n therevive.in
- #9, Beside Hebbal Lake,

Near V-LEAD Hebbal Ring Road Mysuru - 570016



4/4/2018

Acknowledgement Print



Government of India Ministry of Commerce & Industry Department of Industrial Policy & Promotion Controller General of Patents Design & Trade Marks

Online Filing Of Patents



Controller General of Patents, Designs & Trade Marks S.M.Rosa, Antop Hill, Murabai 400037 Fel No. (091)022) 241377010,24141026 Fax No. 022 2433387 E-mail: murabai-potent@nic.in Web Site: wow.ipindia.gov.in

Docket No 15938



INTELLECTUAL PROPERTY INDIA MEDITIONS OF SOME AND TO THE PROPERTY INDIA MEDITIONS OF SOME AND THE PROPERTY OF THE PROPERTY INDIA MEDITIONS OF THE PROPERTY INDICATES OF THE PROPERTY INDICATES OF THE PROPERTY INDICATES OF T

Date/Time 04/04/2018

User ld: Parag

To MORE PARAG MANOHAR

"Intellectual Platform", Ground Floor — Mayuresh, P. R. More Road, Near S. P. More College, Podi No. 1, Sector 15, New Panvel, Navi Mumbai — 410 206, Dist. Raigad, Maharashtra, Iudia

St. No.	Ref. No./Application No.	App. Number	Amount Paid	C.B.R. No.	Form Name	Remarks
1	201821012767	E-3/4081/2018/MUM	0	-	FORM 3	

Total Amount : ₹ 0 Amount in Words: Rupees Only

Print

Medical Laboratory Report



Patient Information

Name : Mr.ASHOK SAINI Age/Gender : 72Y 2M 3D/Male MobileNo : 9892697751 UHID : LDAA00031381

Address : 1102 tulip, dosti acre, behind

antop hill bus depot. 400037

Specimen Information

Visit ID : LDAL442

Collected : 24/Apr/2022 08:02 Received : 24/Apr/2022 15:41

Reported : 24/Apr/2022 16:33

IP/OP/Barcode:

Report Status: Final Report

Client/Doctor Information

Ref Doctor : Dr.SELF Client Code : LMPCC0121 Client Add. : WADALA EAS

Client No. :

Client Name: PCC WADALA DOSTI

ACRES

Test Name	Result	Bio. Ref. Range	Unit	Method

Blood Urea Nitrogen (BUN), SERUM

Blood Urea Nitrogen (BUN)	57.4	8.0-23.0	mg/dl	Kinetic Urease
Result Rechecked				

Creatinine, Serum

Creatinine	6.78	0.70-1.20	mg/dL	Kinetic Jaffe
Result Rechecked				

Electrolytes, Serum

Sodium	140.2	136 - 145	mmol/L	Ion-selective electrode		
Potassium	5.7	3.4 - 5.1	mmol/L	Ion-selective electrode		
Chloride	105.5	98-107	mmol/L	Ion-selective Electrode		
Result Rechecked						





Medical Laboratory Report



Patient Information

Name : Mr.ASHOK SAINI Age/Gender : 72Y 2M 3D/Male MobileNo : 9892697751

UHID : LDAA00031381

Address : 1102 tulip, dosti acre, behind

antop hill bus depot. 400037

Specimen Information

Visit ID : LDAL442

Collected : 24/Apr/2022 08:02 Received : 24/Apr/2022 16:30

: 24/Apr/2022 16:34

IP/OP/Barcode:

Reported

Report Status : Final Report

Client/Doctor Information

Ref Doctor : Dr.SELF Client Code : LMPCC0121 Client Add. : WADALA EAS

Client No. :

Client Name: PCC WADALA DOSTI

ACRES

Test Name	Result	Bio. Ref. Range	Unit	Method
-----------	--------	-----------------	------	--------

Complete Urine Examination, URINE

Physical Examination				
Colour	Pale Yellow			
Specific Gravity	1.015	1.010-1.030		Dipstick Method
Transparency	Clear	Clear		
Chemical Examination				
Protein	Present (++)	Absent		Dipstick Method
Glucose	Absent	Absent		Dipstick Method
рН	7.5	5.0-8.0		Dipstick Method
Blood	Absent	Absent		Dipstick Method
Ketone	Absent	Absent		Dipstick Method
Bile Pigment	Absent	Absent		Dipstick Method
Urobilinogen	Normal	Normal		Dipstick Method
Nitrite	Absent	Absent		Dipstick Method
Leucocyte Esterase	Absent	Absent		Dipstick Method
Microscopic Examination				
WBC/Pus Cells	2-3	0-5	/hpf	Microscopy
Transitional/Squamous epithelial cells	2-4	0-4 /hpf		Microscopy
RBCs	Absent	Absent	/hpf	Microscopy
Crystals	Absent	Absent		Microscopy
Casts	Absent	Absent	/lpf	Microscopy
Others	-	Absent		Microscopy

*** End Of Report ***

DR. SAGAR DAMANI MBBS, MD (PATHOLOGY) CONSULTANT PATHOLOGIST





Patient Information

Name : Mr.ASHOK SAINI Age/Gender : 71Y 3M 9D/Male MobileNo : 9892697751

UHID : LDAA00039220

Address : 1102 Dosti Tulip Dosti Acres

Specimen Information

Visit ID : LDAL715

Collected : 09/Jun/2022 09:42 Received : 09/Jun/2022 12:17

Reported : 09/Jun/2022 13:49

IP/OP/Barcode:

Report Status: Final Report

Client/Doctor Information

Ref Doctor : Dr.SELF Client Code : LMPCC0121 Client Add. : WADALA EAS

Client No. :

Client Name: PCC WADALA DOSTI

ACRES

Test Name	Result	Bio. Ref. Range	Unit	Method

Blood Urea Nitrogen (BUN), SERUM

Blood Urea Nitrogen (BUN)	50.1	8.0-23.0	mg/dl	Kinetic Urease

Creatinine, Serum

6.07	0.70-1.20	mg/dL	Kinetic Jaffe
	6.07	6.07 0.70-1.20	6.07 0.70-1.20 mg/dL

Electrolytes, Serum

Sodium	134.0	136 - 145	mmol/L	Ion-selective electrode
Potassium	5.2	3.4 - 5.1	mmol/L	Ion-selective electrode
Chloride	106.9	98-107	mmol/L	Ion-selective Electrode





Patient Information

Name : Mr.ASHOK SAINI Age/Gender : 71Y 3M 9D/Male MobileNo : 9892697751

UHID : LDAA00039220

Address : 1102 Dosti Tulip Dosti Acres

Specimen Information

Visit ID : LDAL715

Collected : 09/Jun/2022 09:42 Received : 09/Jun/2022 12:23

Reported : 09/Jun/2022 13:59

IP/OP/Barcode:

Report Status: Final Report

Client/Doctor Information

Ref Doctor : Dr.SELF Client Code : LMPCC0121 Client Add. : WADALA EAS

Client No. :

Client Name: PCC WADALA DOSTI

ACRES

	Test Name	Result	Bio. Ref. Range	Unit	Method
--	-----------	--------	-----------------	------	--------

Complete Urine Examination, URINE

Physical Examination				
Colour	Pale Yellow			
Specific Gravity	1.020	1.010-1.030		Dipstick Method
Transparency	Clear	Clear		
Chemical Examination				
Protein	Trace	Absent		Dipstick Method
Glucose	Negative	Absent		Dipstick Method
рН	5.5	5.0-8.0		Dipstick Method
Blood	Negative	Absent		Dipstick Method
Ketone	Negative	Absent		Dipstick Method
Bile Pigment	Negative	Absent		Dipstick Method
Urobilinogen	Normal	Normal		Dipstick Method
Nitrite	Negative	Absent		Dipstick Method
Leucocyte Esterase	Negative	Absent		Dipstick Method
Microscopic Examination				
WBC/Pus Cells	1-2	0-5	/hpf	Microscopy
Transitional/Squamous epithelial cells	0-1	0-4 /hpf		Microscopy
RBCs	Absent	Absent /hpf		Microscopy
Crystals	Absent	Absent		Microscopy
Casts	Absent	Absent	/lpf	Microscopy
Others	Bacteria Present	Absent		Microscopy

*** End Of Report ***


DR. PIYUSH DESHPANDE MD (PATHOLOGY) CHIEF OF LAB











Report from Serum Institute

Before and After the Use of MediMagic

DIABETIS STUDY

Sr.	Name		Name Age		Date	BSL (G	lucome	ter) / mgdl	BSL -R	andom	Serum	Insulin
No				Pre	Post	After 2hrs	1	#	1	Н		
1	Mr.Prakash D Kothawale	56	17/08/2018	123	94	92	126	96	5.9	3		
2	Mr.Sameer Joshi	45	17/08/2018	207	195	153	242	182	12.7	9.3		
3	Mr.Jaysing G Misal	61	17/08/2018	194	164	118	234	116	17.2	7.9		
4	Mr.Sunil Gaikwad	40	17/08/2018	240	179	134	264	162	16.4	6.6		
5	Mr.Aniket K.Tapkir	30	17/08/2018	214	210	188	238	220	5.4	6.1		
6	Mr.Milind Dhatrak	46	17/08/2018	243	177	106	88	102		41		
7	Mr.Abhijit Pawar	34	17/08/2018	102	100	83	243	86.3	12.2	7.8		

medication taken



Patient : Mrs. RUKMINI SHROFF PRN IP No. : 867007 Age/Sex : 62 Yrs/Female Visit No. : OP-2 : 31/01/2018 Date Referred By : Dr. Shashikant Apte Sample Collected : 31/01/2018 11:00 : OPD Location Sample Revd. in Lab : 31/01/2018 11:53 Sponsor Reported On : 31/01/2018 15:56 Collected At : Sahyadri Speciality Hospitals Processed At : SSL Main Lab :0031503118 Status : Verified

HAEMOGRAM

Test Name	Test Value	UOM	Biological Reference Interval
Haemoglobin	10.9	g/dL	12.0 - 15.0
R.B.C. Count	3.26	x 10^6/ul	3.80 - 4.80
Haematocrit	31.6	96	36.0 - 46.0
M.C.V.	96.9	fl	76 - 96
M.C.H	33.6	pg	27 - 32
M.C.H.C.	34.7	gm/dl	31.5 - 34.5
R.D.WCV	18.7	%	11.6 - 14
Total W.B.C. Count	175600	/µL	4000 - 10000
Differential Count			
Blast	5	96	
Myelocytes	8	%	
Meta+Band	9	%	
Neutrophils	63.0	96	40.0 - 80.0
Lymphocytes	6.0	%	20.0 - 40.0
Monocytes	2.0	%	2.0 - 10.0
Eosinophils	4.0	%	1.0 - 6.0
Basophils	3.0	%	<1-2
Platelet Count	198000	/µL	150000 - 410000
MPV	10.3	fl	
Smear Study	Marked neutrophili Normocytic normo Platelets adequate o	chromic anemia, a	n shift to left upto blasts (5%), nisocytosis +.

Performed on Beckman Coulter Haematology Analyzer.

End Of Report-



: Mrs. RUKMINI SHROFF PRN Patient : 867007 IP No. Age/Sex : 62 Yrs/Female Visit No. : OP-2 Date : 31/01/2018 Referred By : Dr. Shashikant Apte Sample Collected : 31/01/2018 11:00 Location : OPD Sample Rcvd. in Lab : 31/01/2018 11:50 Reported On : 02/02/2018 17:48 Sponsor Collected At : Sahyadri Speciality Hospitals Processed At : SSL Main Lab

PCR REPORT _____ Test Value Range Specimen: Peripheral blood RT PCR for BCR ABL Screening 406179.97 ABL Copies Copies/µL BCR-ABL (p210) mRNA Detected 317851.91 BCR - ABL1 (P210) Copies Copies/µL BCR-ABL/ABL (p210) Normalised ratio 78.25

Status

: Verified

Quantity of housekeeping gene (ABL) is within acceptable limit.

Reverse Transcriptase PCR

RNA is converted to cDNA by Reverse Transcription, followed by specific PCRs. In case of haematological malignancies fusion gene transcripts for various translocations are tested.

42.46

Qualitative mRNA detection. Reverse Transcription-PCR (RT-PCR), is designed to screen for all reported BCR/ABL fusion variants. Real Time Quantitative PCR (RQ-PCR)

BCR-ABL of PCR is performed using Real Time PCR method. p190 and p210 BCR-ABL RQ-PCR is performed to monitor minimal residual disease in ALL or CML respectively.

Limitations

RNA is extremely labile.

Presence of PCR inhibitors may interfere with the test.

The importance of International scale (IS) is that it standardizes quantitative BCR-ABL 1 measurement across tests and laboratories, facilitating inter laboratory studies, patient portability and a harmonized definition of treatment response. The IS is anchored to the baseline BCR-ABL 1 expression level from IRIS trial (100% IS) with a major molecular response (MMR) corresponding to 0.1% IS. The IRIS trial and follow up studies have demonstrated that achieving MMR, or a 3-log reduction in BCR-ABL 1 expression from the standardized baseline level, is a key clinical outcome. Percent ratio on the IS is obtained by using following formula. IS % = BCR-ABL 1 / ABL x 100 x Conversion factor.

-----End Of Report-----

Dr. Dolly Joshi Ph.D (Biotechnology)

Entered By:10006492

Dr. Rajesh Phatale M.B.B.S., M.D. (Pathology)

Page 1 of 1



Sahyadri Speciality Labs

e-mail: labinfo@sahyadrihospitals.com www.sahyadrihospital.com



Patient : Mrs. RUKMINI SHROFF IP No. : 867007 Age/Sex : 63 Yrs/Female Visit No. : OP-8 Date : 26/10/2018 Referred By : Dr. Shashikant Apte Sample Collected : 26/10/2018 11:59 Location : OPD Sample Revd. in Lab-: 26/10/2018 12:46 Sponsor Reported On : 26/10/2018 14:35 Collected At : Sahyadri Speciality Labs Processed At : SSL Main Lab :0057229918 Lab No. HAEMOGRAM : Verified

Specimen:	EDTA	Whole	Rload

Test Name	Test Value	UOM	Biological Reference Interval
Haemoglobin	10.0	g/dL	12.0 - 15.0
R.B.C. Count	3.24	x 10^6/ul	3.80 - 4.80
Haematocrit	31.3	%	36.0 - 46.0
M.C.V.	96.5	fl	76 - 96
M.C.H	31	pg	27 - 32
M.C.H.C.	32.1	gm/dl	31.5 - 34.5
R.D.WCV	16.6	96	11.6 - 14
Total W.B.C. Count	7300	/µL	4000 - 10000
Differential Count			
Neutrophils	69.7	96	40.0 - 80.0
Lymphocytes	21.5	%	20.0 - 40.0
Monocytes	3.9	%	2.0 - 10.0
Eosinophils	4.5	%	1.0 - 6.0
Basophils	0.4	%	< 1 - 2
Platelet Count	323000	/µL	150000 - 410000
MPV	8	fl	

Platelets adequate on smear.

Performed on Beckman Coulter Haematology Analyzer.

-End Of Report-

Dr. Rajesh Phatale M.B.B.S., M.D. (Pathology) Reg. No: 67843

Entered By:70000971

Page 1 of 1

Sahyadri Hospitals Ltd. CIN: U85110PN1996PLC099499 Regd. Office: Plot No. 54, S.No.-89-90, Lokmanya Colony, Nr. R K Auto & Jeet. Opp. Vanaz Company, Kothrud, Pune 411038.

: 26/10/2018



Sahyadri Speciality Labs

e-mail: labinfo@sahyadrihospitals.com www.sahyadrihospital.com



: Mrs. RUKMINI SHROFF Patient Age/Sex : 63 Yrs/Female

Referred By : Dr. Shashikant Apte : OPD

Location Sponsor Collected At : Sahyadri Speciality Labs

:0057229918 Lab No.

PRN

Reported On

Processed At

Visit No. Sample Collected Sample Revd. in Lab

: 867007 IP No. : OP-8 Date

: 26/10/2018 11:59 : 26/10/2018 12:46

: 26/10/2018 14:17 : SSL Main Lab

: Verified

Test Name	Test Value	Unit	Biological Reference Interval	Method
Serum Bilirubin Total	0.34	mg/dl	Adult: 0.1 to 1.2 Cord Blood: < 2.0 Full Term: 0 - 1 Day: 2 to 6 1 - 2 Days: 6 to 10 3 - 5 Days: 4 to 8	Diazo
Serum Bilirubin Direct	0.19	mg/dl	0.00 - 0.30	Diazo
Serum Bilirubin Indirect	0.15	mg/dl	0.20 - 1.20	
Serum SGPT	17	IU/L	1 - 34	IFCC without PSP

Dr. Priya Pawar M.B.B.S., DNB Pathology Reg. No. : MCI/ 11-40484

Entered By:70000972



नाशिक महानगरपालिका, नाशिक सार्वजनिक आरोग्य विभाग



दुरध्यनी क्रमांक :- ०२५३- २३१७२९२

२२२२५३२

ई-मेल आयडी - nmcmsmd@gmail.com

pub_health@nmc.gov.in

PANCHAVATI DIVISION

सारजनिक आरोग्य विभाग, ३ रा मजला, राजीव गांधी भवन, शरणपूररोड, नाशिक ४२२ ००२

दिनाक :- 11 / /2/२०२०

MEDICAL CERTIFICATE

(For POSITIVE patient)

Date:-// /2/2020

1 Dr. Paiyanka Raiput working CCC Nashik. I have examined

Mr./Mrs/Miss Vishal . GI. Kharnar Age Soyrat MERI CCC NASHIK

On date oc - 12 - 2020 and have POSITIVE to the Covid 19 by

RTPCR (Swab testing)

Sample ID C.H 1348200

SRFID 2748700/54813

LAB NAME Metrofolis, Mumbai Mexicoc

Men'coc दवाखाना मनपा, नाशिक. Medical officer

MERI COVID CARE CENTER

Nashik Municipal Corporation, Nashik.





Nashik Municipal Corporation Rapid Antigen Testing Report

lame	MAYA V KHAIRWAR
Age	27 YRS
Gender	PEMALE
Test Center	MAICHMALAS NAMCA TEST CENTRE Positive Positive NEGATION NEGATIVE
Test Result	Positive
Technician / Sister	
Doctor's Name	
Referred Hospital (If Positive) / Home Isolation	
	1.04
Signature	While
Stamp	
Date	18/12/2020





Nashik Municipal Corporation Rapid Antigen Testing Report

423
ALE
HMALADAD NAKA TEAT CENTRE
Positive Negative

Signature	Whaves	
Stamp		
Date	18/12/2020	




Before

				A pollo HOSPITA	LS
				*HOO! ***	
	BIOCH	HEMISTRY			
		TEILITE TAX		Age 55Yr 10Mth 13Days Gender Fema	le
Patient Name	Mrs. PUSHPA CHAUHAN ANM1.0000188209		SIN \ LRN	2221545 \ 945046	=
UHID	OP		Specimen	Serum	=
W/BNo/RefNo Collected on	24-MAY-2021 03:12:06 PM		Received on	24-MAY-2021 03:50:35 PM	=
The second second second	24-MAY-2021 04:55:00 PM		PatSer No.	ANMOPP981612	=
Reported on	Dr. MAHESH UPARKAR				
Ref Doctor	DI. WARESH OFAKIOK				
UHID			T PYOLOGY	CAL REFERENCE INTERVALS UNITS	
TEST NAME		RESUL	I BIOLOGI	CAL ICE STATE OF THE STATE OF T	
REATININE - SE	RUM / PLASMA	~ ~ ~	Femal	le: 0.6 - 1.1 mg/dL	
CREATININE - SE Modified Jaffe rea	RUM / PLASMAMethod :	7.63 *	1 01110		
	奥杨涛 苏莱·奥				
	是不是是				
	建筑建筑				
	音級強硬化				
	- Charles and the same of the				
The OTP will be s	ent ONLY to registered phone nu	mber of the p	atient as per ho	spital records (
ote patient phone	e may be different from registered p	mone /			
Report Status:Final		+ END OI	REPORT *		
		ENDO	KLFOKI		
				^ /	
	1062110			amehrotra	
OUTOVED BY				Dr Vishal Mehrotra	
CHECKED BY	1060110			Head - Laboratory Services	
0,120,122	1060110				gy
0,120,122	1060110 d On : 26-MAY-2021 01:03:17	РМ		Consultant Haematology & Clinical Pathology	
0,120,122	100000000000000000000000000000000000000	РМ		Consultant Haematology & Clinical Patholo	
0,120,122	100000000000000000000000000000000000000	РМ		Consultant Haematology & Clinical Patholo	









@ www.emedica.in

Before

Medicare Hospital & Research Centre

4/5, Ravindra Nagar, Old Palasia, INDORE-452 018 (M.P.) Ph.:0731-4271600, 2490577, 2492621, 4065616-17-18 • Fax: 4266243 Mobile: 88899-12611, E-mail: medicarehospitalindore@gmail.com

Website: www.medicarehospitalindore.com



BIOCHEMISTRY

BLOOD BANK

Patient Name :

Mrs. UMA SARAF [MRN-210800808]

Age / Gender :

72 Yr / Female

Address:

BEEMA NAGAR, Indore, MADHYA PRADESH

Req. Doctor:

Self

Regn. ID:

Sample No. :

WALKIN.21-22-5396

BIOCHEMISTRY

09-08-2021 11:08 AM Request Date :

BI2442

09-08-2021 11:56 AM Acceptance Date :

BLOOD UREA NITROGEN *[SERUM]

Reporting Date: 09-08-2021 12:40 PM

REFERENCE RANGE

Reporting Status: Finalized

RESULT INVESTIGATIONS 4.9 mg/dL * CREATININE

0.50 - 1.40 mg/dL 20.00 - 40.00 mg/dL 92 mg/dL *

Blood Urea Blood Urea Nitrogen (BUN) 42.99 mg/dL * 5.2 Meq/L * POTASSIUM.

6.00 - 20.00 mg/dL 3.50 - 5.00 Meq/L

END OF REPORT.

KS Raj =

ent.

Dr. Karamchand Rajani D.C.P (London)

Dr. Chandrashekhar (MD,Pathology)



Page 1 of 1











@ www.emedica.in

info.emedica@gmail.com

After

Medicare Hospital & Research Centre

4/5, Ravindra Nagar, Old Palasia, INDORE-452 018 (M.P.) Ph::0731-4271600, 2490577, 2492621, 4065616-17-18 • Fax: 4266243

Mobile: 88899-12611, E-mail: medicarehospitalindore@gmail.com Website: www.medicarehospitalindore.com





· BIOCHEMISTRY

· BLOOD BANK

Patient Name:

Mrs. UMA SARAF [MRN-210800808]

Age / Gender :

72 Yr / Female

Address:

BEEMA NAGAR, Indore, MADHYA PRADESH

Req. Doctor:

SELF

Regn. ID:

WALKIN.21-22-17438

BIOCHEMISTRY

Request Date:

CREATININE

20-10-2021 06:51 AM

Sample No. :

BI6961

Acceptance Date :

20-10-2021 11:20 AM

Reporting Date: 20-10-2021 11:20 AM

Reporting Status: Finalized

INVESTIGATIONS

RESULT 4.3 mg/dL * REFERENCE RANGE 0.50 - 1.40 mg/dL

GLUCOSE (FASTING)

76 mgm%

70.00 - 110.00 mgm%

END OF REPORT.

KS Raj -

Dr. Karamchand Rajani D.C.P. (London)

Dr. Chandrashekhar (MD, Pathology)

Sunder Port

Dr. Pradeep Apte (M.Sc,DSM,Ph.D)



Page 1 of 1















NOBLE HOSPITALS, PUNE South East Pune's 1st NABH Accredited Hospital

153, Magarpatta City Road, Hadapsar, Pune 411 013. Tel.: 020-6628 5000 Fax : 020 - 6628 5199 CIN NO. U85110PN1996PTC103171, Visit Us at : www.noblehospitalspune.com



DEPARTMENT OF CARDIOLOGY

10th FEB, 2021

MRS.BHUTADA SHOBHA.

CORONARY ANGIOGRAPHY REPORT.

LEFT MAIN

: Distal 60 % stenosis.

LEFT ANTERIOR DESCENDING CORONARY : Mid LAD 85-90 % stenosis. diffuse disease poor target.

LEFT CIRCUMFLEX CORONARY ARTERY.

: OM,90 % calcific stenosis. Moderately calcified.

RIGHT CORONARY

: Proximal 60 % stenosis. Mid RCA diffuse disease RPDA 90 % stenosis.

RECOMMENDATION

: Surgical opinion.

MD MRCP (UK) CCT (Cardiology) UK,

Interventional Fellow, New York, USA. Consultant Interventional Cardiologist.







Dr Rahoul D Sawant

MD (Medicine)

CCT, Cardiology (UK), MRCP (UK), FACC (USA) Interventional Fellow, New York, USA

Consultant Interventional Cardiologist

MMC Reg. No.: 85360

Asst. Professor, Cardiology, BVMCH, Pune

2998: Mrs.Bhutada Shobha (60y, Female)

Date: 03-Feb-2021

BP 159 / 119" mmHg Pulse 88 bpm Height 158 cm Weight 64.9 kg Temperature 97.2 F SPO2 98 % BMI 26.00 Kg/m²

Complaints: SOB ON EXERTION CLASS 3, PND

Diagnosis: DM, HTN

Sys.Exam: CVS: ECG: SR. T wave inversion in lateral leads.

AO 20 LA 36 IVS 14 PW 14 LV D42 LV S 28

E/A 1.49 RVSP 32 +10 mm of Hg

Normal size LV with moderate to severely impaired LV function.

Anterior wall, lateral wall, apex and distal steptum are severely hypokinetic.

Rheumatic involvement of mitral valve. AML mildly thickened and PML movement is restricted. moderate to severe MR

Aortic valve is normal

Mild TR. Mild PH.; General: F 203 PP 336

Lipid Profile: TC-173, TRG-115, HDL-19, LDL-130, NonHDL-153, TC/HDL Ratio:9.0, BSL-183mg.;







Dr Rahoul D Sawant

MD (Medicine) CCT, Cardiology (UK), MRCP (UK), FACC (USA) Interventional Fellow, New York, USA Consultant Interventional Cardiologist MMC Reg. No.: 85360 Asst. Professor, Cardiology, BVMCH, Pune

Date: 01-May-2021

2998: Mrs.Bhutada Shobha (61y, Female)

BP 160 / 84° mmHg Pulse 67 bpm Height 160 cm Weight 58.7 kg Temperature 97.2 F SPO2 98 % BMI 22.93 Kg/m²

Complaints: FLUCTUATING BSL, NO CHEST PAIN OR SOB

Diagnosis: DM, HTN, EF 30%, CAG 10.02.20201 TVD FOR SURGICAL OPINION, CREAT 1.28

Sys.Exam: CVS: ECG: SR. ST T changes in lateral leads.

2DECHO:

Ao 20 LA 37 IVS 12 PW 12 LV D 41 LV S 29

Normal LV size and mildly impaired LV systolic function.

EF 45%. EF has improved significantly.


Rheumatic involvement of mitral valve. AML thickened. PML movement restricted.

moderate MR Normal aortic valve.

Mild TR. RVSP 15 + 10 mm of Hg.;











: 87471 Bill No.

: MRS. MONIKA S. DESARDA **Patient Name** : 40 / Female

Age/Sex

: DIAGNOPEIN, BIBWEWADI Center

: SELF Referred By.

PID : 31137

: 15/04/21, 09:01 AM Registration

: 15/04/21, 01:44 PM Reported Status : Final Report

Investigation	Result	Units	Bio.Ref. Interval	

IMMUNOASSAY TFT - THYROID FUNCTION TEST Tri-iodothyronine, Total (T3) 1.173 ng/ml 0.60 - 2.15 Thyroxine, Total (T4) 93.59 ng/ml 52 - 127 Method : (Serum, CLIA) Ultra TSH 3.824 uIU/mL 0.3 - 4.5Method: (Serum, CLIA)

Note:

Reference ranges are age dependent and somewhat method dependent, the above values are approximate expected values. Reference range for Pregnant women are as per American Thyroid Association guidelines. T3 & T4 levels may be abnormal in euthyroid sick syndrome. Physiological rise in Total T3 / T4 levels is seen in pregnancy and in patients on steroid therapy. TSH may be the only parameter abnormal in subclinical hypothyroidism. Many drugs and intercurrent illnesses are associated with alterations in serum TSH. Hence all results should be clinically correlated and if required repeated when patient is clinically stable.

END OF REPORT

Dr. Payal Kalwar M.D. Pathologist







Name: Mr. RAJKUMAR HAEMDEV

MR No: 00001010/PUNE

Ref by:

Date : 16/Apr/2015 Age/Sex : /Male

VISIT REPORT

Complaints: FOR RETINAL EVALUATION & MANAGEMENT USING SPECTS

SINCE THE AGE OF 20YRS -

: DM SINCE 45YRS ON RX, **BORN WITH HERNIA-NOT OPERATED**

On Examination Right Eye Left Eye 6/9 N/6 6/6 N/6 **BCVA**

KH: 41.00/8.22X4 KV: 41.25/8.17X94 K'metry (AutoK) KH: 41.25/8.20X1

KV: 40.75/8.26X91 -0.25/-1.00X13 +0.25/-0.50X70 **Autoref**

IOP 17mmHg 15mmHg Slit Lamp Exam. NS₁ NS₁


MODERATE NPDR MODERATE NPDR **Fundus**

Advice

TAB MACUGOLD ONCE A DAY FOR 3 MONTH EYE DROPS REFRESH TEARS 3 TIMES A DAY A MONTH

		Right	t Eye			Lei	ft Eye	
	Sph	Cyl	Axis	VA	Sph	Cyl	Axis	VA
Dist	-0.50	-0.75	70	6/9	0.00	-1.00	10	6/6
Near Ad	d +2.50			N/6	+2.50	W		N/6

Dr VARDHAMAN Kankariya







After

Dr. Agarwals Eye Hospital

For eyes like new

31/1, Kutika, Pune - Solapur Road, Hadapsar, Pune - 411013 Call: 7338987777

GST No.: 33AAACD2373G1Z2

Patient:

MR. RAJKUMAR HEMDEV

Age/Sex:

79 Years /Male

Contact: MR No.:

9823338118 HDP/4725/20 Doctor :

Dr. MAHESH PATHAK

Facility:

Dr Agarwal's Eye Hospital-HDP

Appt. Dt:

24 Nov'20

Note Dt:

24 Nov'20

OPD SUMMARY

HISTORY

WANT FULL EYE CHECKUP

Known cases of OU CAT SX DONE 1 YEAR BACK, Diabetes since 40 years - on medication, Hypertension since 40 years - ON MEDICATION.

ASSES PRESCRIPTIONS

	R/OD			
	Sph	Cyl	Axis	Vision
Distant	+0.00			6/6-2
Near	+1.75			N6

	Sph	Cyl	Axis	Vision
Distant	0.00		-	6/6P
Near	+1.75			N6

EFRACTION





Doc No - F/TR, Rev: Issue No.: 00:01, Rev: Issue Date: 00: 01.03.12

 Name
 Mr. Deepak Moghe

 Ref. By Dr.
 Mrs. Mardikar MD

 Sample Rec/Coll. Dt
 25/05/2020

 Sample Rec/Coll Time
 7:17:00 AM

Age / Sex 58 Yrs. M / Sample ID No. 4

58 Yrs. M / 2005254

Type of Sample

EDTA Blood, EDTA BLOOD FASTING, Seru

Recd. From Outside Yes

HAEMATOLOGY

Test Name Value Unit Biological Ref. Interval

HbAIC (GLYCOSYLATED HAEMOGLOBIN)

Investigation	Results	Interpretation
HbA1c % :-	11.45 %	Non diabetic: 4.3 - 5.7 % Prediabetic: 5.7-6.3 % Good diabetic control: 6.3 - 7.3 % Fair control: 7.3 - 8.3 %
		Poor control : 8.3 % & above

Method:- Nephelometry & Turbidometry Done on MISPA -i2

Note: - * HbA1c (Or GlycoHb) is made by post synthetic modification of Haemoglobin A at a slow rate directly dependant on blood glucose concentration during the 120 day life span of RBC.HbA1c levels may double or even triple in diabetics, depending on level of hyperglycemia, and correlate well with control of diabetes.

BIOCHEMISTRY

Biochemistry done on VITROS 250 Dry Chemistry Analyzer

Test Name	Value	Unit	Biological Ref. Interval
BLOOD SUGAR FASTING	173	mg/dl	74 - 106
BLOOD SUGAR FASTING	160	mg/dl	74 - 106
	IMMUNO	LOGY	
Test Name	Value	Unit	Biological Ref. Interval

Contd...2



Doc No - F/TR, Rev: Issue No.: 00:01, Rev: Issue Date::00: 01.03.12

Name	Mr. Deepak Moghe		Age / Sex	м /
Ref. By Dr.	SELF		Sample ID No.	19 20061419
Sample Rec/0	Coll. Dt 14/06/2020			
Sample Rec/0	Coll Time 12:50:07		Type of Sample	EDTA Blood, EDTA BLOOD RANDAM,
LIVER FUNCT	TION TEST (LFT)		Recd. Fr	om Outside Yes
Test Name		Value	Unit	Biological Ref. Interval
VITROS 250 Dry	Chem. Analyzer			
TOTAL PROTE	IN	8.6	gm/dl	6.3 - 8.2
ALBUMIN		4.70	gm/dl	3.5 - 5.0
GLOBULIN*		3.90	gm/dl	2.0 - 4.0
SGOT		26	U/L	17 - 59
SGPT		34	U/L	21 - 72
ALKALINE PHO	DSPHATASE	83	U/L	38 - 126
BILIRUBIN TO	ΓAL	0.7	mg/dl	0.2 - 1.3

mg/dl

mg/dl

0.0 - 0.30

0.1 - 1.1

HAEMATOLOGY

HbAIC (GLYCOSYLATED HAEMOGLOBIN)

DIRECT BILIRUBIN (BC)

INDIRECT BILIRUBIN (BU)

LFT INTERPRET

1	Investigation	Results	Interpretation
%	HbAlc % :-	9.0 %	Non diabetic: 4.3 - 5.7 % Prediabetic: 5.7-6.3 % Good diabetic control: 6.3 - 7.3
70			Fair control : 7.3 - 8.3 % Poor control : 8.3 % & above

0.4

0.30

Method: HPLC (Done By HB-VARIO from ERBA)

Contd...4





Dr. Pravin Gadkari M.B.B.S., MD (Path) Director NRPL & Ayush Blood Bank

Shop No. 26, Upper Ground Floor, Madhu Madhav Towers, Laxmi Bhavan Square, Dharampeth, Nagpur - 10
Branch: C/o. Dr. Dhondse Hospital, Radke Layout, Balaji Nagar, Hingna Road, MIDC, Nagpur.
 Tel. No.: 8237067621, 8087045795 | E-mail: gadkaripravin@yahoo.co.in

Name :-

Dr. Inder Gundecha

Age/Sex :- Male

Ref. By :-

Self

Date :- 20/7/19

SAMPLE NUMBER :- 35

357 (Pre-Trail)

REPORT ON BIOCHEMISTRY

INVESTIGATION	RESULTS	NORMAL RANGE
Blood Glucose Random	87 mg/dl.	Less than 160 mg/dl.
LIPID PROFILI		
Cholesterol Total	360 mg/dl.	130-250 mg/dl.
HDL	48 mg/dl.	30-70 mg/dl.
L.DL.	288 mg/dl.	Upto 155 mg/dl.
VLDL	27 mg/dl.	Upto 35 mg/dl.
Şr. Triglycerides	135 mg/dl.	Upto 170 mg/dl.
Chol./HDL Ratio	7.5	Upto 4.5

^{*} Done on ion selective Analyzer,

REPORT ON HARMONE ESTIMATION

INVESTIGATION RESULT NORML RANGE

Insulin

16.1 uU/mL

0 -- 24 uU/mL ·

Dr. Pravis Cadkari MD (Path)

Timing: 8.00 A.M. to 9.00 P.M.

Sunday: 8.00 A.M. to 1.00 P.M.

Timing: MIDC Morning 9,00 A.M. to 2,30 P.M. Eve.: 6.30 P.M. to 8.15 P.M. Sunday: 9,00 A.M. to 12,00 P.M.





GADKARI PATHOLOGY

Dr. Pravin Gadkari M.B.B.S., MD (Path) Director NRPL & Ayush Blood Bank

Shop No. 26, Upper Ground Floor, Madhu Madhav Towers, Laxmi Bhavan Square, Dharampeth, Nagpur - 10
 Branch: C/o. Dr. Dhondse Hospital, Radke Layout, Balaji Nagar, Hingna Road, MIDC, Nagpur.
 Tel. No.: 8237067621, 8087045795 | E-mail: gadkaripravin@yahoo.co.in

Name :-

Dr. Inder Gundecha

Age/Sex :- Male

Ref. By :-

Self

Date :- 20/7/19

SAMPLE NUMBER :- 361 (Post - Trail)

REPORT ON BIOCHEMISTRY

INVESTIGATION	RESULTS	NORMAL RANGE
Blood Glucose Random LIPID PROFILE	74 mg/dl.	Less than 160 mg/dl.
Cholesterol Total	195 mg/dl.	130-250 mg/dl.
HDL.	52 mg/dl.	30-70 mg/dl.
LDL	125 mg/dl.	Upto 155 mg/dl.
VLDL	18 mg/dl.	Upto 35 mg/dl.
Sr. Triglycerides	92 mg/dl.	Upto 170 mg/dl.
Chol./HDL Ratio	3.75	Upto 4.5

⁹ Done on ion selective Analyzer.

REPORT ON HARMONE ESTIMATION

INVESTIGATION	RESULT .	NORML RANGE
Insulin	7.5 uU/mL	0 24 uU/mL

Dr. Pravin Gadkari MD (Path)

Timing: 8.00 A.M. to 9.00 P.M.

Sunday: 8.00 A.M. to 1.00 P.M.

Timing: MIDC Morning 9.00 A.M. to 2.30 P.M. Eve.: 6.30 P.M. to 8.15 P.M.





Name :-

GADKARI PATHOLOGY ELISA & MICRO BIOLOGY LABORATORY

Dr. Pravin Gadkari M.B.B.S., MD (Path) Director NRPL & Ayush Blood Bank

 Shop No. 26, Upper Ground Floor, Madhu Madhav Towers, Laxmi Bhavan Square, Dharampeth, Nagpur - 10 Branch: C/o. Dr. Dhondse Hospital, Radke Layout, Balaji Nagar, Hingna Road, MIDC, Nagpur. Tel. No.: 8237067621, 8087045795 | E-mail: gadkaripravin@yahoo.co.in

Mrs. Amisha Gundecha

Age/Sex :- Female

Self Ref. By :-

Date :- 20/7/19

358 (Pre - Trail) SAMPLE NUMBER :-

REPORT ON BIOCHEMISTRY

INVESTIGATION	RESULTS	NORMAL RANGE
Blood Glucose Random	101 mg/dl.	Less than 160 mg/dl.
LIPID PROFILE		
Cholesterol Total	281 mg/dl.	130-250 mg/dl.
HDL	40 mg/dl.	30-70 mg/dl.
LDL	196 mg/dl.	Upto 155 mg/dl.
VLDL	45 mg/dl.	Upto 35 mg/dl.
Sr. Triglycerides	223 mg/dl.	Upto 170 mg/dl.
Chol./HDL Ratio	7.0	Upto 4.5

Oone on ion selective Analyzer. .

REPORT ON HARMONE ESTIMATION

INVESTIGATION	RESULT	NORML RANGE
Insulin	43.3 uU/mL	0 24 uU/mL

Dr. Pravin Gadkari MD (Path)

Timing: 8.00 A.M. to 9.00 P.M.

Sunday: 8.00 A.M. to 1.00 P.M.

Timing: MIDC Morning 9.00 A.M. to 2.30 P.M. Eve.: 6.30 P.M. to 8.15 P.M. Sunday: 9.00 A.M. to 12.00 P.M.





Dr. Pravin Gadkari M.B.B.S., MD (Path) Director NRPL & Ayush Blood Bank

Shop No. 26, Upper Ground Floor, Madhu Madhav Towers, Laxmi Bhavan Square, Dharampeth, Nagpur - 10
 Branch: C/o. Dr. Dhondse Hospital, Radke Layout, Balaji Nagar, Hingna Road, MIDC, Nagpur.
 Tel. No.: 8237067621, 8087045795 | E-mail: gadkaripravin@yahoo.co.in

Name :- Mrs. Amisha Gundecha

Age/Sex :- Female

Ref. By :-

Self

Date :- 20/7/19

SAMPLE NUMBER :- 360 (Post - Trail)

REPORT ON BIOCHEMISTRY

INVESTIGATION	RESULTS	NORMAL RANGE
Blood Glucose Random	91 mg/dl.	Less than 160 mg/dl
LIPID PROFILE		
Cholesterol Total	234 mg/dl.	130-250 mg/dl.
HDL .	48 mg/dl.	30-70 mg/dl.
LDL	156 mg/dl.	Upto 155 mg/dl.
VLDL	30 mg/dl.	Upto 35 mg/dl.
Sr. Triglycerides	151 mg/dl.	Upto 170 mg/dl.
Chol./HDL Ratio	4.87	Upto 4.5

^{*} Done on ion selective Analyzer.

REPORT ON HARMONE ESTIMATION

INVESTIGATION		RESULT		NORML RANGE
Insulin	-	22.8	uU/mL	0 24 uU/mL

Dr. .Pravin Gadkari MD (Path)

Timing: 8.00 A.M. to 9.00 P.M.

Sunday: 8.00 A.M. to 1.00 P.M.

Timing: MIDC Morning 9.00 A.M. to 2.30 P.M. Eve.: 6.30 P.M. to 8.15 P.M. Sunday: 9.00 A.M. to 12.00 P.M.





Dr. Pravin Gadkari M.B.B.S., MD (Path) Director NRPL & Ayush Blood Bank

Shop No. 26, Upper Ground Floor, Madhu Madhav Towers, Laxmi Bhavan Square, Dharampeth, Nagpur - 10
 Branch: C/o. Dr. Dhondse Hospital, Radke Layout, Balaji Nagar, Hingna Road, MIDC, Nagpur.
 Tel. No.: 8237067621, 8087045795 | E-mail: gadkaripravin@yahoo.co.in

Name :-

Mr. Vinay Battalwar

Age/Sex :- Male

Ref. By :-

Self

Date :- 20/7/19

SAMPLE NUMBER :- 352 (Pre - Trail)

REPORT ON BIOCHEMISTRY

INVESTIGATION

RESULTS

NORMAL RANGE

Blood Glucose Random

99 mg/dl.

Less than 160 mg/dl.

REPORT ON HARMONE ESTIMATION

INVESTIGATION

RESULT

NORML RANGE

Insulin

9.0 uU/mL

0 -- 24 uU/mL

Dr. .Pravin Gadkari - MD (Path)

Timing: 8.00 A.M. to 9.00 P.M.

Sunday: 8.00 A.M. to 1.00 P.M.





Dr. Pravin Gadkari M.B.B.S., MD (Path) Director NRPL & Ayush Blood Bank

 Shop Ño. 26, Upper Ground Floor, Madhu Madhav Towers, Laxmi Bhavan Square, Dharampeth, Nagpur - 10 Branch: C/o. Dr. Dhondse Hospital, Radke Layout, Balaji Nagar, Hingna Road, MIDC, Nagpur. • Tel. No.: 8237067621, 8087045795 | E-mail: gadkaripravin@yahoo.co.in

Name :- Mr. Vinay Battalwar

Age/Sex :- Male

Ref. By :- Self

Date :- 20/7/19

SAMPLE NUMBER :- 354 (Post - Trail)

REPORT ON BIOCHEMISTRY

INVESTIGATION

RESULTS

NORMAL RANGE

Blood Glucose Random

80 mg/dl.

Less than 160 mg/dl.

REPORT ON HARMONE ESTIMATION

INVESTIGATION

RESULT

NORML RANGE

Insulin

8.6 uU/mL

0 -- 24 uU/mL

Dr. Pravio Gadkari - MD (Path)

Timing: 8.00 A.M. to 9.00 P.M.

Sunday: 8.00 A.M. to 1.00 P.M.

Timing: MIDC Morning 9.00 A.M. to 2.30 P.M. Eve.: 6.30 P.M. to 8.15 P.M. Sunday: 9.00 A.M. to 12.00 P.M.





Dr. Pravin Gadkari M.B.B.S., MD (Path) Director NRPL & Ayush Blood Bank

• Shop No. 26, Upper Ground Floor, Madhu Madhav Towers, Laxmi Bhavan Square, Dharampeth, Nagpur - 10 Branch: C/o. Dr. Dhondse Hospital, Radke Layout, Balaji Nagar, Hingna Road, MIDC, Nagpur. • Tel. No.: 8237067621, 8087045795 | E-mail: gadkaripravin@yahoo.co.in

Name :-

Mr. Gautam Gundecha

· Age/Sex :- Male

Ref. By :-

Self

Date :- 20/7/19

SAMPLE NUMBER :-

353 (Pre-Trail)

REPORT ON BIOCHEMISTRY

Post-Trail

INVESTIGATION	RESULTS	NORMAL RANGE
Blood Glucose Random	123 mg/dl.	Less than 160 mg/dl.
LIPID PROFILE	74	
Cholesterol Total	157 mg/dl.	130-250 mg/dl.
HDL	48 mg/dl.	30-70 mg/dl.
LDL	89 mg/dl.	Upto 155 mg/dl.
VLDL	20 mg/dl.	Upto 35 mg/dl.
Sr. Triglycerides	100 mg/dl.	Upto 170 mg/dl.
Chol./HDL Ratio	3.27	Upto 4.5

Done on ion selective Analyzer,

REPORT ON HARMONE ESTIMATION

NORML RANGE RESULT INVESTIGATION

0 -- 24 uU/mL 22.3 uU/mL Insulin (Pre-Trail)

Dr. Pravis Gadkari MD (Path).

Timing: 8.00 A.M. to 9.00 P.M.

Sunday: 8.00 A.M. to 1.00 P.M.

Timing: MIDC Morning 9.00 A.M. to 2.30 P.M. Eve.: 6.30 P.M. to 8.15 P.M. Sunday: 9.00 A.M. to 12.00 P.M.





Dr. Pravin Gadkari M.B.B.S., MD (Path) Director NRPL & Ayush Blood Bank

Shop No. 26, Upper Ground Floor, Madhu Madhav Towers, Laxmi Bhavan Square, Dharampeth, Nagpur - 10
 Branch: C/o. Dr. Dhondse Hospital, Radke Layout, Balaji Nagar, Hingna Road, MIDC, Nagpur.
 Tel. No.: 8237067621, 8087045795 | E-mail: gadkaripravin@yahoo.co.in

Name :- Mr. Gautam Gundecha

Age/Sex :- Male

. · Ref. By :- Self

Date :- 20/7/19

SAMPLE NUMBER :- 356 (Post - Trail)

REPORT ON BIOCHEMISTRY

INVESTIGATION	RESULTS	NORMAL RANGE
Blood Glucose Random	101 mg/dl.	Less than 160 mg/dl.
LIPID PROFILE		
Cholesterol Total	183 mg/dl.	130-250 mg/dl.
HDL	49 mg/dl.	30-70 mg/dl.
LDL	. 102 ing/dl.	Upto 155 mg/dl.
·VLDL	32 mg/dl.	Upto 35 mg/dl.
Sr. Triglycerides	158 mg/dl.	Upto 170 mg/dl.
Chol./HDL Ratio	3.73	Upto 4.5

^{*} Done on io slective Analyzer.

REPORT ON HARMONE ESTIMATION

INVESTIGATION			RES	SULT	NORML RANGE	
	Insulin	9	11.5	uU/mL	0 24 uU/mL	

Dr. Pravit Gadkari MD (Path)

Timing: 8.00 A.M. to 9.00 P.M.

Sunday: 8.00 A.M. to 1.00 P.M.

Timing: MIDC Morning 9.00 A.M. to 2.30 P.M. Eve.: 6.30 P.M. to 8.15 P.M. Sunday: 9.00 A.M. to 12.00 P.M.





Dr. Pravin Gadkari M.B.B.S. MD (Path) Director NRPL & Ayush Blood Bank

• Shop No. 26, Upper Ground Floor, Madhu Madhav Towers, Laxmi Bhavan Square, Dharampeth, Nagpur - 10 Branch : C/o. Dr. Dhondse Hospital, Radke Layout, Balaji Nagar, Hingna Road, MIDC, Nagpur.

• Tel. No. : 8237067621, 8087045795 | E-mail : gadkaripravin@yahoo.co.in

Name:-

Mr. Deepak Moghe

Age/Sex :- Male

Ref. By :-

Self

SAMPLE NUMBER :- 348

Date :- 20/7/19

REPORT ON BIOCHEMISTRY Pre - Trail

INVESTIGATION	RES	ULTS	NORMAL RANGE
Blood Glucose Random	178	mg/dl.	Less than 160 mg/dl.
LIPID PROFILE			
Cholesterol Total	183	mg/dl.	130-250 mg/dl.
HDL	41	mg/dl.	30-70 mg/dl.
LDL	124	mg/dl.	Upto 155 mg/dl.
VLDL	18	mg/dl.	Upto 35 mg/dl.
Sr. Triglycerides	90	mg/dl.	Upto 170 mg/dl.
Chol./HDL Ratio	4.4		Upto 4.5

^{*} Done on ion steetive \nalyzer.

REPORT ON HARMONE ESTIMATION

INVESTIGATION

RESULT

NORML RANGE

Insulin (Pre-Trail)

32.9 uU/mL

0 -- 24 uU/mL

Dr. .Pravin Gadkari MD (Path)

Timing: 8.00 A.M. to 9.00 P.M.

Sunday: 8.00 A.M. to 1.00 P.M.

Timing: MIDC Morning 9.00 A.M. to 2.30 P.M. Eve.: 6.30 P.M. to 8.15 P.M. Sunday: 9.00 A.M. to 12.00 P.M.





GADKARI PATHOLOGY

Dr. Pravin Gadkari M.B.B.S., MD (Path) Director NRPL & Ayush Blood Bank

Shop No. 26, Upper Ground Floor, Madhu Madhav Towers, Laxmi Bhavan Square, Dharampeth, Nagpur - 10
 Branch: C/o. Dr. Dhondse Hospital, Radke Layout, Balaji Nagar, Hingna Road, MIDC, Nagpur.
 Tel. No.: 8237067621, 8087045795 | E-mail: gadkaripravin@yahoo.co.in

Name :-

Mr. Deepak Moghe

Age/Sex :- Male

Ref. By :-

. Self

Date :- 20/7/19

SAMPLE NUMBER :- 348 (Post - Trail)

REPORT ON BIOCHEMISTRY Post-Trail

INVESTIGATION	DECLU DO		OTT MO	
INVESTIGATION	RESULTS			NORMAL RANGE
Blood Glucose Random		123	mg/dl.	Less than 160 mg/dl
LIPID PROFILE				
Cholesterol Total	1	195	mg/dl.	130-250 mg/dl.
-HDL		43	mg/dl.	30-70 mg/dl.
LDL		<u>130</u>	mg/dl.	Upto 155 mg/dl.
VLDL		<u>22</u>	mg/dl.	Upto 35 mg/dl.
Sr. Triglycerides		110	mg/dl.	Upto 170 mg/dl.
Chol./HDL Ratio		4.5		Upto 4.5

* Done on io: -:lective Analyzer.

REPORT ON HARMONE ESTIMATION

Insulin (Post-Trail) RESULT NORML RANGE

17 uU/mL 0 -- 24 uU/mL

1 trans

Dr. .Pravir Jadkari MD (Path)

Timing: 8.00 A.M. to 9.00 P.M.

Sunday: 8.00 A.M. to 1.00 P.M.

Timing : MIDC Morning 9.00 A.M. to 2.30 P.M. Eve. : 6.30 P.M. to 8.15 P.M. Sunday : 9.00 A.M. to 12.00 P.M.





GADKARI PATHOLOGY

Dr. Pravin Gadkari M.B.B.S., MD (Path) Director NRPL & Ayush Blood Bank

Shop No. 26, Upper Ground Floor, Madhu Madhav Towers, Laxmi Bhavan Square, Dharampeth, Nagpur - 10
 Branch : C/o. Dr. Dhondse Hospital, Radke Layout, Balaji Nagar, Hingna Road, MIDC, Nagpur.
 Tel. No. : 8237067621, 8087045795 | E-mail : gadkaripravin@yahoo.co.in

Name :-

Mrs. Vaidehi Tannirwar

Age/Sex :- Female

Ref. By :-

Self

Date :- 20/7/19

SAMPLE NUMBER :- 346

REPORT ON BIOCHEMISTRY

INVESTIGATION

RESULTS

NORMAL RANGE

Blood Glucose Random (Pre- Trail)

152 mg/dl.

Less than 160 mg/dl.

REPORT ON HARMONE ESTIMATION

INVESTIGATION

RESULT

NORML RANGE

Insulin (Pre- Trail)

26.7 uU/mL - 0 -- 24 uU/mL

Dr. .Pravin Gadkari MD (Path)

Timing: 8.00 A.M. to 9.00 P.M.

Sunday: 8.00 A.M. to 1.00 P.M.





Dr. Pravin Gadkari M.B.B.S., MD (Path) Director NRPL & Ayush Blood Bank

• Shop No. 26, Upper Ground Floor, Madhu Madhav Towers, Laxmi Bhavan Square, Dharampeth, Nagpur - 10 Branch : C/o. Dr. Dhondse Hospital, Radke Layout, Balaji Nagar, Hingna Road, MIDC, Nagpur. • Tel. No. : 8237067621, 8087045795 | E-mail : gadkaripravin@yahoo.co.in

Name :-

Mrs. Vaidehi Tannirwar

Age/Sex :- Female

Ref. By :-

Self 349 (Post - Trail) SAMPLE NUMBER :-

Date :- 20/7/19

REPORT ON BIOCHEMISTRY

INVESTIGATION

RESULTS

NORMAL RANGE

Blood Glucose Random (Post-Trail) 107 mg/dl.

Less than 160 mg/dl.

REPORT ON HARMONE ESTIMATION

INVESTIGATION

RESULT

NORML RANGE

Insulin (Post - Trail)

14.7 uU/mL

0 -- 24 uU/mL

Dr. .Pravin Gadkari MD (Path)

Timing: 8.00 A.M. to 9.00 P.M.

Sunday: 8.00 A.M. to 1.00 P.M.

Timing: MIDC Morning 9.00 A.M. to 2.30 P.M. Eve, : 6.30 P.M. to 8.15 P.M. Sunday: 9.00 A.M. to 12.00 P.M.





Dr. Pravin Gadkari M.B.B.S., MD (Path) Director NRPL & Ayush Blood Bank

Shop No. 26, Upper Ground Floor, Madhu Madhav Towers, Laxmi Bhavan Square, Dharampeth, Nagpur - 10
 Branch : C/o. Dr. Dhondse Hospital, Radke Layout, Balaji Nagar, Hingna Road, MIDC, Nagpur.
 Tel. No. : 8237067621, 8087045795 | E-mail : gadkaripravin@yahoo.co.in

Name :-

Mrs. Nandini Paithankar

Age/Sex :- Female

Ref. By :-

Self

Date :- 21/7/19

SAMPLE NUMBER :-

371 (Pre-Trial)

REPORT ON BIOCHEMISTRY

INVESTIGATION

RESULTS

NORMAL RANGE

Blood Glucose Random

227 mg/dl.

Less than 160 mg/dl.

REPORT ON HARMONE ESTIMATION

INVESTIGATION

RESULT

NORML RANGE

Insulin

47.8 uU/mL . 0 -- 24 uU/mL

Dr. .Pravin Gadkari MD (Path)

Timing: 8.00 A.M. to 9.00 P.M.

Sunday: 8.00 A.M. to 1.00 P.M.

Timing: MIDC Morning 9.00 A.M. to 2.30 P.M. Eve.: 6.30 P.M. to 8,15 P.M. Sunday: 9.00 A.M. to 12.00 P.M.





Dr. Pravin Gadkari M.B.B.S., MD (Path) Director NRPL & Ayush Blood Bank

• Shop No. 26, Upper Ground Floor, Madhu Madhav Towers, Laxmi Bhavan Square, Dharampeth, Nagpur - 10 Branch : C/o. Dr. Dhondse Hospital, Radke Layout, Balaji Nagar, Hingna Road, MIDC, Nagpur.

• Tel. No. : 8237067621, 8087045795, E-mail : gadkaripravin@yahoo.co.in

Name :-

Mrs. Nandini Paithankar

Age/Sex :- Female

Ref. By:- . Self

Date :- 21/7/19

SAMPLE NUMBER :- 374 (Post - Trial)

REPORT ON BIOCHEMISTRY

INVESTIGATION

RESULTS

NORMAL RANGE

Blood Glucose Random

173 mg/dl.

Less than 160 mg/dl.

REPORT ON HARMONE ESTIMATION

INVESTIGATION .

RESULT

NORML RANGE

Insulin

24.4 uU/mL

0 - 24 uU/mL

Dr. .Pravin Gadkari MD (Path)

Timing: 8.00 A.M. to 9.00 P.M.

Sunday: 8.00 A.M. to 1.00 P.M.

Timing: MIDC Morning 9.00 A.M. to 2.30 P.M. Eve.: 6.30 P.M. to 8.15 P.M. Sunday: 9.00 A.M. to 12.00 P.M:





GADKARI PATHOLOGY

Dr. Pravin Gadkari M.B.B.S., MD (Path) Director NRPL & Ayush Blood Bank

Shop No. 26, Upper Ground Floor, Madhu Madhav Towers, Laxmi Bhavan Square, Dharampeth, Nagpur - 10
 Branch: C/o. Dr. Dhondse Hospital, Radke Layout, Balaji Nagar, Hingna Road, MIDC, Nagpur.
 Tel. No.: 8237067621, 8087045795 | E-mail: gadkaripravin@yahoo.co.in

Name :-

Mrs. Rachana Jain

Age/Sex :- Female

Ref. By :-

Self

Date :- 21/7/19

SAMPLE NUMBER :- 370

370 (Pre - Trial)

REPORT ON BIOCHEMISTRY

INVESTIGATION

RESULTS

NORMAL RANGE

Blood Glucose Random

167 mg/dl.

Less than 160 mg/dl.

REPORT ON HARMONE ESTIMATION

INVESTIGATION

RESULT

NORML RANGE

Insulin

20.7 uU/mL

0 -- 24 uU/mL

Dr. .Pravin Gadkari MD (Path)

Timing: 8.00 A.M. to 9.00 P.M.

Sunday: 8.00 A.M. to 1.00 P.M.

Timing: MIDC Morning 9.00 A.M. to 2.30 P.M. Eve.: 6.30 P.M. to 8.15 P.M. Sunday: 9.00 A.M. to 12.00 P.M.





Dr. Pravin Gadkari M.B.B.S., MD (Path) Director NRPL & Ayush Blood Bank

Shop No. 26, Upper Ground Floor, Madhu Madhav Towers, Laxmi Bhavan Square, Dharampeth, Nagpur - 10
Branch: C/o. Dr. Dhondse Hospital, Radke Layout, Balaji Nagar, Hingna Road, MIDC, Nagpur.
 Tel. No.: 8237067621, 8087045795 | E-mail: gadkaripravin@yahoo.co.in

Name :-

Mrs. Rachana Jain

. Age/Sex :- Female

Ref. By :-

Self

Date :- 21/7/19

SAMPLE NUMBER :-

373 (Post - Trial)

REPORT ON BIOCHEMISTRY

INVESTIGATION

RESULTS

NORMAL RANGE

Blood Glucose Random

146 mg/dl.

Less than 160 mg/dl.

REPORT ON HARMONE ESTIMATION

INVESTIGATION -

RESULT

NORML RANGE

Insulin

18.6 uU/mL

0 -- 24 uU/mL

Dr. .Pravin Gadkari MD (Path)

Timing: 8.00 A.M. to 9.00 P.M.

Sunday: 8.00 A.M. to 1.00 P.M.

Timing: MIDC Morning 9.00 A.M. to 2.30 P.M. Eve.: 6.30 P.M. to 8.15 P.M. Sunday: 9.00 A.M. to 12.00 P.M.





Dr. Pravin Gadkari M.B.B.S., MD (Path) Director NRPL & Ayush Blood Bank

Shop No. 26, Upper Ground Floor, Madhu Madhav Towers, Laxmi Bhavan Square, Dharampeth, Nagpur - 10
 Branch: C/o. Dr. Dhondse Hospital, Radke Layout, Balaji Nagar, Hingna Road, MIDC, Nagpur.

 Tel. No.: 8237067621, 8087045795 | E-mail: gadkaripravin@yahoo.co.in

Name:-

Mr. Suresh Daware

Age/Sex :- Male

Ref. By :-

Self

Date :- 21/7/19

SAMPLE NUMBER :-

369 (Pre - Trial)

REPORT ON BIOCHEMISTRY

INVESTIGATION

RESULTS

NORMAL RANGE

Blood Glucose Random

304 mg/dl.

Less than 160 mg/dl.

REPORT ON HARMONE ESTIMATION

INVESTIGATION

RESULT

NORML RANGE

Insulin

24.5 uU/mL

0 -- 24 uU/mL

Dr. .Pravin Gadkari MD (Path)

Timing: 8.00 A.M. to 9.00 P.M.

Sunday: 8.00 A.M. to 1.00 P.M.

Timing : MIDC Morning 9.00 A.M. to 2.30 P.M. Evc. : 6.30 P.M. to 8.15 P.M.





GADKARI PATHOLOGY ELISA & MICRO BIOLOGY LABORATORY

Dr. Pravin Gadkari M.B.B.S., MD (Path) Director NRPL & Ayush Blood Bank

 Shop No. 26, Upper Ground Floor, Madhu Madhav Towers, Laxmi Bhavan Square, Dharampeth, Nagpur - 10 Branch : C/o. Dr. Dhondse Hospital, Radke Layout, Balaji Nagar, Hingna Road, MIDC, Nagpur. • Tel. No.: 8237067621, 8087045795 | E-mail: gadkaripravin@yahoo.co.in

Name :-

Mr. Suresh Daware

Age/Sex :- Male

Ref. By :-

Self

Date :- 21/7/19

SAMPLE NUMBER :- 372 (Post - Trial)

REPORT ON BIOCHEMISTRY

INVESTIGATION

RESULTS

NORMAL RANGE

Blood Glucose Random

· 252 mg/dl.

Less than 160 mg/dl.

REPORT ON HARMONE ESTIMATION

INVESTIGATION

RESULT

NORML RANGE

Insulin

19.7 uU/mL

0 -- 24 uU/mL

Dr. .Pravin Gadkari MD (Path)

Timing: 8.00 A.M. to 9.00 P.M.

Sunday: 8.00 A.M. to 1.00 P.M.

Timing: MIDC Morning 9.00 A.M. to 2.30 P.M. Eve.: 6.30 P.M. to 8.15 P.M. Sunday: 9.00 A.M. to 12.00 P.M.

Scanned by CamScanner



Nagpur Reference Pathology Laboratory & Research Institute Pvt. Ltd., Nagpur.

ISO 9001-2008 Certified

Reach Us:

NRPL House, Plot No. 22/1, Khare Marg, Dhantoli, Nagpur - 440 012 Tel: 0712- 2455156, 2448769

24/7 & 365 Days Support Service:

Tel.: 8237067627, 8087067628, 7276075693, 8087055164 E-mail: nrplnagpur12@gmail.com

Name

SELF

Ref. By Dr. Sample Rec/Coll. Dt 20/07/2019 Sample Rec/Coll Time 11:41:51 PM Age / Sex Sample ID No.

Type of Sample

EDTA Blood, EDTA BLOOD RAND

Recd. From Outside Yes

HAEMATOLOGY

Test Name	Value	Unit	Biological Ref. Interval
HAEMOGRAM (SYSMEX XP 100)			
HAEMOGLOBIN (Hb)*	11.2	gm/dl	13.0 - 17.0
P.C.V / HAEMATOCRIT*	36.5	%	35 - 52
MCV*	82.4	11.	76 - 96
M C H*	25.3	Picogram	27 - 34
MCHC*	30.7	gm/dl	31 - 36
R B C COUNT'	4.43	Millions/cmm	4.5 - 5.5
RDW*	13.1	%	10.8 - 14.9
PLATELET COUNT*	2.44	Lakh/cmm	1.4 - 4.4
TOTAL LEUCOCYTE COUNT (TLC)*	6,900	/cumm	4000 - 11000
DIFFERENTIAL LEUCOCYTE CO	UNT (DLC)		
NEUTROPHIL	60	%	45 - 65
LYMPHOCYTE	35	%	25 - 45
EOSINOPHIL	03	%	0 - 06
MONOCYTE	02	%	2-8
	**** End Of Repo	ort ****	

MBBS, MD Pathologist/Microbiologist

Dr.Lubna Seemi MBBS,DPB Pathologist/Microbiologist Dr. Ashutosh Deshmukh MBBS,MD Pathologist/Microbiologist

Reported by: vuy

Checked by Dr. Sanjay Madankar M.D. (Path) * - Test not in NABL Preview

Dr. Avinash Sapre M.D., (Path) DCP (UK) M.D. (Path)

Dr. Avinash Deshmukh Dr. Pravin Gadkari Dr. Rajiv Marawar M.D. (Path)

M.D. (Path)

Cont

Dr. Director
Dr. Dinkar Kumbhalkar
M.D. (Path)

Dr. Ajay A. Lanjewar
M.D. (Path)
Dr. Kailash Agrawal
Dr. Milind Dharmadhikari
Dr. Raj Angnani
M.D. (Bombay) D.P.B.
M.D. (Path)
Dr. Raj Angnani

Additional Director



Nagpur Reference Pathology Laboratory & Research Institute Pvt. Ltd., Nagpur.



Reach Us:

NRPL House, Plot No. 22/1, Khare Marg, Dhantoli, Nagpur - 440 012 Tel: 0712- 2455156, 2448769

24/7 & 365 Days Support Service:

Tel.: 8237067627, 8087067628, 7276075693, 8087055164 E-mail: nrplnagpur12@gmail.com

Name

Ref. By Dr.

SELF

Sample Rec/Coll. Dt 21/07/2019 Sample Rec/Coll Time 1:45:44 AM Age / Sex

Age / Sex Sample ID No. –

M / 1907214

Type of Cample

EDTA Blood, EDTA BLOOD RA

Nacd. From Outside Yes

HAEMATOLOGY

Test Name	Value	Unit	Biological Ref. Interval
HAEMOGRAM (SYSMEX XP 100)			
HAEMOGLOBIN (Hb)	11.3	gm/dl	13.0 - 17.0
P.C.V / HAEMATOCRIT*	36.1	%	35 - 52
MCV.	81.5	n.	76 - 96
MCH.	25.5	Picogram	27 - 34
MCHC.	31.3	gm/dl	31 - 36
RBC COUNT	4.43	Millions/cmm	4.5 - 5.5
RDW*	13.0	%	10.8 - 14.9
PLATELET COUNT*	2.45	Lakt/cmm	1.4 - 4.4
TOTAL LEUCOCYTE COUNT (TLC)*	7,600	/cumm	4000 - 11000
DIFFERENTIAL LEUCOCYTE COU	NT (DLC)		
NEUTROPHIL	56	%	45 - 65
LYMPHOCYTE	40	%	25 - 45
EOSINOPHIL	02	%	0 - 06
MONOCYTE	02	%	2-8
	**** End Of Rep	port ****	

Dr. Cawal MBBS, MD. Pathologist/Microbiologist

Dr.Lubna Scemi MBBS,DPB Pathologist/Microbiologist

Dr. Ashutosh Deshmukh MBBS,MD Pathologist/Microbiologist

Reported by: Vuy

Checked by Dr. Sanjay Madankar
M.D. (Path)

Dr. Avinash Sapre
M.D. (Path)

Dr. Avinash Deshmukh
Dr. Pravin Gadkari
M.D. (Path)

Dr. Avinash Deshmukh
Dr. Pravin Gadkari
M.D. (Path)

Dr. Avinash Deshmukh
Dr. Pravin Gadkari
M.D. (Path)

Director
Dr. Dinkar Kumbhalkar
M.D. (Path)

Contd

Additional Director Dr. Ajay A. Lanjewar M.D. (Path) Dr. Kailash Agrawal Dr. Milind Dharmadhikari Dr. Raj Angnani M.D. (Path) M.D. (Bombay) D.P.B. M.D. (Path) M.D.



Nagpur Reference Pathology Laboratory of & Research Institute Pvt. Ltd., Nagpur.

ISO 9001-2008 Certified



Reach Us :

NRPL House, Plot No. 22/1, Khare Marg, Dhantoli, Nagpur - 440 012 Tel : 0712- 2455156, 2448769

24/7 & 365 Days Support Service:

Tel.: 8237067627, 8087067628, 727607 5693, 8087055164 E-mail: nrplnagpur12@gmail.com

Ref. By Dr.

SELF

Sample Rec/Coll. Dt 20/07/2019 Sample Rec/Coll Time 11:41:51 PM Age / Sex Sample ID No.

216

Type of Sample

EDTA Blood, EDTA BLOOD RAN

Recd. From Outside Yes

BIOCHEMISTRY

Biochemistry done on VITROS 250 Dry Chemistry Analyzer

Test Name

Value

Biological Ref. Interval

BLOOD SUGAR RANDOM

324

mg/dl

70 - 140

IMMUNOLOGY

Test Name

Value

Biological Ref. Interval

INSULIN "

Test

Results

Normal Range

Insulin

25.6 μU/mL

2 - 24 µU/mL

Method :- Done by CMIA (chemiluminescent microparticle Immunoassay) on ARCHITECT.

**** End Of Report ****

Dr. Gawal MBBS; MD. Pathologist/Microbiologist

Dr.Lubna Secmi MBBS,DPB Pathologist/Microbiologist

Dr. Ashutosh Deshmukh MBBS,MD Pathologist/Microbiologist

Reported by: vuy

Checked by Dr. Sanjay Madankar Dr. Avinash Sapre M.D. (Path)

Dr. Avinash Deshmukh Dr. Pravin Gadkari Dr. Rajiv Marawar M.D. (Path)

M.D. (Path)

M.D. (Path)

M.D., (Path) DCP (UK) * - Test not in NABL Preview

Dr. Director
Dr. Dinkar Kumbhalkar
M.D. (Path)

Additional Director

Dr. Ajay A. Lanjewar Dr. Kailash Agrawal Dr. Millind Dharmadhikari Dr. Raj Angnani M.D. (Path) M.D. (Bombay) D.P.B. M.D. (Path) M.D.

M.D. (Path)



Nagpur Reference Pathology Laboratory & Research Institute Pvt. Ltd., Nagpur. ISO 9001-2008 Certified

Reach Us:

NRPL House, Plot No. 22/1, Khare Marg, Dhantoli, Nagpur - 440 012 Tel : 0712- 2455156, 2448769

24/7 & 365 Days Support Service:

Tel.: 8237067627, 8087067628, 7276075693, 8087055164 E-mail: nrplnagpur12@gmail.com

Ref. By Dr.

SELF Sample Rec/Coll. Dt 21/07/2019

Sample ID No.

Age / Sex

Type of Sample EDTA Blood, EDTA BLOOD RAN:

Recd. From Outside Yes

KIDNEY FUNCTION TEST (KFT)

Sample Rec/Coll Time 1:45:44 AM

Test Name	Value	Unit	Biological Ref. Interval
VITROS 250 Dry Chem. Analyzer			
BLOOD UREA	17.0	mg /dl	19 - 43
SERUM CREATININE	0.7	mg/dl	0.6 - 1.4
SERUM SODIUM & POTASSIUM	ř.		
Serum Sodium*	138 mmol/lit.	135 - 148 r	nmol/lit
Serum Potassium*	4.31 mmol/lit.	3.5 - 5.3	mmol/lit

^{*} Done on XD 685 ion selective electrode analyzer .

**** End Of Report ****

Dr. Gawal MBBS, MD. Pathologist/Microbiologist

Dr.Lubna Scemi MBBS,DPB Pathologist/Microbiologist

Dr. Ashutosh Deshmukh MBBS,MD Pathologist/Microbiologist

Reported by: vuy
Checked by: M.D. (Path)

M.D., (Path) DCP (UK)

M.D. (Path)

Dr. Avinash Deshmukh Dr. Pravin Gadkari Dr. Rajiv Marawar M.D. (Path) M.D. (Path)

Contd

Dr. Dinkar Kumbhalkar M.D. (Path)

Additional Director

Dr. Ajay A. Lanjewar Dr. Kailash Agrawal Dr. Millind Dharmadhikari Dr. Raj Angnani M.D. (Path) M.D. (Bombay) D.P.B. M.D. (Path) M.D.



Nagpur Reference Pathology Laboratory & Research Institute Pvt. Ltd., Nagpur.

ISO 9001-2008 Certified

Reach Us:

NRPL House, Plot No. 22/1, Khare Marg, Dhantoli, Nagpur - 440 012 Tel: 0712- 2455156, 2448769

Sample Rec/Coll Time 11:41:51 PM

24/7 & 365 Days Support Service:

Tel.: 8237067627, 8087067628, 7276075693, 8087055164 E-mail: nrplnagpur12@gmail.com

190720216 Name Age / Sex Ref. By Dr. SELF Sample ID No. 216 Sample Rec/Coll. Dt 20/07/2019

Type of Sample EDTA Blood, EDTA BLOOD RAND

LIPID PROFILE*		Reca, Fi	rom Outside Yes
Test Name	Value	Unit	Biological Ref. Interval
VITROS 250 Dry Chem. Analyzer			
TRIGLYCERIDES	132	mg/dL	100 - 150
TOTAL CHOLESTEROL	125	mg/dL	100 - 200
H D L CHOLESTEROL DIRECT	45	mg/dL	30 - 60
ALDL,	26.4	mg/dL	20 - 35
L D L CHOLESTEROL	53.6	mg/dL	60 - 130
TOTAL CHOLESTEROL/HDL RATIO*	2.8		3.0 - 5.0
LDL / HDL CHOLESTEROL RATIO*	1.2		0.00 - 3.55
LIPID PROF INTERPRET			

**** End Of Report *****

MEES, MD. Pathologist/Microbiologist

Dr.Luhna Seemi MBBS,DPB Pathologist/Microbiologist

Dr. Ashutosh Deshmukh MBBS,MD Pathologist/Microbiologist

Reported by: Vuy
Checked by: M.D. (Path)

Dr. Avinash Sapre
M.D., (Path)

Dr. Avinash Deshmukh
Dr. Pravin Gadkari
Dr. Rajiv Marawar
M.D., (Path)

Dr. Avinash Deshmukh
Dr. Pravin Gadkari
Dr. Rajiv Marawar
M.D., (Path)

* - Test not in NABL Preview

Dr. Director
Dr. Dinkar Kumbhalkar
M.D. (Path)

Additional Director

Dr. Ajay A. Lanjewar
M.D. (Path)
Dr. Kailash Agrawal
Dr. Milind Dharmadhikari
Dr. Raj Angnani
M.D. (Path)
Dr. Kailash Agrawal
Dr. Milind Dharmadhikari
M.D. (Path)
Dr. Raj Angnani

Cont



Nagpur Reference Pathology Laboratory & Research Institute Pvt. Ltd., Nagpur. ISO 9001-2008 Certified पंथांलांजी लंब

NRPL House, Plot No. 22/1, Khare Marg, Dhantoli, Nagpur - 440 012 Tel : 0712- 2455156, 2448769

24/7 & 365 Days Support Service: Tel.: 8237067627, 8087067628, 7276075693, 8087055164 E-mail: nrplnagpur12@gmail.com

Name

SELF

Age / Sex Sample ID No.

Ref. By Dr. Sample Rec/Coll. Dt 21/07/2019

Sample Rec/Coll Time 1:45:44 AM

Type of Sample EDTA Blood, EDTA BLOOD RAN Recd. From Outside Yes

LIVER FUNCTION TEST (LFT)

Test Name	Value	Unit	Biological Ref. Interval
VITROS 250 Dry Chem. Analyzer			
TOTAL PROTEIN	6.0	gm/dl	6.3 - 8.2
ALBUMIN	3.20	gm/dl	3.5 - 5.0
GLOBULIN*	2.80	gm/dl	2.0 - 4.0
SGOT	27	U/L	17 - 59
SGPT	30	U/L	21 - 72
ALKALINE PHOSPHATASE	43	U/L	38 - 126
BILIRUBIN TOTAL	0.8	mg/dl	0.2 - 1.3
DIRECT BILIRUBIN (BC)	0.5	mg/dl	0.0 - 0.30
INDIRECT BILIRUBIN (BU)	0.30	mg/dl	0.1 - 1.1
FT INTERPRET			

**** End Of Report ****

Dr. Gawal MBBS, MD. Pathologist/Microbiologist

Dr.Lubna Seemi MBBS,DPB Pathologist/Microbiologist Dr. Ashutosh Deshmukh MBBS,MD Pathologist/Microbiologist

Reported by: vuy

Checked by pr. Sanjay Madankar
M.D. (Path)

Dr. Avinash Sapre
M.D. (Path)

Dr. Avinash Deshmukh
Dr. Pravin Gadkari
M.D. (Path)

Dr. Rajiv Marawar

Contd...5

* - Test not in NABL Preview.

Director
Dr. Dinkar Kumbhalkar
M.D. (Path)

Additional Director

Dr. Ajay A. Lanjewar
M.D. (Path)
Dr. Kailash Agrawal
Dr. Millind Dharmadhikari
Dr. Raj Angnani
M.D. (Bombay) D.P.B.
M.D. (Path)
M.D.



Nagpur Reference Pathology Laboratory & Research Institute Pvt. Ltd., Nagpur. ISO 9001-2008 Certified

Reach Us:

NRPL House, Plot No. 22/1, Khare Marg, Dhantoli, Nagpur - 440 012 Tel : 0712- 2455156, 2448769

24/7 & 365 Days Support Service:

Tel.: 8237067627, 8087067628, 7276075693, 8087055164 E-mail: nrplnagpur12@gmail.com

Ref. By Dr.

SELF

Sample Rec/Coll. Dt 20/07/2019 Sample Rec/Coll Time 11:41:51 PM Sample ID No.

Age / Sex

EDTA Blood, EDTA BLOOD RAN Type of Sample Recd. From Outside Yes

KIDNEY FUNCTION TEST (KFT)

Test Name	Value	Unit	Biological Ref. Interval
VITROS 250 Dry Chem, Analyzer			biological Rel. Interval
	00.4		42 (62)
BLOOD UREA	28.1	mg /dl	19 - 43
SERUM CREATININE	0.8	mg/dl	0.6 - 1.4
SERUM SODIUM & POTASSIUM			
Serum Sodium*	137 mmol/lit.	135 - 148 m	mol/lit
Serum Potassium*	4.38 mmol/lit.	3.5 - 5.3 r	nmol/lit

^{*} Done on XD 685 ion selective electrode analyzer .

**** End Of Report ****

MBBS, MD. Pathologist/Microbiologist

Dr.Lubna Seemi MBBS,DPB Pathologist/Microbiologist Dr. Ashutosh Deshmukh MBBS,MD Pathologist/Microbiologist

Reported by: vuy

Checked by Dr. Sanjay Mada M.D. (Path)

M.D., (Path) DCP (UK)

M.D. (Path)

Dr. Avinash Sapre Dr. Avinash Deshmukh Dr. Pravin Gadkari Dr. Rajiv Mara M.D. (Path)

M.D. (Path)

Contd.

Dr. Dinkar Kumbhalkar M.D. (Path)

Dr. Ajay A. Lanjewar Dr. Kailash Agrawal Dr. Millind Dharmadhikari Dr. Raj Angnani M.D. (Path) M.D. (Bombay) D.P.B. M.D. (Path) M.D.



Nagpur Reference Pathology Laboratory & Research Institute Pvt. Ltd., Nagpur.



Reach Us:

NRPL House, Plot No. 22/1, Khare Marg, Dhantoli, Nagpur - 440 012 Tel: 0712- 2455156, 2448769

24/7 & 365 Days Support Service:

Tel.: 8237067627, 8087067628, 7276075693, 8087055164 E-mail: nrplnagpur12@gmail.com

Ref. By Dr. SELF Sample ID No. 216

Sample Rec/Coll. Dt 20/07/2019 Sample Rec/Coll Time 11:41:51 PM

Type of Sample

EDTA Blood, EDTA BLOOD RAN Recd. From Outside Yes

LIVER FUNCTION TEST (LFT)

Test Name	Value	Unit	Biological Ref. Interval
VITROS 250 Dry Chem. Analyzer			
TOTAL PROTEIN	5.79	gm/dl	6.3 - 8.2
ALBUMIN	3.07	gm/dl	3.5 - 5.0
GLOBULIN*	2.72	gm/dl	2.0 - 4.0
SGOT	28	U/L	17 - 59
SGPT	31	U/L	21 - 72
ALKALINE PHOSPHATASE	44	U/L	38 - 126
BILIRUBIN TOTAL	0.7	mg/dl	0.2 - 1.3
DIRECT BILIRUBIN (BC)	0.5	mg/dl	0.0 - 0.30
INDIRECT BILIRUBIN (BU)	0.20	mg/dl	0.1 - 1.1

**** End Of Report ****

Dr. Gawal MBBS, MD. Pathologist/Microbiologist

Dr.Lubna Seemi MBBS,DPB Pathologist/Microbiologist Dr. Ashutosh Deshmukh MBBS,MD Pathologist/Microbiologist

Reported by: vuy

Checked by **Dr. Sanjay Madankar** M.D. (Path) * - Test not in NABL Preview. M.D., (Path) DCP (UK)

 Dr. Avinash Sapre
 Dr. Avinash Deshmukh
 Dr. Pravin Gadkari
 Dr. Rajiv Marawar

 M.D. (Path)
 DCP (UK)
 M.D. (Path)
 M.D. (Path)
 M.D. (Path)

Director
Dr. Dinkar Kumbhalkar
M.D. (Path)

Dr. Ajay A. Lanjewar Dr. Kallash Agrawal Dr. M.D. (Path) M.D. (Bombay) D.P.B. M.D. (Path) Dr. Raj Angnani M.D. (Path) M.D. (Bombay) D.P.B. M.D. (Path) M.D.



Nagpur Reference Pathology Laboratory & Research Institute Pvt. Ltd., Nagpur. ISO 9001-2008 Certified

Reach Us:

NRPL House, Plot No. 22/1, Khare Marg, Dhantoli, Nagpur - 440 012 Tel: 0712- 2455156, 2448769

24/7 & 365 Days Support Service:

Tel.: 8237067627, 8087067628, 7276075693, 8087055164 E-mail: nrplnagpur12@gmail.com

Name Ref. By Dr.

SELF

Sample Rec/Coll. Dt 21/07/2019 Sample Rec/Coll Time 1:45:44 AM Sample ID No. Type of Sample

89 %

Age / Sex

EDTA Blood, EDTA BLOOD RAN

Recd. From Outside Yes

HAEMATOLOGY

Test Name Value Unit Biological Ref. Interval PROTHROMBIN TIME Mean Normal Prothrombin Time 11.5 Sec On Patients Blood 12.8 Sec International Normalized Ratio (INR) 1.11

Prothrombin Ratio

* Method - Electromechanical * Done on Trinity Biotech Coagulometer

**** End Of Report ****

Dr. Gawai MBBS, MD. Pathologist/Microbiologist

Dr.Lubna Seemi MBBS,DPB Pathologist/Microbiologist

Dr. Ashutosh Deshmukh MBBS,MD Pathologist/Microbiologist

Reported by: vuy
Checked by Dr. Sanjay Madankar
M.D. (Path)

Dr. Avinash Sapre M.D., (Path) DCP (UK)

M.D. (Path)

M.D. (Path)

Dr. Avinash Deshmukh Dr. Pravin Gadkari Dr. Rajiv Marawar Contd...6

M.D. (Path)

Dr. Director

Dr. Dinkar Kumbhalkar

M.D. (Path)

Additional Director

Dr. Ajay A. Lanjewar Dr. Kailash Agrawal Dr. Millind Dharmadhikari Dr. Raj Angnani M.D. (Path) M.D. (Bombay) D.P.B. M.D. (Path) M.D. (M.D.



Nagpur Reference Pathology Laboratory & Research Institute Pvt. Ltd., Nagpur.

ISO 9001-2008 Certified

Reach Us:

NRPL House, Plot No. 22/1, Khare Marg, Dhantoli, Nagpur - 440 012 Tel: 0712- 2455156, 2448769

24/7 & 365 Days Support Service:

Tel.: 8237067627, 8087067628, 7276075693, 8087055164 E-mail: nrplnagpur12@gmail.com

Name

Ref. By Dr.

SELF

Age / Sex Sample ID No.

Sample Rec/Coll. Dt 21/07/2019 Sample Rec/Coll Time 1:45:44 AM

Type of Sample

EDTA Blood, EDTA BLOOD RAN'

Recd. From Outside Yes

IMMUNOLOGY

Biological Ref. Interval

INSULIN*

Test Name

Value

Normal Range

Insulin

Test

22.4 µU/mL

Results

2 - 24 µU/mL

Method :- Done by CMIA (chemiluminescent microparticle Immunoassay) on ARCHITECT.

**** End Of Report ****

Dr. Gawal MBBS, MD. Pathologist/Microbiologist

Dr.Lubna Seemi MBBS,DPB Pathologist/Microbiologist

Dr. Ashutosh Deshmukh MBBS,MD Pathologist/Microbiologist

M.D. (Path)

Reported by: vuy

Checked by Dr. Sanjay Madankar Dr. Avinash Sapre Dr. Avinash Deshmukh Dr. Pravin Gadkari Dr. Rajiv Marawar M.D. (Path) M.D. (Path) DCP (UK) M.D. (Path) DCP (UK) M.D. (Path) M.D. (Path) M.D. (Path)

* - Test not in NABL Preview

M.D., (Path) DCP (UK)

Director
Dr. Dinkar Kumbhalkar
M.D. (Path) Additional Director

Dr. Ajay A. Lanjewar Dr. Kailash Agrawal Dr. Millind Dharmadhikari Dr. Raj Angnani M.D. (Path) M.D. (Bombay) D.P.B. M.D. (Path) M.D.



Nagpur Reference Pathology Laboratory & Research Institute Pvt. Ltd., Nagpur. ISO 9001-2008 Certified

Reach Us:

NRPL House, Plot No. 22/1, Khare Marg, Dhantoli, Nagpur - 440 012 Tel: 0712- 2455156, 2448769

24/7 & 365 Days Support Service:

Tel.: 8237067627, 8087067628, 7276075693, 8087055164 E-mail: nrplnagpur12@gmail.com

Name

Ref. By Dr.

SELF

Sample Rec/Coll. Dt 21/07/2019 Sample Rec/Coll Time 1:45:44 AM Age / Sex Sample ID No.

M / 1907214

Type of Sample

EDTA Blood, EDTA BLOOD RA*1

Recd. From Outside Yes

BIOCHEMISTRY

Biochemistry done on VITROS 250 Dry Chemistry Analyzer

Test Name

Value

Unit

Biological Ref. Interval

BLOOD SUGAR RANDOM

210

mg/dl

70 - 140

**** End Of Report ****

Dr. Gawal MBBS, MD. Pathologist/Microbiologist

Dr.Lubna Scemi MBBS,DPB Pathologist/Microbiologist

Dr. Ashutosh Deshmukh MBBS,MD Pathologist/Microbiologist

Reported by vuy
Checked by Pr. Saniay Madankar M.D. (Path)

M.D., (Path) DCP (UK)

Dr. Avinash Sapre Dr. Avinash Deshmukh Dr. Pravin Gadkari Dr. Rajiv Marawar Contd...7 M.D. (Path)

M.D. (Path)

M.D. (Path)

Dr. Dinkar Kumbhalkar M.D. (Path)

Additional Director

Dr. Ajay A. Lanjewar Dr. Kailash Agrawal Dr. Millind Dharmadhikari Dr. Raj Angnani M.D. (Path) M.D. (Bombay) D.P.B. M.D. (Path) M.D.



Nagpur Reference Pathology Laboratory & Research Institute Pvt. Ltd., Nagpur.



Reach Us:

NRPL House, Plot No. 22/1, Khare Marg, Dhantoli, Nagpur - 440 012 Tel : 0712- 2455156, 2448769

24/7 & 365 Days Support Service:

Tel.: 8237067627, 8087067628, 7276075693, 8087055164 E-mail: nrplnagpur12@gmail.com

Name Ref. By Dr.

SELF

Age / Sex Sample ID No.

Sample Rec/Coll. Dt 21/07/2019 Sample Rec/Coll Time 1:45:44 AM

Type of Sample

EDTA Blood, EDTA BLOOD RAN: Recd. From Outside Yes

LIPID	PROFILE "

Test Name	Value	Unit	Biological Ref. Interval	
VITROS 250 Dry Chem. Analyzer				
TRIGLYCERIDES	94	mg/dL	100 - 150	
TOTAL CHOLESTEROL	87	mg/dL	100 - 200	
H D L CHOLESTEROL DIRECT	53	mg/dL	30 - 60	
ALDL.	18.8	mg/dL	20 - 35	
L D L CHOLESTEROL	15.2	mg/dL	60 - 130	
TOTAL CHOLESTEROL/HDL RATIO	1.6		3.0 - 5.0	
LIPID PROF INTERPRET				

**** End Of Report ****

MBBS, MD. Pathologist/Microbiologist

Dr.Lubna Seemi MBBS,DPB Pathologist/Microbiologist Dr. Ashutosh Deshmukh MBBS,MD Pathologist/Microbiologist

Reported by: vuy

Checked by R. Sanjay Madankar Checked by M.D. (Path)

Dr. Avinash Sapre Dr. Avinash Deshmukh Dr. Pravin Gadkari Dr. Rajiv Marawar M.D. (Path)

M.D. (Path)

Dr. Avinash Deshmukh Dr. Pravin Gadkari Dr. Rajiv Marawar M.D. (Path) * - Test n ot in NABL Preview

Director
Dr. Dinkar Kumbhalkar
M.D. (Path)

Dr. Ajay A. Lanjewar Dr. Kallash Agrawal Dr. Millind Dharmadhikari Dr. Raj Angnani M.D. (Path) M.D. (Bombay) D.P.B. M.D. (Path) M.D.





IP/OP NO





Method

Patient Name : Mr.JAYENDRA SINGH Age/Gender : 38 Y 0 M 0 D /M UHID/MR No : DPVP.0000000718 Visit ID : DPVPOPV1096 Ref Doctor : Dr.SELF

Test Name

Collected : 24/Aug/2018 02:26PM Received : 24/Aug/2018 05:14PM Reported : 24/Aug/2018 05:33PM Status : Final Report Client Name : PCC VADGAONSHERI PUNE Client Code : PCC0157

Bio. Ref. Range

DEPARTMENT OF BIOCHEMISTRY

Unit

Result

LIPID PROFILE, SERUM				
TOTAL CHOLESTEROL	269	mg/dL	<200	Enzymatic (CHE/CHO/POD)
TRIGLYCERIDES	258	mg/dL	<150	Enzymatic(Lipase/GK/GPO/POD
HDL CHOLESTEROL	39	mg/dL	40-60	Direct Measure PEG
NON-HDL CHOLESTEROL	230	mg/dL	<130	Calculated
LDL CHOLESTEROL	178.4	mg/dL	<100	Calculated
VLDL CHOLESTEROL	51.6	mg/dL	<30	Calculated
CHOL / HOL BATIO	6.00		0.4.07	C-levisa - I

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240	
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥500
LDL	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190
HDL	≥ 60			
NON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220

Measurements in the same patient can show physiological and analytical variations.

NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.

*** End Of Report ***





(CIN - UBS 113TN 2000PLC046889)
Regd. Office: 19 Bishop Gardent, R.A. Puram, Chennai 600 028, Tamil Nadu, India: Email ID: info@apollobl.com

Page 1 of 1

www.apollodiagnostics.in



PATIENT NAME : Mr. Jayendra Singh AGE: 38 Yrs / M

REFFERED BY: Dr. Self DATE: 25-08-2018

BIOCHEMISTRY LIPID PROFILE

LITTO TROTTEL				
Test Name	Value	Unit	Reference Range	
T.CHOLESTEROL	206	mg/dl	Upto 200	
S.TRIGLYCERIDES	146	mg/dl	25-200	
HDL CHOLESTEROL	41	mg/dl	M:30-70; F:35-90	
VLDL	29.2	mg/dl	5-40	
LDL CHOLESTEROL	135.8	mg/dl	85-130	
T.CHOLESTEROL/HDL	5.02	Ratio	3.0-5.0	
LDL/HDL	3.31	Ratio	1.5-3.5	
NHDL CHOLESTEROL	165	mg/dl	<160	

This is only a professional opinion & not a diagnosis. Please Correlate with clinical conditions. Alert !!! 10-12 hours fasting is mandatory for lipid parameters. If not, values might fluctuate.

DR.SAMIR AGARWAL DNB (PATH)

CONSULTANT PATHOLOGIST







HEMANT ROHERA

wanori pune pune Tel No : 8669114143 PID NO: P116190015907 Age: 43.5 Year(s) Sex: Male Reference:

Sample Collected At: MUKUND NAGAR COLLECTION CENTER Construction House, Ground Floor, 796/189-B, Bhandarkar Institute Road,

Pune 411004

VID: 116193004972

Registered On: 17/04/2019 01:17 PM Collected On: 17/04/2019 1:17PM

Reported On: 17/04/2019 08:34 PM

Investigation Glucose Random (Plasma-R,Hexokinase)

Insulin (Random)

(Serum, CMIA)

Observed Value 139

29.9

Unit mg/dL

µIU/mL

Biological Reference Interval

Normal: 70-140 Diabetes mellitus: >= 200 (on more than one occassion) (American diabetes association guidelines 2018)

Post glucose samples after: 30 minutes: 18-172 60 minutes: 12-134 90 minutes: 12-107

120 minutes: 12-82 180 minutes: 2-23

Please Note change in Method

Interpretation:

- 1. Levels are increased in insulinomas, factitious hypoglycemia, insulin autoimmmune syndrome, acromegaly (after ingestion of glucose), Cushings syndrome, corticosteroid administration and levodopa usage.

 2. Levels are depressed to absent in diabetes mellitus, pituitary tumors and chronic pancreatic diseases i.e. cystic fibrosis.

 3. Insulin/ C-peptide ratio is used for differentiating between factitious hypoglycemia and insulinomas where a ratio< 1.0 indicates insulinoma; but results may vary in renal failure.

 4. Antibodies to insulin form in longstanding diabetes mellitus treated with insulin hence in these patients monitoring insulin levels gives better prognosis.
- levels gives better prognosis.

-- End of Report --

Page 1 of 1

Dr. Sneha Arvind Dhawale MBBS, DCP, DNB-Pathology

HEMANT ROHERA

wanori pune pune Tel No : 8669114143

PID NO: P116190015907 Age: 43.5 Year(s) Sex: Male Reference:

Sample Collected At: MUKUND NAGAR COLLECTION CENTER

Construction House, Ground Floor, 796/189-B, Bhandarkar Institute Road,

Pune 411004

VID: 116193005010

Registered On: 17/04/2019 04:50 PM Collected On:

17/04/2019 4:50PM Reported On:

17/04/2019 09:35 PM

Investigation

Glucose Random (Plasma-R,Hexokinase)

Insulin (Random)

(Serum, CMIA)

Observed Value

105

20.7

Unit mg/dL

Biological Reference Interval

Normal: 70-140 Diabetes mellitus: >= 200 (on more than one occassion)

(American diabetes association guidelines 2018)

µIU/mL

Post glucose samples after: 30 minutes: 18-172 60 minutes: 12-134 90 minutes: 12-107

120 minutes: 12-82 180 minutes: 2-23

Please Note change in Method

Interpretation:

- Levels are increased in insulinomas, factitious hypoglycemia, insulin autoimmmune syndrome, acromegaly (after ingestion of glucose), Cushings syndrome, corticosteroid administration and levodopa usage.
 Levels are depressed to absent in diabetes mellitus, pituitary tumors and chronic pancreatic diseases i.e. cystic fibrosis.
 Insulin/ C-peptide ratio is used for differentiating between factitious hypoglycemia and insulinomas where a ratio< 1.0 indicates insulinoma; but results may vary in renal failure.
 Antibodies to insulin form in longstanding diabetes mellitus treated with insulin hence in these patients monitoring insulin levels gives better prognosis.

-- End of Report --

Page 1 of 1

Missingl Dr. Naziya Maner MBBS, DCP, D.N.B.





Doc No - F/TR, Rev: Issue No. : 00:01, Rev : Issue Date :00: 01.03.12

Name Mr. Deepak Moghe Mrs. Mardikar MD Ref. By Dr. Sample Rec/Coll. Dt 25/05/2020

Age / Sex Sample ID No.

58 Yrs. M /

Sample Rec/Coll Time 7:17:00 AM

EDTA Blood, EDTA BLOOD FASTING, Seru Type of Sample

Recd. From Outside Yes

INSULIN*

Results

Normal Range

Insulin (F)

8.0 μU/mL 2 - 24 μU/mL

Method: - Done by CMIA (chemiluminescent microparticle Immunoassay) on ARCHITECT.

INSULIN*

Test

Results **Normal Range**

Insulin (F)

6.2 µU/mL

2 - 24 µU/mL

Method:- Done by CMIA (chemiluminescent microparticle Immunoassay) on ARCHITECT.

**** End Of Report ****

Dr. Gawal MBBS, MD. Pathologist/Microbiologist Dr.Lubna Seemi MBBS,DPB Pathologist/Microbiologist Dr. Ashutosh Deshmukh MBBS,MD Pathologist/Microbiologist

Reported by: &'y Checked by: -

^{* -} Test not in NABL Preview.





Doc No - F/TR, Rev: Issue No.: 00:01, Rev: Issue Date: 00: 01:03:12

Name Mr. Deepak Moghe Ref. By Dr. SELF Sample Rec/Coll Dt 14/06/2020 Sample Rec/Coll Time 12:50:07

Age / Sex Sample ID No.

M /

Type of Sample EDTA Blood, EDTA BLOOD RANDAM, F Recd. From Outside Yes

HAEMATOLOGY

Test Name	Value	Unit	Biological Ref. Interval
HAEMOGRAM (SYSMEX XP 100)			
HAEMOGLOBIN (Hb)*	12.8	gm/dl	13.0 - 17.0
P.C.V / HAEMATOCRIT*	38.4	%	35 - 52
MCV*	88.9	fl.	76 - 96
MCH.	29.6	Picogram	27 - 34
WCHC.	33.3	gm/dl	31 - 36
R B C COUNT*	4.32	Millions/cmm	4.5 - 5.5
RDW*	13.2	%	10.8 - 14.9
PLATELET COUNT*	3.24	Lakh/cmm	1.4 - 4.4
TOTAL LEUCOCYTE COUNT (TLC)*	6,500	/cumm	4000 - 11000
DIFFERENTIAL LEUCOCYTE COU	NT (DLC)		
NEUTROPHIL	53	%	45 - 65
LYMPHOCYTE	43	%	25 - 45
EOSINOPHIL	03	%	0 - 06
MONOCYTE	01	%	2-8
	**** End Of Rep	port ****	

Dr. Gawal MBBS, MD. Pathologist/Microbiologist

Dr.Lubna Seemi MBBS,DPB Pathologist/Microbiologist

Dr. Ashutosh Deshmukh MBBS,MD Pathologist/Microbiologist

Reported by: w4G Checked by: ----

* - Test not in NABL Preview.





Doc No - F/TR, Rev: Issue No.: 00:01, Rev: Issue Date: 00: 01:03:12

Name Mr. Deepak Moghe Ref. By Dr. SELF

Sample Rec/Coll. Dt 14/06/2020 Sample Rec/Coll Time 12:50:07

Age / Sex Sample ID No.

3.5 - 5.3 mmol/lit

EDTA Blood, EDTA BLOOD RANDAM, F Type of Sample Recd. From Outside Yes

KIDNEY FUNCTION TEST (KFT)

Serum Potassium*

Test Name	Value	Unit	Biological Ref. Interval
VITROS 250 Dry Chem. Analyzer			
BLOOD UREA	27.9	mg /dl	19 - 43
SERUM CREATININE	1.2	mg/dl	0.6 - 1.4
SERUM SODIUM & POTASS	IUM		
Serum Sodium*	134 mmol/lit.	135 - 148	mmol/lit

4.1 mmol/lit.

**** End Of Report ****

Dr. Gawal MBBS, MD. Pathologist/Microbiologist Dr.Lubna Seemi MBBS,DPB Pathologist/Microbiologist Dr. Ashutosh Deshmukh MBBS,MD Pathologist/Microbiologist

Reported by: w4G Checked by : --

^{*} Done on $\textbf{\textit{XD}}$ **685** ion selective electrode analyzer .





Doc No - F/TR, Rev: Issue No.: 00:01, Rev: Issue Date:00: 01.03.12

Name Mr. Deepak Moghe Age / Sex M /

Ref. By Dr. SELF Sample ID No. 1

Sample Rec/Coll. Dt 14/06/2020 Sample Rec/Coll Time 12:50:07 Type of Sample EDTA Blood, EDTA BLOOD RANDAM, F

Bood From Outside Van

Note:-* HbA1c (Or GlycoHb) is made by post synthetic modification of Haemoglobin A at a slow rate directly dependant on blood glucose concentration during the 120 day life span of RBC.HbA1c levels may double or even triple in diabetics, depending on level of hyperglycemia, and correlate well with control of diabetes.

REPORT ON VITAMIN B12 LEVEL SERUM

TEST RESULT NORMAL RANGE

VITAMIN B12 161 pg/ml 187 - 883 pg/ml

Method: Done by CMIA (chemiluminescent microparticle Immunoassay) on ARCHITECT.

BIOCHEMISTRY

Biochemistry done on VITROS 250 Dry Chemistry Analyzer

Test Name Value Unit Biological Ref. Interval

BLOOD SUGAR RANDOM **141** mg/dl 70 - 140

IMMUNOLOGY

Test Name Value Unit Biological Ref. Interval

INSULIN*

^{* -} Test not in NABL Preview.





Doc No - F/TR, Rev: Issue No.: 00:01, Rev: Issue Date::00: 01.03.12

Method:- Done by CMIA (chemiluminescent microparticle Immunoassay) on ARCHITECT.

**** End Of Report ****

Dr. Gawal MBBS, MD. Pathologist/Microbiologist Dr.Lubna Seemi MBBS,DPB Pathologist/Microbiologist Dr. Ashutosh Deshmukh MBBS,MD Pathologist/Microbiologist

Reported by : w4G

Checked by : ----





Doc No - F/TR, Rev: Issue No. : 00:01, Rev : Issue Date :00: 01.03.12

Name Mr. Deepak Moghe Ref. By Dr. SELF

Sample Rec/Coll. Dt 14/06/2020 Sample Rec/Coll Time 12:50:07

Age / Sex Sample ID No. м /

Type of Sample EDTA Blood, EDTA BLOOD RANDAM, F

Recd. From Outside Yes
SEROLOGY SPECIAL TEST

NRPL SPECIAL TESTS

VITAMIN D*

25 HYDROXY VITAMIN D (Calcidiol)

Test Result

25 HYDROXY VITAMIN D

6.7 ng/ml

Expected Values

Deficiency 0-10 ng/ml Insufficiency - 10-30 ng/ml sufficiency - 30-150 ng/ml Toxicity - >150 ng/ml

Method: Done by CMIA (chemiluminescent microparticle Immunoassay) on ARCHITECT.

Note :-- Vit D3 serum sample to be separated the earliest - Transportation - wrapped in paper (to protect from sunlight)

**** End Of Report ****

Dr. Gawal MBBS, MD.

Pathologist/Microbiologist

Dr.Lubna Seemi MBBS,DPB Pathologist/Microbiologist Dr. Ashutosh Deshmukh MBBS,MD Pathologist/Microbiologist

Reported by: w4G Checked by : ---

* - Test not in NABL Preview.









: Mr.AMARJEET SINGH : 47 Y 0 M 0 D /M : DWKA.0000000014 Patient Name Age/Gender UHID/MR No Visit ID : DWKAOPV22

Ref Doctor IP/OP NO : Dr.SELF

: 07/Sep/2020 01:59PM : 07/Sep/2020 06:02PM : 07/Sep/2020 06:46PM : Final Report : SL WAKAD Collected Received Reported Status

Client Name : WAKAD,Pune Patient location

DEPARTMENT OF HAEMATOLOGY					
Test Name	Result	Unit	Bio. Ref. Range	Method	
COMPLETE BLOOD COUNT (CBC) , v	VHOLE BLOOD-EDTA		74		
HAEMOGLOBIN	13.7	g/dL	13-17	Spectrophotometer	
PCV	42.30	%	40-50	Electronic pulse & Calculation	
RBC COUNT	5.53	Million/cu.mm	4.5-5.5	Electrical Impedenc	
MCV	77	fL	83-101	Calculated	
MCH	24.8	pg	27-32	Calculated	
MCHC	32.4	g/dL	31.5-34.5	Calculated	
R.D.W	15.4	%	11.6-14	Calculated	
TOTAL LEUCOCYTE COUNT (TLC)	9,800	cells/cu.mm	4000-10000	Electrical Impedanc	
DIFFERENTIAL LEUCOCYTIC COUNT (DL	C)				
NEUTROPHILS	54.4	%	40-80	Electrical Impedanc	
LYMPHOCYTES	34.6	%	20-40	Electrical Impedanc	
EOSINOPHILS	3.2	%	1-6	Electrical Impedanc	
MONOCYTES	7.8	%	2-10	Electrical Impedance	
BASOPHILS	0	%	<1-2	Electrical Impedance	
ABSOLUTE LEUCOCYTE COUNT			7		
NEUTROPHILS	5331.2	Cells/cu.mm	2000-7000	Electrical Impedanc	
LYMPHOCYTES	3390.8	Cells/cu.mm	1000-3000	Electrical Impedanc	
EOSINOPHILS	313.6	Cells/cu.mm	20-500	Electrical Impedanc	
MONOCYTES	764.4	Cells/cu.mm	200-1000	Electrical Impedanc	
PLATELET COUNT	245000	cells/cu.mm	150000-410000	Electrical impedence	



Page 1 of 4

www.apollodiagnostics.in

After





IP/OP NO





: 07/Sep/2020 05:16PM

: 07/Sep/2020 08:32PM : 07/Sep/2020 08:54PM

: Mr.AMARJEET SINGH Patient Name Age/Gender UHID/MR No : 47 Y 0 M 0 D /M : DWKA.0000000014 Visit ID : DWKAOPV26 Ref Doctor : Dr.SELF

Received Reported Status

: Final Report : SL WAKAD Client Name : WAKAD, Pune Patient location

Collected

Test Name	Result	Unit	Bio. Ref. Range	Method
COMPLETE BLOOD COUNT (CBC) , W	HOLE BLOOD-EDTA		U.	
HAEMOGLOBIN	13.9	g/dL	13-17	Spectrophotometer
PCV	43.10	%	40-50	Electronic pulse & Calculation
RBC COUNT	5.62	Million/cu.mm	4.5-5.5	Electrical Impedence
MCV	77	fL	83-101	Calculated
MCH	24.7	pg	27-32	Calculated
MCHC	32.2	g/dL	31.5-34.5	Calculated
R.D.W	15.5	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	9,800	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUNT (DL	C)			
NEUTROPHILS	49.2	%	40-80	Electrical Impedance
LYMPHOCYTES	39.9	%	20-40	Electrical Impedance
EOSINOPHILS	2.9	%	1-6	Electrical Impedance
MONOCYTES	8	%	2-10	Electrical Impedance
BASOPHILS	0	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT	11.80		7	
NEUTROPHILS	4821.6	Cells/cu.mm	2000-7000	Electrical Impedance
LYMPHOCYTES	3910.2	Cells/cu.mm	1000-3000	Electrical Impedance
EOSINOPHILS	284.2	Cells/cu.mm	20-500	Electrical Impedance
MONOCYTES	784	Cells/cu.mm	200-1000	Electrical Impedance
PLATELET COUNT	247000	cells/cu.mm	150000-410000	Electrical impedence

DEPARTMENT OF HAEMATOLOGY



Page 1 of 4







Patient Name : Mr.AMARJEET SINGH Collected : 07/Sep/2020 01:59PM Age/Gender : 47 Y O M O D /M Received : 07/Sep/2020 06:01PM UHID/MR No : DWKA.000000014 Reported : 07/Sep/2020 07:55PM Visit ID : DWKAOPV22 Status : Final Report

Ref Doctor : Dr.SELF Client Name : SL WAKAD IP/OP NO Patient location : WAKAD, Pune

DEPARTMENT OF COAGULATION					
Test Name	Result	Unit	Bio. Ref. Range	Method	

Prothrombin Time	16.5	Seconds	11-16	Optomechanical clot detection
Control (MNPT)	14.50	Seconds		Optomechanical clot detection
Ratio	1.14			Calculated
Prothrombin Index	87.88	%		Calculated
International Normalized Ratio (INR)	1.15			Calculated

Comment:

REFERENCE GROUP	INTERNATIONAL NORMALIZED RATIO (INR)
NORMAL POPULATION	0.9 – 1.1
PATIENTS ON ANTICOAGULANT THERAPY	A PAPER I S
STANDARD DOSE THERAPY	2.0 – 3.0
HIGH DOSE THERAPY	2.5 – 3.5

INR is the parameter of choice in monitoring adequacy of oral anticoagulant therapy. Marked elevation of INR in patients receiving oral anticoagulant therapyis a marker of excessive anticoagulation and requires prompt action; an INR below 2.0 reflects insufficient anticoagulation.

Page 2 of 4

www.apollodiagnostics.in

After







Patient Name : Mr.AMARJEET SINGH Collected : 07/Sep/2020 05:16PM : 47 Y O M O D /M Age/Gender Received : 07/Sep/2020 08:35PM UHID/MR No : DWKA.000000014 Reported : 07/Sep/2020 09:11PM : DWKAOPV26 Visit ID Status : Final Report Ref Doctor IP/OP NO : Dr.SELF

Client Name : SL WAKAD : WAKAD, Pune Patient location

DEPARTMENT OF COAGULATION					
Test Name	Result	Unit	Bio. Ref. Range	Method	

Prothrombin Time	14.6	Seconds	11-16	Optomechanical clot detection
Control (MNPT)	14.50	Seconds		Optomechanical clot detection
Ratio	1.01			Calculated
Prothrombin Index	99.32	%		Calculated
International Normalized Ratio (INR)	1.01			Calculated

Comment:

REFERENCE GROUP	INTERNATIONAL NORMALIZED RATIO (INR)
NORMAL POPULATION	0.9 – 1.1
PATIENTS ON ANTICOAGULANT THERAPY	APPEN
STANDARD DOSE THERAPY	2.0 – 3.0
HIGH DOSE THERAPY	2.5 – 3.5

INR is the parameter of choice in monitoring adequacy of oral anticoagulant therapy. Marked elevation of INR in patients receiving oral anticoagulant therapyis a marker of excessive anticoagulation and requires prompt action; an INR below 2.0 reflects insufficient anticoagulation.











Patient Name : Mr.AMARJEET SINGH Age/Gender : 47 Y O M O D /M UHID/MR No : DWKA.000000014 Visit ID : DWKAOPV22

Ref Doctor : Dr.SELF

IP/OP NO

Collected : 07/Sep/2020 01:59PM Received : 07/Sep/2020 06:02PM Reported : 07/Sep/2020 06:48PM Status : Final Report

Client Name : SL WAKAD Patient location : WAKAD, Pune

DEPARTMENT OF BIOCHEMISTRY						
Test Name	Result	Unit	Bio. Ref. Range	Method		
GLUCOSE, RANDOM , SODIUM FLUORIDE PLASMA	449	mg/dL	70 - 140	Glucose oxidase		
HBA1C, GLYCATED HEMOGLOBIN , WHOLE BLOOD-EDTA	11.4	%		HPLC		
ESTIMATED AVERAGE GLUCOSE (eAG) , WHOLE BLOOD-EDTA	280	mg/dL		Calculated		

Comment:

Reference Range as per American Diabetes Association (ADA):

REFERENCE GROUP	HBA1C IN %
NON DIABETIC ADULTS > 18 YEARS	<5.7
AT RISK (PREDIABETES)	5.7 – 6.4
DIAGNOSING DIABETES	>= 6,5
DIABETICS	to the pro-
EXCELLENT CONTROL	6-7
FAIR TO GOOD CONTROL	7 – 8
UNSATISFACTORY CONTROL	8 – 10
POOR CONTROL	>10

Note: Dietary preparation or fasting is not required.

- 1. A1C test should be performed at least two times a year in patients who are meeting treatment goals (and who have stable glycemic control).
- 2. Lowering A1C to below or around 7% has been shown to reduce microvascular and neuropathic complications of type 1 and type 2 diabetes. When mean annual HbA1c is <1.1 times ULN (upper limit of normal), renal and retinal complications are rare, but complications occur in >70% of cases when HbA1c is >1.7 times ULN.
- 3. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present. Fructosamine may be used as an alternate measurement of glycemic control

Page 3 of 4

www.apollodiagnostics.in

After









: Mr.AMARJEET SINGH : 47 Y 0 M 0 D /M Patient Name Age/Gender UHID/MR No : DWKA.000000014 Visit ID : DWKAOPV26

Ref Doctor : Dr.SELF

IP/OP NO

: 07/Sep/2020 05:16PM : 07/Sep/2020 08:36PM : 07/Sep/2020 08:52PM : Final Report Collected Received Reported Status

Client Name : SL WAKAD : WAKAD, Pune Patient location

DEPARTMENT OF BIOCHEMISTRY					
Test Name Result Unit Bio. Ref. Range Meth					
GLUCOSE, RANDOM, SODIUM FLUORIDE PLASMA	308	mg/dL	70-140	HEXOKINASE	





Page 3 of 4





IP/OP NO



Patient Name	: Mr.AMARJEET SINGH
Age/Gender	: 47 Y O M O D /M
UHID/MR No	: DWKA.000000014
Visit ID	: DWKAOPV22
Ref Doctor	: Dr.SELF

	Collected	: 07/Sep/2020 01:59PM
	Received	: 07/Sep/2020 06:00PM
	Reported	: 07/Sep/2020 07:34PM
ı	Status	: Final Report
	Client Name	: SL WAKAD
J	Patient location	: WAKAD, Pune

DEPARTMENT OF IMMUNOLOGY					
Test Name	Result	Unit	Bio. Ref. Range	Method	
INSULIN - RANDOM , SERUM	24.5	mIU/mL		CMIA	

*** End Of Report ***

DR. SANJAY INGLE Dr. Keerthi Prakash
MBBS, MD (PATH) M.B.B.S., MD (Path) M,B.B.S., MD (Path) Consultant Pathologist

Page 4 of 4

www.apollodiagnostics.in

After





IP/OP NO



: 07/Sep/2020 05:16PM

: 07/Sep/2020 08:36PM

: 07/Sep/2020 09:15PM

: Mr.AMARJEET SINGH
: 47 Y O M O D /M
: DWKA.000000014
: DWKAOPV26
: Dr.SELF

: Dr.SELF

Reported Status : Final Report Client Name : SL WAKAD Patient location : WAKAD, Pune

Collected

Received

DEPARTMENT OF IMMUNOLOGY					
Test Name	Result	Unit	Bio. Ref. Range	Method	
NSULIN - RANDOM , SERUM	12.6	mIU/mL		CMIA	

*** End Of Report ***

DR. SANJAY INGLE MBBS, MD (PATH)

DR. SHIRISH POPHALIKAR MBBS,MD (PATH)

Dr. Keerthi Prakash M,B.B.S., MD (Path) Consultant Pathologist

SIN No:IM01797612
This test has been performed at Apollo Health and Lifestyle Ltd/Reference Regional Lab, Pune

Page 4 of 4









: Mrs.JYOTI KALSI : 47 Y 0 M 0 D /F : DWKA.0000000015 Patient Name Age/Gender UHID/MR No Visit ID Ref Doctor : DWKAOPV23

: Dr.SELF

IP/OP NO

Test Name

: 07/Sep/2020 02:03PM : 07/Sep/2020 06:02PM : 08/Sep/2020 02:58PM : Final Report : SL WAKAD Collected Received Reported Status

Client Name Patient location : WAKAD, Pune

DEPARTMENT OF HAEMATOLOGY					
Result	Unit	Bio. Ref. Range	Method		

HAEMOGLOBIN	12.4	g/dL	12-15	Spectrophotometer
PCV	37.50	%	36-46	Electronic pulse & Calculation
RBC COUNT	4.48	Million/cu.mm	3.8-4.8	Electrical Impedence
MCV	84	fL	83-101	Calculated
MCH	27.6	pg	27-32	Calculated
MCHC	33	g/dL	31.5-34.5	Calculated
R.D.W	13	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	9,100	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUNT (DL	C)			
NEUTROPHILS	64.1	%	40-80	Electrical Impedance
LYMPHOCYTES	28.4	%	20-40	Electrical Impedance
EOSINOPHILS	2.6	%	1-6	Electrical Impedance
MONOCYTES	4.9	%	2-10	Electrical Impedance
BASOPHILS	0	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT	11.50		7/	
NEUTROPHILS	5833.1	Cells/cu.mm	2000-7000	Electrical Impedance
LYMPHOCYTES	2584.4	Cells/cu.mm	1000-3000	Electrical Impedance
EOSINOPHILS	236.6	Cells/cu.mm	20-500	Electrical Impedance
MONOCYTES	445.9	Cells/cu.mm	200-1000	Electrical Impedance
PLATELET COUNT	370000	cells/cu.mm	150000-410000	Electrical impedence



Page 1 of 4

www.apollodiagnostics.in

After









: Mrs.JYOTI KALSI : 47 Y 0 M 0 D /F : DWKA.0000000016 Patient Name Age/Gender UHID/MR No Visit ID Ref Doctor : DWKAOPV27

: Dr.SELF

IP/OP NO

: 07/Sep/2020 05:27PM : 07/Sep/2020 08:32PM : 07/Sep/2020 08:54PM : Final Report : SL WAKAD Collected Received Reported Status

Client Name Patient location : WAKAD, Pune

	DEPARTMENT OF HAEMATOLOGY					
Test Name	Result	Unit	Bio. Ref. Range	Method		

HAEMOGLOBIN	12.3	g/dL	12-15	Spectrophotometer
PCV	37.20	%	36-46	Electronic pulse & Calculation
RBC COUNT	4.46	Million/cu.mm	3.8-4.8	Electrical Impedence
MCV	83	fL	83-101	Calculated
MCH	27.7	pg	27-32	Calculated
MCHC	33.2	g/dL	31.5-34.5	Calculated
R.D.W	13.2	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	9,800	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUNT (DLC				
NEUTROPHILS	58.2	%	40-80	Electrical Impedance
LYMPHOCYTES	33.5	%	20-40	Electrical Impedance
EOSINOPHILS	2.5	%	1-6	Electrical Impedance
MONOCYTES	5.8	%	2-10	Electrical Impedance
BASOPHILS	0	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT	10,000		/	
NEUTROPHILS	5703.6	Cells/cu.mm	2000-7000	Electrical Impedance
LYMPHOCYTES	3283	Cells/cu.mm	1000-3000	Electrical Impedance
EOSINOPHILS	245	Cells/cu.mm	20-500	Electrical Impedance
MONOCYTES	568.4	Cells/cu.mm	200-1000	Electrical Impedance
PLATELET COUNT	359000	cells/cu.mm	150000-410000	Electrical impedence



Page 1 of 4







Patient Name : Mrs.JYOTI KALSI Age/Gender UHID/MR No Visit ID : 47 Y 0 M 0 D /F : DWKA.000000015 : DWKAOPV23

: Dr.SELF Ref Doctor

IP/OP NO

: 07/Sep/2020 02:03PM : 07/Sep/2020 06:01PM : 08/Sep/2020 02:57PM Collected Received Reported

: Final Report Status Client Name : SL WAKAD Patient location : WAKAD, Pune

DEPARTMENT OF COAGULATION					
Test Name	Result	Unit	Bio. Ref. Range	Method	

Prothrombin Time	13.5	Seconds	11-16	Optomechanical clot detection
Control (MNPT)	14.50	Seconds		Optomechanical clot detection
Ratio	0.93			Calculated
Prothrombin Index	107.41	%		Calculated
International Normalized Ratio (INR)	0.92			Calculated

Comment:

REFERENCE GROUP	INTERNATIONAL NORMALIZED RATIO (INR)		
NORMAL POPULATION	0.9 – 1.1		
PATIENTS ON ANTICOAGULANT THERAPY	A PAPER I S		
STANDARD DOSE THERAPY	2.0 – 3.0		
HIGH DOSE THERAPY	2.5 – 3.5		

INR is the parameter of choice in monitoring adequacy of oral anticoagulant therapy. Marked elevation of INR in patients receiving oral anticoagulant therapyis a marker of excessive anticoagulation and requires prompt action; an INR below 2.0 reflects insufficient anticoagulation.



Page 2 of 4

After







Patient Name : Mrs.JYOTI KALSI Age/Gender UHID/MR No Visit ID : 47 Y 0 M 0 D /F : DWKA.0000000016 : DWKAOPV27

: Dr.SELF Ref Doctor

IP/OP NO

: 07/Sep/2020 05:27PM : 07/Sep/2020 08:35PM Collected Received Reported : 07/Sep/2020 09:06PM

: Final Report : SL WAKAD Status Client Name Patient location : WAKAD, Pune

DEPARTMENT OF COAGULATION				
Test Name	Result	Unit	Bio. Ref. Range	Method

Prothrombin Time	12.4	Seconds	11-16	Optomechanical clot detection
Control (MNPT)	14.50	Seconds		Optomechanical clot detection
Ratio	0.86			Calculated
Prothrombin Index	116.94	%		Calculated
International Normalized Ratio (INR)	0.84			Calculated

Comment:

REFERENCE GROUP	INTERNATIONAL NORMALIZED RATIO (INR)		
NORMAL POPULATION	0.9 – 1.1		
PATIENTS ON ANTICOAGULANT THERAPY	A Pare		
STANDARD DOSE THERAPY	2.0 – 3.0		
HIGH DOSE THERAPY	2.5 – 3.5		

INR is the parameter of choice in monitoring adequacy of oral anticoagulant therapy. Marked elevation of INR in patients receiving oral anticoagulant therapyis a marker of excessive anticoagulation and requires prompt action; an INR below 2.0 reflects insufficient anticoagulation.



Page 2 of 4









Patient Name : Mrs.JYOTI KALSI Age/Gender : 47 Y O M O D /F UHID/MR No : DWKA.000000015 : DWKAOPV23 Visit ID

: Dr.SELF Ref Doctor

IP/OP NO

Collected : 07/Sep/2020 02:03PM : 07/Sep/2020 06:02PM Received : 08/Sep/2020 02:58PM Reported Status : Final Report

: SL WAKAD Client Name Patient location : WAKAD, Pune

DEPARTMENT OF BIOCHEMISTRY						
Test Name	Result	Unit	Bio. Ref. Range	Method		
GLUCOSE, RANDOM , SODIUM FLUORIDE PLASMA	329	mg/dL	70-140	HEXOKINASE		
HBA1C, GLYCATED HEMOGLOBIN , WHOLE BLOOD-EDTA	9.6	%		HPLC		
ESTIMATED AVERAGE GLUCOSE (eAG) , WHOLE BLOOD-EDTA	229	mg/dL		Calculated		

Comment:

Reference Range as per American Diabetes Association (ADA):

REFERENCE GROUP	HBA1C IN %
NON DIABETIC ADULTS > 18 YEARS	<5.7
AT RISK (PREDIABETES)	5.7 – 6.4
DIAGNOSING DIABETES	>= 6,5
DIABETICS	Park Charles I I I I I I I I I I I I I I I I I I I
EXCELLENT CONTROL	6-7
FAIR TO GOOD CONTROL	7 – 8
UNSATISFACTORY CONTROL	8 – 10
POOR CONTROL	>10

Note: Dietary preparation or fasting is not required.

- 1. A1C test should be performed at least two times a year in patients who are meeting treatment goals (and who have stable glycemic control).
- 2. Lowering A1C to below or around 7% has been shown to reduce microvascular and neuropathic complications of type 1 and type 2 diabetes. When mean annual HbA1c is <1.1 times ULN (upper limit of normal), renal and retinal complications are rare, but complications occur in >70% of cases when HbA1c is >1.7 times ULN.
- 3. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present. Fructosamine may be used as an alternate measurement of glycemic control



Page 3 of 4

After









Patient Name Age/Gender UHID/MR No Visit ID Ref Doctor : Mrs.JYOTI KALSI : 47 Y 0 M 0 D /F : DWKA.0000000016 : DWKAOPV27

: Dr.SELF

IP/OP NO

: 07/Sep/2020 05:27PM : 07/Sep/2020 08:36PM : 07/Sep/2020 08:52PM : Final Report : SL WAKAD Collected Received Reported Status

Client Name Patient location : WAKAD, Pune

EMISTRY	BIOCH	OF	MENT	DEPART	
----------------	-------	----	------	--------	--

Test Name	Result	Unit	Bio. Ref. Range	Method

-				
GLUCOSE, RANDOM, SODIUM FLUORIDE	207	mg/dL	70-140	HEXOKINASE
PLASMA		100 mark 100 mark		PERMANDISTRATION PRODUCTION





Page 3 of 4







Patient Name : Mrs.JYOTI KALSI Age/Gender UHID/MR No Visit ID : 47 Y 0 M 0 D /F : DWKA.0000000015 : DWKAOPV23

Ref Doctor : Dr.SELF

IP/OP NO

: 07/Sep/2020 02:03PM : 07/Sep/2020 06:01PM : 08/Sep/2020 02:57PM : Final Report : SL WAKAD Collected Received Reported Status

Client Name Patient location : WAKAD, Pune

DEPARTMENT OF IMMUNOLOGY					
Test Name	Result	Unit	Bio. Ref. Range	Method	
NSULIN - RANDOM , SERUM	57	mIU/mL		MIA	

*** End Of Report ***





Page 4 of 4

After







Patient Name : Mrs.JYOTI KALSI Age/Gender UHID/MR No Visit ID : 47 Y 0 M 0 D /F : DWKA.0000000016 : DWKAOPV27

Ref Doctor : Dr.SELF IP/OP NO

: 07/Sep/2020 05:27PM : 07/Sep/2020 08:37PM : 07/Sep/2020 09:15PM : Final Report Collected Received Reported

Status : SL WAKAD Client Name Patient location : WAKAD, Pune

DEPARTMENT OF IMMUNOLOGY						
Test Name	Result	Unit	Bio. Ref. Range	Method		
INSTITUTE PANDOM SERVING	16.9	mll I/ml		CMIA		

*** End Of Report ***

DR. SHIRISH POPHALIKAR MBBS,MD (PATH)

Dr. Keerthi Prakash

M,B.B.S., MD (Path) Consultant Pathologist

Page 4 of 4



Before After

REG NO. : OPD / 559

NAME : Mr. Badari Nimakwala SEX : Male

REF BY : DATE : 24/09/2020

BLOOD SUGAR (RANDOM)

<u>TESTS</u>	<u>RESULTS</u>	<u>UNIT</u>	REFERENCE RANGE
BSL(Random I)	: 157	mg/dl	65 - 150
BSL (Random II)	: 110	mg/dl	65 - 150

*** End Of Report ***



Dr.Manish Beri (MD Path) Consulting Pathologist Reg No.74978



Before After

REG NO. : OPD / 558

NAME : Mrs. Rajkumari Hemdev SEX : Female

REF BY : DATE : 24/09/2020

BLOOD SUGAR (RANDOM)

<u>TESTS</u>	<u>RESULTS</u>	<u>UNIT</u>	REFERENCE RANGE
BSL(Random I)	: 89	mg/dl	65 - 150
BSL (Random II)	: 75	mg/dl	65 - 150

*** End Of Report ***



Dr.Manish Beri (MD Path) Consulting Pathologist Reg No.74978



Before After

REG NO. : OPD / 560

NAME : Mr. Rajkumar Hemdev SEX : Male

REF BY : DATE : 24/09/2020

BLOOD SUGAR (RANDOM)

<u>TESTS</u>	<u>RESULTS</u>	<u>UNIT</u>	REFERENCE RANGE
BSL(Random I)	: 196	mg/dl	65 - 150
BSL (Random II)	: 160	mg/dl	65 - 150

*** End Of Report ***



Dr.Manish Beri (MD Path) Consulting Pathologist Reg No.74978





Regd. Office/National Reference Lab: Dr. Lal PathLabs Ltd., Block E, Sector-18, Rohini, New Delhi - 110085 Tel: +91-11-3024-4100, 3988-5050, Fax: +91-11-2788-2134, E-mail: talpathlabs@laipathlabs.com Web: www.laipathlabs.com, CIN No.: L74899DL1995PLC065388

A48 - NANDINI LABORATORY S/O SHAMRAO RAJARAM DALVI,PLOT NO17 507/ B OPP SAMRATNAGAR GARDEN GATE SAMRATH Kolhapur

: 25/11/2020 12:27:00PM Name Mr. NARAYAN BHOSALE Collected 25/11/2020 2:35:57PM Received : 277228141 Age: 54 Years Lab No. Male Gender: 25/11/2020 5:48:58PM Reported Ref By : SELF A/c Status : P Report Status Final

 Test Name
 Results
 Units
 Bio. Ref. Interval

 GLUCOSE, RANDOM (R), PLASMA (Hexokinase)
 293.00
 mg/dL
 70.00 - 140.00

 INSULIN, RANDOM, SERUM
 50.80
 μU/mL
 Not Established

Note

- A single random blood sample for insulin may provide insufficient information due to wide variation in the time responses of insulin levels and blood glucose.
- Stimulation of insulin secretion may be caused by many factors like hyperglycemia, glucagon, amino acids, growth hormone and catecholamines.
- Interference in insulin assay is seen due to insulin antibodies which develop in patients treated with bovine or porcine insulin.

Clinical Utility

- · Evaluation of fasting hypoglycemia
- Evaluation of Polycystic Ovary syndrome
- · Classification of Diabetes mellitus
- · Predict Diabetes mellitus
- Assessment of Beta cell activity
- · Select optimal therapy for Diabetes
- · Investigation of insulin resistance
- Predict the development of Coronary Artery Disease

Increased levels - Insulinoma, Some Type II diabetic patients, Infantile hypoglycemia, Hyperinsulinism,
Obesity, Cushing's syndrome, Oral contraceptives, Acromegaly, Hyperthyroidism





8 Dr Lal PathLabs

Regd. Office/National Reference Lab: Dr. Lat PatriLab: Ltd., Block E., Sector-18, Rohini, New Dehi - 110085 Tel: +91-11-3024-4100, 3988-3939, Fax: +91-11-2788-2134, E-mail: sipathiabs@laipathiabs.com Web: www.lapathiabs.com. CTN No. 174999011999FL0055388

A48 - NANDINI LABORATORY S/O SHAMRAO RAJARAM DALVI,PLOT NO17 507/ B OPP SAMRATNAGAR GARDEN GATE SAMRATH

Kolhapur

Name : NARAYAN BHOSALE Collected : 25/11/2020 2:53:00PM Received · 25/11/2020 4:46:36PM : 277228136 Age: 54 Years Lab No. Gender: Male 25/11/2020 6:43:29PM Reported Ref By : SELF Report Status A/c Status : P Final

Test Name	Results	Units	Bio. Ref. Interval
GLUCOSE, RANDOM (R), PLASMA (Hexokinase)	205.00	mg/dL	70.00 - 140.00
INSULIN, RANDOM, SERUM	37.32	μU/mL	Not Established

Note

- A single random blood sample for insulin may provide insufficient information due to wide variation in the time responses of insulin levels and blood glucose.
- Stimulation of insulin secretion may be caused by many factors like hyperglycemia, glucagon, amino acids, growth hormone and catecholamines.
- Interference in insulin assay is seen due to insulin antibodies which develop in patients treated with bovine or porcine insulin.

Clinical Utility

- · Evaluation of fasting hypoglycemia
- · Evaluation of Polycystic Ovary syndrome
- Classification of Diabetes mellitus
- Predict Diabetes mellitus
- Assessment of Beta cell activity
- Select optimal therapy for Diabetes
- Investigation of insulin resistance
- Predict the development of Coronary Artery Disease

Increased levels - Insulinoma, Some Type II diabetic patients, Infantile hypoglycemia, Hyperinsulinism, Obesity, Cushing's syndrome, Oral contraceptives, Acromegaly, Hyperthyroidism







Regd. Office/National Reference Lab: Dr. Lai Pathilabs Ltd., Block E, Sector-18, Rohini, New Delhi - 110085 Tel: +91-11-3024-4100, 3988-5050, Fax: +91-11-2788-2134, E-mail: laipathiabs@laipathiabs.com Web: www.laipathiabs.com, CIN No.: I/34899DL1995PLC065388

A48 - NANDINI LABORATORY S/O SHAMRAO RAJARAM DALVI,PLOT NO17 507/B OPP SAMRATNAGAR GARDEN GATE SAMRATH Kolhapur

25/11/2020 12:22:00PM Name : Mrs. PRABHA SHINGTE Collected 25/11/2020 2:34:40PM Received 277228143 Age: 78 Years Lab No. Female Gender: 25/11/2020 5:48:39PM Reported Ref By : SELF A/c Status : P Report Status Final

 Test Name
 Results
 Units
 Bio. Ref. Interval

 GLUCOSE, RANDOM (R), PLASMA (Hexokinase)
 322.00
 mg/dL
 70.00 - 140.00

 INSULIN, RANDOM, SERUM
 129.00
 μU/mL
 Not Established

Note

- A single random blood sample for insulin may provide insufficient information due to wide variation in the time responses of insulin levels and blood glucose.
- Stimulation of insulin secretion may be caused by many factors like hyperglycemia, glucagon, amino acids, growth hormone and catecholamines.
- Interference in insulin assay is seen due to insulin antibodies which develop in patients treated with bovine or porcine insulin.

Clinical Utility

- · Evaluation of fasting hypoglycemia
- · Evaluation of Polycystic Ovary syndrome
- Classification of Diabetes mellitus
- Predict Diabetes mellitus
- Assessment of Beta cell activity
- Select optimal therapy for Diabetes
- Investigation of insulin resistance
- Predict the development of Coronary Artery Disease

Increased levels - Insulinoma, Some Type II diabetic patients, Infantile hypoglycemia, Hyperinsulinism,
Obesity, Cushing's syndrome, Oral contraceptives, Acromegaly, Hyperthyroidism







Regd. Office/National Reference Lab: Dr. Lal PathLabs Ltd., Block E, Sector-18, Rohini, New Delhi - 110085 Tel: +91-11-3024-4100, 3989-5090, Fax: +91-11-2788-2134, E-mail: talpathlabs@laipathlabs.com Web: www.laipathlabs.com, CIN No.: L/4899DL1995PLC065388

A48 - NANDINI LABORATORY S/O SHAMRAO RAJARAM DALVI,PLOT NO17 507/ B OPP SAMRATNAGAR GARDEN GATE SAMRATH Kolhapur

Collected 25/11/2020 2:25:00PM Name : Mrs. PRABHA SHINGTE 25/11/2020 4:42:47PM Received Lab No. : 277228137 Age: 78 Years Gender: Female Reported 25/11/2020 6:56:42PM Ref By : SELF A/c Status : P Report Status Final

 Test Name
 Results
 Units
 Bio. Ref. Interval

 GLUCOSE, RANDOM (R), PLASMA (Hexokinase)
 151.00
 mg/dL
 70.00 - 140.00

 INSULIN, RANDOM, SERUM
 63.81
 μU/mL
 Not Established

Note

- A single random blood sample for insulin may provide insufficient information due to wide variation in the time responses of insulin levels and blood glucose.
- Stimulation of insulin secretion may be caused by many factors like hyperglycemia, glucagon, amino acids, growth hormone and catecholamines.
- Interference in insulin assay is seen due to insulin antibodies which develop in patients treated with bovine or porcine insulin.

Clinical Utility

- Evaluation of fasting hypoglycemia
- · Evaluation of Polycystic Ovary syndrome
- · Classification of Diabetes mellitus
- Predict Diabetes mellitus
- · Assessment of Beta cell activity
- Select optimal therapy for Diabetes
- Investigation of insulin resistance
- Predict the development of Coronary Artery Disease

Increased levels - Insulinoma, Some Type II diabetic patients, Infantile hypoglycemia, Hyperinsulinism,
Obesity, Cushing's syndrome, Oral contraceptives, Acromegaly, Hyperthyroidism





& Dr Lal PathLabs

Regd. Office/National Reference Lab: Dr. Lal PatriLabs Ltd., Block E, Sector-18, Rohini, New Delhi - 110085 Tel: +91-11-3024-4100, 3988-5050, Fax: +91-11-2788-2134, E-mail; lalpathlabs@lalpatrilabs.com Web: www.lalpathlabs.com, CIN No.: L74899DL1995PLC065388

A48 - NANDINI LABORATORY S/O SHAMRAO RAJARAM DALVI,PLOT NO17 507/ B OPP SAMRATNAGAR GARDEN GATE SAMRATH

Test Name	Results	Units	Bio. Ref. Interval
GLUCOSE, RANDOM (R), PLASMA (Hexokinase)	132.00	mg/dL	70.00 - 140.00
INSULIN, RANDOM, SERUM	12.04	μU/mL	Not Established

Note

Kolhapur

- A single random blood sample for insulin may provide insufficient information due to wide variation in the time responses of insulin levels and blood glucose.
- Stimulation of insulin secretion may be caused by many factors like hyperglycemia, glucagon, amino acids, growth hormone and catecholamines.
- Interference in insulin assay is seen due to insulin antibodies which develop in patients treated with bovine or porcine insulin.

Clinical Utility

- · Evaluation of fasting hypoglycemia
- · Evaluation of Polycystic Ovary syndrome
- · Classification of Diabetes mellitus
- Predict Diabetes mellitus
- · Assessment of Beta cell activity
- Select optimal therapy for Diabetes
- · Investigation of insulin resistance
- Predict the development of Coronary Artery Disease

Increased levels - Insulinoma, Some Type II diabetic patients, Infantile hypoglycemia, Hyperinsulinism, Obesity, Cushing's syndrome, Oral contraceptives, Acromegaly, Hyperthyroidism





& Dr Lal PathLabs

Regd. Office/National Reference Lab: Dr. Lal Pathilabs Ltd., Block E, Sector-18, Rohini, New Dehi - 110085 Tel-49-11-3024-4100, 3998-3950, Fax: +91-11-2288-2134, E-mail: lapathlabs@lapathlabs.com Web: www.lapathlabs.com

A48 - NANDINI LABORATORY S/O SHAMRAO RAJARAM DALVI,PLOT NO17 507/ B OPP SAMRATNAGAR GARDEN GATE SAMRATH Kolhapur

Name : PRITI MANTRI Collected 25/11/2020 2:19:00PM Received 25/11/2020 4:49:09PM : 277228138 Age: 44 Years Lab No. Gender: Female Reported 25/11/2020 6:52:40PM A/c Status P Ref By : SELF Report Status Final

Test Name	Results	Units	Bio. Ref. Interval
GLUCOSE, RANDOM (R), PLASMA (Hexokinase)	94.00	mg/dL	70.00 - 140.00
INSULIN, RANDOM, SERUM	7.05	μU/mL	Not Established

Note

- A single random blood sample for insulin may provide insufficient information due to wide variation in the time responses of insulin levels and blood glucose.
- Stimulation of insulin secretion may be caused by many factors like hyperglycemia, glucagon, amino acids, growth hormone and catecholamines.
- Interference in insulin assay is seen due to insulin antibodies which develop in patients treated with bovine or porcine insulin.

Clinical Utility

- · Evaluation of fasting hypoglycemia
- · Evaluation of Polycystic Ovary syndrome
- · Classification of Diabetes mellitus
- Predict Diabetes mellitus
- · Assessment of Beta cell activity
- Select optimal therapy for Diabetes
- · Investigation of insulin resistance
- Predict the development of Coronary Artery Disease

Increased levels - Insulinoma, Some Type II diabetic patients, Infantile hypoglycemia, Hyperinsulinism, Obesity, Cushing's syndrome, Oral contraceptives, Acromegaly, Hyperthyroidism









DEDOD

NAME : ASHISH KEJRIWAL(47Y/M)

REF. BY :SELF

TEST ASKED : ADV FULL BODY CHECKUP

SAMPLE COLLECTED AT :ADDRESS IS L703 PALM COURT COMPLEX LINK ROAD MALAD WEST MUMBAI , - 400064

TEST NAME	OBSERVATION	UNITS	REFERENCE RANGE
COMPLETE URINOGRAM			
URINARY GLUCOSE	100	mg/dl	Negative
JRINARY BILIRUBIN	NEGATIVE	mg/dl	Negative
JRINE KETONE	NEGATIVE	mg/dl	Negative
PECIFIC GRAVITY	1.02	-	1.003-1.030
JRINE BLOOD	NEGATIVE	Cells/ul*	Negative
РН	5.5	-	5 - 8
JRINARY PROTEIN	NEGATIVE	mg/dl	Negative
JROBILINOGEN	0.2	mg/dl	<=0.2
IITRITE	NEGATIVE	-	Negative
RINARY LEUCOCYTES	NEGATIVE	Cells/ul*	Negative
COLOUR	PALE YELLOW	-	Pale Yellow
PPEARANCE	CLEAR	-	Clear
BILE SALT	NEGATIVE	-	Negative
BILE PIGMENT	NEGATIVE	-	Negative
PITHELIAL CELLS	1-2	-	2-3
CASTS	ABSENT	-	Absent
CRYSTALS	ABSENT	-	Absent
BACTERIA	ABSENT	-	Absent

* To Obtain Counts in Cells / HPF Divide the Cells / ul by 5

Please correlate with clinical conditions.

Method: Manual Dipstick Method

Remarks :Alert!!!

Yeast cells are present.

Sample Collected on (SCT)
Sample Received on (SRT)

Sample Received on (SRT)
Report Released on (RRT)

Sample Type

Labcode Barcode

:30 Aug 2020 12:00

30 Aug 2020 23:31

:31 Aug 2020 01:26

URINE

:3008006545/PP004

:Q3810426

Prachlukan

Dr.Prachi Sinkar MD(Path)



Dr.Caesar Senguta MD(Micro)

Page : 1 of 21









:ASHISSH KEJRIWAL(47Y/M) NAME

REF. BY :SELF

TEST ASKED : COMPLETE URINE ANALYSIS

SAMPLE COLLECTED AT : L703 TAMCOLD COMPLEX LINK ROAD MALAD WEST MUMBAI , - ,

TEST NAME	OBSERVATION	UNITS	REFERENCE RANGE
COMPLETE URINOGRAM			
JRINARY GLUCOSE	NEGATIVE	mg/dl	Negative
JRINARY BILIRUBIN	NEGATIVE	mg/dl	Negative
IRINE KETONE	NEGATIVE	mg/dl	Negative
PECIFIC GRAVITY	1.02	-	1.003-1.030
RINE BLOOD	NEGATIVE	Cells/ul*	Negative
Н	5.5	-	5 - 8
RINARY PROTEIN	NEGATIVE	mg/dl	Negative
ROBILINOGEN	0.2	mg/dl	<=0.2
TRITE	NEGATIVE	-	Negative
RINARY LEUCOCYTES	NEGATIVE	Cells/ul*	Negative
DLOUR	PALE YELLOW	-	Pale Yellow
PPEARANCE	CLEAR	-	Clear
ILE SALT	NEGATIVE	-	Negative
ILE PIGMENT	NEGATIVE	-	Negative
PITHELIAL CELLS	1-2	-	2-3
ASTS	ABSENT	-	Absent
RYSTALS	ABSENT	-	Absent
ACTERIA	PRESENT	-	Absent

st To Obtain Counts in Cells / HPF Divide the Cells / ul by 5

Please correlate with clinical conditions.

Method: Manual Dipstick Method

Remarks :Alert!!!

Yeast cells are present. Bacteria present.

Sample Collected on (SCT)

Sample Received on (SRT) Report Released on (RRT)

Sample Type

Labcode Barcode

:05 Oct 2020 09:42 :06 Oct 2020 01:03

:06 Oct 2020 02:26

: URINE

:0510005271/A9992

:Q5237108

Dr.Prachi Sinkar MD(Path)

Dr.Caesar Senguta MD(Micro)

Page: 1 of 21







: ASHISH KEJRIWAL(47Y/M) NAME

REF. BY : SELF

TEST ASKED : ADV FULL BODY CHECKUP SAMPLE COLLECTED AT :

ADDRESS IS L703 PALM COURT COMPLEX LINK ROAD MALAD WEST MUMBAI , - 400064

TEST NAME TECHNOLOGY VALUE UNITS HOMOCYSTEINE **PHOTOMETRY** 25.9 µmol/L Reference Range :-

CLINICAL SIGNIFICANCE:

HOMOCYSTEINE IS LINKED TO INCREASED RISK OF PREMATURE CORONARY ARTERY DISEASE, STROKE AND THROMBOEMBOLISM. ${\tt MOREOVER, ALZHEIMER'S\ DISEASE, OSTEOPOROSIS, VENOUS\ THROMBOSIS, SCHIZOPHRENIA, COGNITIVE\ DEFICIENCY\ AND}$ PREGNANCY COMPLICATIONS ALSO ELEVATES HOMOCYSTEINE LEVELS.

HIGH VALUES:

ELEVATED HOMOCYSTEINE LEVELS MIGHT BE DUE TO INCREASING AGE, GENETIC TRAITS, DRUGS, RENAL DYSFUNCTION AND DIETARY DEFICIENCY OF VITAMINS OR SMOKING. TO LOWER YOUR HOMOCYSTEINE, EAT MORE GREEN VEGETABLES, STOP SMOKING, ALCOHOL, FOLIC ACID HELPS LOWERING ELEVATED LEVELS.

Please correlate with clinical conditions.

Method:- ENZYMATIC ASSAY

Sample Collected on (SCT) Sample Received on (SRT)

Report Released on (RRT)

Sample Type

Labcode

: 3008037375/PP004 :Q3891620 Barcode

30 Aug 2020 12:00

:31 Aug 2020 00:45 :31 Aug 2020 05:27

:SERUM

Dr.Prachi Sinkar MD(Path)

Dr.Caesar Senguta MD(Micro)

Page : 2 of 21



After





REPOR

NAME : ASHISSH KEJRIWAL(47Y/M)

REF. BY : SELF

TEST ASKED : AAROGYAM 1.3,BLOOD SUGAR (F),COMPLETE URINE

ANALYSIS

SAMPLE COLLECTED AT :

L703 TAMCOLD COMPLEX LINK ROAD MALAD

WEST MUMBAI , - ,

TEST NAME	TECHNOLOGY	VALUE	UNITS
HOMOCYSTEINE	PHOTOMETRY	32.3	μmol/L
Reference Range :-			-

< 30

CLINICAL SIGNIFICANCE:

HOMOCYSTEINE IS LINKED TO INCREASED RISK OF PREMATURE CORONARY ARTERY DISEASE, STROKE AND THROMBOEMBOLISM. MOREOVER, ALZHEIMER□S DISEASE, OSTEOPOROSIS, VENOUS THROMBOSIS, SCHIZOPHRENIA, COGNITIVE DEFICIENCY AND PREGNANCY COMPLICATIONS ALSO ELEVATES HOMOCYSTEINE LEVELS.

HIGH VALUES

ELEVATED HOMOCYSTEINE LEVELS MIGHT BE DUE TO INCREASING AGE, GENETIC TRAITS, DRUGS, RENAL DYSFUNCTION AND DIETARY DEFICIENCY OF VITAMINS OR SMOKING. TO LOWER YOUR HOMOCYSTEINE, EAT MORE GREEN VEGETABLES, STOP SMOKING, ALCOHOL. FOLIC ACID HELPS LOWERING ELEVATED LEVELS.

Please correlate with clinical conditions.

Method:- ENZYMATIC ASSAY

 Sample Collected on (SCT)
 : 05 Oct 2020 09:42

 Sample Received on (SRT)
 : 06 Oct 2020 00:36

 Report Released on (RRT)
 : 06 Oct 2020 07:59

 Sample Type
 : SERUM

 Labcode
 : 0510057841/A9992

Barcode : Q9429007

Practimen

Dr.Prachi Sinkar MD(Path)

(Der

Dr.Caesar Senguta MD(Micro)

Page: 3 of 21







: ASHISH KEJRIWAL(47Y/M) NAME

REF. BY : SELF

TEST ASKED : ADV FULL BODY CHECKUP SAMPLE COLLECTED AT :

ADDRESS IS L703 PALM COURT COMPLEX LINK ROAD MALAD WEST MUMBAI , - 400064

TEST NAME TECHNOLOGY VALUE UNITS CYSTATIN C **IMMUNOTURBIDIMETRY** 1.1 mg/L Reference Range :-

<= 60 years: <= 1.03 mg/L

> 60 years : < 1.50 mg/L

Clinical significance

Cystatin c, is a small 13-kda protein and is a member of the cysteine proteinase inhibitor family, it is produced at a constant rate by all nucleated cells. Due to its small size it is freely filtered by the glomerulus and is not secreted but is fully reabsorbed and broken down by the renal tubules. This means that the primary determinate of blood Cystatin c levels is the rate at which it is filtered at the glomerulus making it an excellent gfr marker. Cystatin c is also a marker of inflammation and like many other markers of inflammation; its serum concentration may be higher in patients with decreased renal clearance. There is mounting evidence, however, that Cystatin c may be a predictor of adverse outcomes independent of renal function with its higher sensitivity to detect a reduced GFR than Creatinine determination, also in the so-called "Creatinine-blind" range. Thus, Cystatin c is suggested to be a better marker for GFR than the ubiquitous serum Creatinine.

Reference

1. Barrett aj, Davies me, Grubb a. the place of human gamma-trace (Cystatin c) among the cysteine proteinase inhibitors. Biochem biophys res common 1984; 120: 631-6.

2. Grubb a. diagnostic value of analysis of Cystatin c and protein HC in biological fluids. Clin Nephrol 1992; 38: S20-7.

Please correlate with clinical conditions.

Method:- LATEX ENHANCED IMMUNOTURBIDIMETRY

Sample Collected on (SCT) Sample Received on (SRT) Report Released on (RRT)

Sample Type

Labcode

:Q3891620 Barcode

.30 Aug 2020 12:00 .31 Aug 2020 00:45

. 31 Aug 2020 05:27

. SERUM

: 3008037375/PP004

Dr.Prachi Sinkar MD(Path)

Dr.Caesar Senguta MD(Micro)

Page: 3 of 21









REPOR

NAME : ASHISSH KEJRIWAL(47Y/M)

REF. BY : SELF

TEST ASKED : AAROGYAM 1.3,BLOOD SUGAR (F),COMPLETE URINE

ANALYSIS

SAMPLE COLLECTED AT :

L703 TAMCOLD COMPLEX LINK ROAD MALAD

WEST MUMBAI , - ,

TEST NAME TECHNOLOGY VALUE UNITS

CYSTATIN C IMMUNOTURBIDIMETRY 1.22 mg/L

Reference Range :-

<= 60 years: <= 1.03 mg/L > 60 years : < 1.50 mg/L

Clinical significance

Cystatin c, is a small 13-kda protein and is a member of the cysteine proteinase inhibitor family, it is produced at a constant rate by all nucleated cells. Due to its small size it is freely filtered by the glomerulus and is not secreted but is fully reabsorbed and broken down by the renal tubules. This means that the primary determinate of blood Cystatin c levels is the rate at which it is filtered at the glomerulus making it an excellent gfr marker. Cystatin c is also a marker of inflammation and like many other markers of inflammation; its serum concentration may be higher in patients with decreased renal clearance. There is mounting evidence, however, that Cystatin c may be a predictor of adverse outcomes independent of renal function with its higher sensitivity to detect a reduced GFR than Creatinine determination, also in the so-called

Creatinine-blind range. Thus, Cystatin c is suggested to be a better marker for GFR than the ubiquitous serum Creatinine.

Reference

1. Barrett aj, Davies me, Grubb a. the place of human gamma-trace (Cystatin c) among the cysteine proteinase inhibitors. Biochem biophys res common 1984; 120: 631-6.

2. Grubb a. diagnostic value of analysis of Cystatin c and protein HC in biological fluids. Clin Nephrol 1992; 38: S20-7.

Please correlate with clinical conditions.

Method:- LATEX ENHANCED IMMUNOTURBIDIMETRY

 Sample Collected on (SCT)
 : 05 Oct 2020 09:42

 Sample Received on (SRT)
 : 06 Oct 2020 00:36

: 06 Oct 2020 07:59

Report Released on (RRT)
Sample Type

 Sample Type
 : SERUM

 Labcode
 : 0510057841/A9992

Barcode : Q9429007

Practimen

Dr.Prachi Sinkar MD(Path)

91

Dr.Caesar Senguta MD(Micro)

Page: 4 of 21







: ASHISH KEJRIWAL(47Y/M) NAME

REF. BY : SELF

TEST ASKED : ADV FULL BODY CHECKUP SAMPLE COLLECTED AT :

ADDRESS IS L703 PALM COURT COMPLEX LINK ROAD MALAD WEST MUMBAI , - 400064

TEST NAME TECHNOLOGY VALUE UNITS LIPOPROTEIN (A) [LP(A)] **IMMUNOTURBIDIMETRY** 21.7 mg/dl Reference Range :-

ADULTS: < 30.0 MG/DL

INTERPRETATION:

DETERMINATION OF LPA MAY BE USEFUL TO GUIDE MANAGEMENT OF INDIVIDUALS WITH A FAMILY HISTORY OF CHD OR WITH EXISTING DISEASE, THE LEVELS OF LPA IN THE BLOOD DEPENDS ON GENETIC FACTORS; THE RANGE OF VARIATION IN A POPULATION IS RELATIVELY LARGE AND HENCE FOR DIAGNOSTIC PURPOSE, RESULTS SHOULD ALWAYS BE ASSESSED IN CONJUNCTION WITH THE PATIENT'S MEDICAL HISTORY, CLINICAL EXAMINATION AND OTHER FINDINGS.

SPECIFICATIONS:

PRECISION: INTRA ASSAY (%CV): 3.4 %, INTER ASSAY (%CV): 2.0 %; SENSITIVITY: 0.002 GM/L

EXTERNAL QUALITY CONTROL PROGRAM PARTICIPATION:

COLLEGE OF AMERICAN PATHOLOGISTS: GENERAL CHEMISTRY AND TDM; CAP NUMBER: 7193855-01

KIT VALIDATION REFERENCES:

KOSCHINSKY ML, MARCOVINA SM. LIPOPROTEIN A: STRUCTURAL IMPLICATION FOR PATHOPHYSIOLOGY. INT J CLIN LAB RES, 1997; 27: 14-23.

Please correlate with clinical conditions.

Method:- LATEX ENHANCED IMMUNOTURBIDIMETRY

Sample Collected on (SCT) Sample Received on (SRT)

Report Released on (RRT)

Sample Type

Labcode

Barcode

.30 Aug 2020 12:00

:31 Aug 2020 00:45

.31 Aug 2020 05:27 :SERUM

:3008037375/PP004

:Q3891620

Dr.Prachi Sinkar MD(Path)

Dr.Caesar Senguta MD(Micro)

Page: 4 of 21









: ASHISSH KEJRIWAL(47Y/M) NAME

REF. BY : SELF

TEST ASKED : AAROGYAM 1.3,BLOOD SUGAR (F),COMPLETE URINE

ANALYSIS

SAMPLE COLLECTED AT :

L703 TAMCOLD COMPLEX LINK ROAD MALAD

WEST MUMBAI , - ,

TEST NAME TECHNOLOGY VALUE UNITS LIPOPROTEIN (A) [LP(A)] **IMMUNOTURBIDIMETRY** 16.4 mg/dl Reference Range :-

ADULTS: < 30.0 MG/DL

INTERPRETATION:

DETERMINATION OF LPA MAY BE USEFUL TO GUIDE MANAGEMENT OF INDIVIDUALS WITH A FAMILY HISTORY OF CHD OR WITH EXISTING DISEASE. THE LEVELS OF LPA IN THE BLOOD DEPENDS ON GENETIC FACTORS; THE RANGE OF VARIATION IN A POPULATION IS RELATIVELY LARGE AND HENCE FOR DIAGNOSTIC PURPOSE, RESULTS SHOULD ALWAYS BE ASSESSED IN CONJUNCTION WITH THE PATIENT S MEDICAL HISTORY, CLINICAL EXAMINATION AND OTHER FINDINGS.

SPECIFICATIONS:

PRECISION: INTRA ASSAY (%CV): 3.4 %, INTER ASSAY (%CV): 2.0 %; SENSITIVITY: 0.002 GM/L

EXTERNAL QUALITY CONTROL PROGRAM PARTICIPATION:

COLLEGE OF AMERICAN PATHOLOGISTS: GENERAL CHEMISTRY AND TDM; CAP NUMBER: 7193855-01

KIT VALIDATION REFERENCES:

KOSCHINSKY ML, MARCOVINA SM. LIPOPROTEIN A: STRUCTURAL IMPLICATION FOR PATHOPHYSIOLOGY. INT J CLIN LAB RES, 1997; 27: 14-23

Please correlate with clinical conditions.

Method:- LATEX ENHANCED IMMUNOTURBIDIMETRY

Sample Collected on (SCT) : 05 Oct 2020 09:42 Sample Received on (SRT) :06 Oct 2020 00:36 Report Released on (RRT) :06 Oct 2020 07:59

Sample Type

: SERUM Labcode :0510057841/A9992

: Q9429007 Barcode

Dr.Prachi Sinkar MD(Path)

Dr.Caesar Senguta MD(Micro)

Page: 5 of 21







REPORT

NAME : ASHISH KEJRIWAL(47Y/M)

REF. BY : SELF

TEST ASKED : ADV FULL BODY CHECKUP

SAMPLE COLLECTED AT :

ADDRESS IS L703 PALM COURT COMPLEX LINK ROAD MALAD WEST MUMBAI , - 400064

TEST NAME TECHNOLOGY VALUE UNITS IMMUNOTURBIDIMETRY 138 mg/dL **APOLIPOPROTEIN - A1 (APO-A1)** Reference Range: MALE : 86 - 152 FEMALE : 94 - 162 Method: FULLY AUTOMATED RATE IMMUNOTURBIDIMETRY - BECKMAN COULTER **APOLIPOPROTEIN - B (APO-B) IMMUNOTURBIDIMETRY** 81 mg/dL Reference Range: MALE : 56 - 145 FEMALE : 53 - 138 Method: FULLY AUTOMATED RATE IMMUNOTURBIDIMETRY - BECKMAN COULTER APO B / APO A1 RATIO (APO B/A1) CALCULATED 0.6 Ratio Reference Range : MALE : 0.40 - 1.26 FEMALE : 0.38 - 1.14

Method: DERIVED FROM SERUM APO A1 AND APO B VALUES

Please correlate with clinical conditions.

 Sample Collected on (SCT)
 :30 Aug 2020 12:00

 Sample Received on (SRT)
 :31 Aug 2020 00:45

Report Released on (RRT) : 31 Aug 2020 05:27
Sample Type : SERUM

Labcode : 3008037375/PP004

Barcode : Q3891620

Chachental

Dr.Prachi Sinkar MD(Path)

(an

Dr.Caesar Senguta MD(Micro)

Page : 5 of 21









NAME : ASHISSH KEJRIWAL(47Y/M)

REF. BY : SELF

TEST ASKED : AAROGYAM 1.3,BLOOD SUGAR (F),COMPLETE URINE

ANALYSIS

SAMPLE COLLECTED AT :

L703 TAMCOLD COMPLEX LINK ROAD MALAD WEST MUMBAI , - ,

TEST NAME	TECHNOLOGY	VALUE	UNITS
APOLIPOPROTEIN - A1 (APO-A1)	IMMUNOTURBIDIMETRY	151	mg/dL
Reference Range :			
MALE : 86 - 152			
FEMALE : 94 - 162			
Method: FULLY AUTOMATED RATE IMMUNOTURBIDI	METRY □ BECKMAN COULTER		
APOLIPOPROTEIN - B (APO-B)	IMMUNOTURBIDIMETRY	88	mg/dL
Reference Range :			
MALE : 56 - 145			
FEMALE : 53 - 138			
Method: FULLY AUTOMATED RATE IMMUNOTURBIDI	METRY □ BECKMAN COULTER		
APO B / APO A1 RATIO (APO B/A1)	CALCULATED	0.6	Ratio
Reference Range :			
MALE 0.40 4.20			

MALE : 0.40 - 1.26
FEMALE : 0.38 - 1.14
Method : DERIVED FROM SERUM APO A1 AND APO B VALUES

Please correlate with clinical conditions.

Sample Collected on (SCT) :05 Oct 2020 09:42 Sample Received on (SRT) :06 Oct 2020 00:36 Report Released on (RRT) :06 Oct 2020 07:59

: SERUM Sample Type

Labcode

: Q9429007 Barcode

:0510057841/A9992 Dr.Prachi Sinkar MD(Path)

Dr.Caesar Senguta MD(Micro)

Page : 6 of 21







DEHADI

NAME : ASHISH KEJRIWAL(47Y/M)

REF. BY : SELF

TEST ASKED : ADV FULL BODY CHECKUP

SAMPLE COLLECTED AT :

ADDRESS IS L703 PALM COURT COMPLEX LINK ROAD MALAD WEST MUMBAI , - 400064

TEST NAME TECHNOLOGY VALUE UNITS
HIGH SENSITIVITY C-REACTIVE PROTEIN (HS-CRP) IMMUNOTURBIDIMETRY 2.1 mg/L
Reference Range:-

ADULT: <=3.0 MG/L

INTERPRETATION:

HIGH SENSITIVITY C-REACTIVE PROTEIN, WHEN USED IN CONJUNCTION WITH OTHER CLINICAL LABORATORY EVALUATION OF ACUTE CORONARY SYNDROMES, MAY BE USEFUL AS AN INDEPENDENT MARKER OF PROGNOSIS FOR RECURRENT EVENTS, IN PATIENTS WITH STABLE CORONARY DISEASE OR ACUTE CORONARY SYNDROMES. HSCRP LEVELS SHOULD NOT BE SUBSTITUTED FOR ASSESSMENT OF TRADITIONAL CARDIOVASCULAR RISK FACTORS. PATIENTS WITH PERSISTENTLY UNEXPLAINED, MARKED EVALUATION OF HSCRP AFTER REPEATED TESTING SHOULD BE EVALUATED FOR NON - CARDIOVASCULAR ETIOLOGIES

CLINICAL SIGNIFICANCE:

HSCRP MEASUREMENTS MAY BE USED AS AN INDEPENDENT RISK MARKER FOR THE IDENTIFICATION OF INDIVIDUALS AT RISK FOR FUTURE CARDIOVASCULAR DISEASE. ELEVATED CRP VALUES MAY BE INDICATIVE OF PROGNOSIS OF INDIVIDUALS WITH ACUTE CORONARY SYNDROMES, AND MAY BE USEFUL IN THE MANAGEMENT OF SUCH INDIVIDUALS.

SPECIFICATIONS: PRECISION: WITHIN RUN %CV HAS BEEN RECORDED <=5%.

REFERENCES:

- 1. CHENILLOT O, HENNY J, STEINMEZ J, ET AL. HIGH SENSITIVITY C-REACTIVE PROTEIN: BIOLOGICAL VARIATIONS AND REFERENCE LIMITS. CLIN CHEM LAB MED 2000;38:1003-11.
- 2. HIND CRH, PEPYS MB. THE ROLE OF SERUM C-REACTIVE PROTEIN MEASUREMENTS IN CLINICAL PRACTICE. INT MED 1984;5:112-51.

Please correlate with clinical conditions.

Method:- FULLY AUTOMATED LATEX AGGLUTINATION - BECKMAN COULTER

 Sample Collected on (SCT)
 : 30 Aug 2020 12:00

 Sample Received on (SRT)
 : 31 Aug 2020 00:45

 Report Released on (RRT)
 : 31 Aug 2020 05:27

Sample Type : SERUM

 Labcode
 : 3008037375/PP004

 Barcode
 : Q3891620

Dr.Prachi Sinkar MD(Path)

Dr.Caesar Sengu**t**a MD(Micro)

Page : 6 of 21









After

: ASHISSH KEJRIWAL(47Y/M) NAME

REF. BY : SELF

TEST ASKED : AAROGYAM 1.3,BLOOD SUGAR (F),COMPLETE URINE

ANALYSIS

SAMPLE COLLECTED AT :

L703 TAMCOLD COMPLEX LINK ROAD MALAD

WEST MUMBAI , - ,

TEST NAME	TECHNOLOGY	VALUE	UNITS
HIGH SENSITIVITY C-REACTIVE PROTEIN (HS-CRP)	IMMUNOTURBIDIMETRY	2.1	mg/L
Reference Range :-			

ADULT: <=3.0 MG/L

INTERPRETATION:

HIGH SENSITIVITY C-REACTIVE PROTEIN, WHEN USED IN CONJUNCTION WITH OTHER CLINICAL LABORATORY EVALUATION OF ACUTE CORONARY SYNDROMES, MAY BE USEFUL AS AN INDEPENDENT MARKER OF PROGNOSIS FOR RECURRENT EVENTS, IN PATIENTS WITH STABLE CORONARY DISEASE OR ACUTE CORONARY SYNDROMES. HSCRP LEVELS SHOULD NOT BE SUBSTITUTED FOR ASSESSMENT OF TRADITIONAL CARDIOVASCULAR RISK FACTORS. PATIENTS WITH PERSISTENTLY UNEXPLAINED, MARKED EVALUATION OF HSCRP AFTER REPEATED TESTING SHOULD BE EVALUATED FOR NON - CARDIOVASCULAR ETIOLOGIES

CLINICAL SIGNIFICANCE:

HSCRP MEASUREMENTS MAY BE USED AS AN INDEPENDENT RISK MARKER FOR THE IDENTIFICATION OF INDIVIDUALS AT RISK FOR FUTURE CARDIOVASCULAR DISEASE. ELEVATED CRP VALUES MAY BE INDICATIVE OF PROGNOSIS OF INDIVIDUALS WITH ACUTE CORONARY SYNDROMES, AND MAY BE USEFUL IN THE MANAGEMENT OF SUCH INDIVIDUALS.

SPECIFICATIONS: PRECISION: WITHIN RUN %CV HAS BEEN RECORDED <=5%.

- 1. CHENILLOT O, HENNY J, STEINMEZ J, ET AL. HIGH SENSITIVITY C-REACTIVE PROTEIN: BIOLOGICAL VARIATIONS AND REFERENCE LIMITS. CLIN CHEM LAB MED 2000;38:1003-11.
- 2. HIND CRH, PEPYS MB. THE ROLE OF SERUM C-REACTIVE PROTEIN MEASUREMENTS IN CLINICAL PRACTICE. INT MED 1984;5:112-51.

Please correlate with clinical conditions.

Method:- FULLY AUTOMATED LATEX AGGLUTINATION □ BECKMAN COULTER

Sample Collected on (SCT) : 05 Oct 2020 09:42 Sample Received on (SRT) :06 Oct 2020 00:36 Report Released on (RRT) :06 Oct 2020 07:59

Sample Type

Barcode

: SERUM Labcode :0510057841/A9992

: Q9429007

Dr.Prachi Sinkar MD(Path)

Dr.Caesar Senguta MD(Micro)

Page: 7 of 21







PEPOPI

NAME : ASHISH KEJRIWAL(47Y/M)

REF. BY : SELF

TEST ASKED : ADV FULL BODY CHECKUP

SAMPLE COLLECTED AT :

ADDRESS IS L703 PALM COURT COMPLEX LINK ROAD MALAD WEST MUMBAI , - 400064

TEST NAME TECHNOLOGY VALUE UNITS

25-OH VITAMIN D (TOTAL) C.L.I.A 16.25 ng/ml

Reference Range:
DEFICIENCY: <20 ng/ml
INSUFFICIENCY: 20-<30 ng/ml
SUFFICIENCY: 30-100 ng/ml
TOXICITY: 100 ng/ml

Vitamin D Total test is analyzed on Siemens ADVIA Centaur, standardized against ID-LC/MS/MS, as per Vitamin D Standardization

Program (VDSP).

Method: FULLY AUTOMATED CHEMI LUMINESCENT IMMUNO ASSAY

VITAMIN B-12 C.L.I.A 254 pg/ml

Reference Range: Normal: 211 - 911 pg/ml

Clinical significance:

Vitamin B12 or cyanocobalamin, is a complex corrinoid compound found exclusively from animal dietary sources, such as meat, eggs and milk. It is critical in normal DNA synthesis, which in turn affects erythrocyte maturation and in the formation of myelin sheath. Vitamin-B12 is used to find out neurological abnormalities and impaired DNA synthesis associated with macrocytic anemias. For diagnostic purpose, results should always be assessed in conjunction with the patients medical history, clinical examination and other findings.

Specifications: Intra assay (%CV):4.0%, Inter assay (%CV):4.4 %; Sensitivity:45 pg/ml

External quality control program participation:

College of American pathologists: ligand assay (general) survey; CAP number: 7193855-01

Kit validation references:

Chen IW, Sperling MI, Heminger IA. Vitamin B12.In: Pesce AJ, Kalpan LA, editors. Methods in clinical chemistry. St. Louis: CV

Mosby,1987.P.569-73.

Method: FULLY AUTOMATED BIDIRECTIONALLY INTERFACED CHEMI LUMINESCENT IMMUNO ASSAY

Please correlate with clinical conditions.

Sample Collected on (SCT) :30 Aug 2020 12:00
Sample Received on (SRT) :31 Aug 2020 00:45

Report Released on (RRT) : 31 Aug 2020 05:27
Sample Type : SERUM

Labcode : 3008037375/PP004

Barcode : Q3891620

Practitution

Dr.Prachi Sinkar MD(Path)

(an .

Dr.Caesar Senguta MD(Micro)

Page: 7 of 21









DEPORT

NAME : ASHISSH KEJRIWAL(47Y/M)

REF. BY : SELF

TEST ASKED : AAROGYAM 1.3,BLOOD SUGAR (F),COMPLETE URINE

ANALYSIS

SAMPLE COLLECTED AT :

L703 TAMCOLD COMPLEX LINK ROAD MALAD

WEST MUMBAI , - ,

TEST NAME	TECHNOLOGY	VALUE	UNITS
25-OH VITAMIN D (TOTAL)	C.L.I.A	40.32	ng/ml

Reference Range:
DEFICIENCY : <20 ng/ml
INSUFFICIENCY : 20-<30 ng/ml
SUFFICIENCY : 30-100 ng/ml
TOXICITY : >100 ng/ml

Vitamin D Total test is analyzed on Siemens ADVIA Centaur, standardized against ID-LC/MS/MS, as per Vitamin D Standardization

Program (VDSP).

Method: FULLY AUTOMATED CHEMI LUMINESCENT IMMUNO ASSAY

VITAMIN B-12 C.L.I.A 672 pg/ml

Reference Range: Normal: 211 - 911 pg/ml

Clinical significance:

Vitamin B12 or cyanocobalamin, is a complex corrinoid compound found exclusively from animal dietary sources, such as meat, eggs and milk. It is critical in normal DNA synthesis, which in turn affects erythrocyte maturation and in the formation of myelin sheath. Vitamin-B12 is used to find out neurological abnormalities and impaired DNA synthesis associated with macrocytic anemias. For diagnostic purpose, results should always be assessed in conjunction with the patients medical history, clinical examination and other findings.

Specifications: Intra assay (%CV):4.0%, Inter assay (%CV):4.4 %; Sensitivity:45 pg/ml

External quality control program participation:

College of American pathologists: ligand assay (general) survey; CAP number: 7193855-01

Kit validation references:

Chen IW, Sperling MI, Heminger IA. Vitamin B12.In: Pesce AJ, Kalpan LA, editors. Methods in clinical chemistry. St. Louis: CV

Mosby,1987.P.569-73.

Method: FULLY AUTOMATED BIDIRECTIONALLY INTERFACED CHEMI LUMINESCENT IMMUNO ASSAY

:06 Oct 2020 07:59

Please correlate with clinical conditions.

 Sample Collected on (SCT)
 :05 Oct 2020 09:42

 Sample Received on (SRT)
 :06 Oct 2020 00:36

Sample Type : SERUM

Report Released on (RRT)

Labcode : 0510057841/A9992

Barcode : Q9429007

(nachture

: 0510057841/A9992 Dr.Prachi Sinkar MD(Path)

an.

Dr.Caesar Senguta MD(Micro)

Page: 8 of 21







: ASHISH KEJRIWAL(47Y/M) NAME

: SELF REF. BY

TEST ASKED : ADV FULL BODY CHECKUP SAMPLE COLLECTED AT :

ADDRESS IS L703 PALM COURT COMPLEX LINK ROAD MALAD WEST MUMBAI , - 400064

TEST NAME TECHNOLOGY VALUE UNITS SERUM COPPER **PHOTOMETRY** 93.8 μg/dL Reference Range :-

MALE : 63.5 - 150 FEMALE: 80 - 155

CLINICAL SIGNIFICANCE

COPPER IS AN IMPORTANT TRACE ELEMENT AND A COMPONENT OF NUMEROUS ENZYMES AND PROTEINS INVOLVED IN ENERGY PRODUCTION, CONNECTIVE TISSUE FORMATION, MELANIN SYNTHESIS, IRON METABOLISM, DEVELOPMENT OF CENTRAL NERVOUS SYSTEM, ANGIOGENESIS AS WELL AS AN ANTIOXIDANT.

DEFICIENCY CAN CAUSE - MALNOURISHMENT, CARDIOVASCULAR DISEASE, ANEMIA & NEUROPATHY. TOXICITY MAY BE MANIFESTED AS ACUTE RENAL FAILURE, GASTROENTERITIS & CHRONIC LIVER DISEASE.

REFERENCE: CARL A. BURTIS, EDWARD R. ASHWOOD, DAVID E. BRUNS. TIETZ TEXTBOOK OF CLINICAL CHEMISTRY AND MOLECULAR DIAGNOSTICS. CHAPTER 31.VITAMINS AND TRACE ELEMENTS, PAGE: 948-952.

Please correlate with clinical conditions.

Method:- 3,5-DIBR-PAESA

Sample Collected on (SCT)

Sample Received on (SRT) Report Released on (RRT)

Sample Type

Labcode

:3008037375/PP004 Barcode

:Q3891620

:SERUM

.30 Aug 2020 12:00 :31 Aug 2020 00:45

.31 Aug 2020 05:27

Dr.Prachi Sinkar MD(Path)

Dr.Caesar Senguta MD(Micro)

Page: 8 of 21









REPOR

NAME : ASHISSH KEJRIWAL(47Y/M)

REF. BY : SELF

TEST ASKED : AAROGYAM 1.3,BLOOD SUGAR (F),COMPLETE URINE

ANALYSIS

SAMPLE COLLECTED AT :

L703 TAMCOLD COMPLEX LINK ROAD MALAD

WEST MUMBAI , - ,

TEST NAMETECHNOLOGYVALUEUNITSSERUM COPPERPHOTOMETRY115.52μg/dL

Reference Range :-

MALE : 63.5 - 150 FEMALE : 80 - 155

CLINICAL SIGNIFICANCE

COPPER IS AN IMPORTANT TRACE ELEMENT AND A COMPONENT OF NUMEROUS ENZYMES AND PROTEINS INVOLVED IN ENERGY PRODUCTION, CONNECTIVE TISSUE FORMATION, MELANIN SYNTHESIS, IRON METABOLISM, DEVELOPMENT OF CENTRAL NERVOUS SYSTEM, ANGIOGENESIS AS WELL AS AN ANTIOXIDANT.

DEFICIENCY CAN CAUSE - MALNOURISHMENT, CARDIOVASCULAR DISEASE, ANEMIA & NEUROPATHY. TOXICITY MAY BE MANIFESTED AS ACUTE RENAL FAILURE, GASTROENTERITIS & CHRONIC LIVER DISEASE.

REFERENCE: CARL A. BURTIS, EDWARD R. ASHWOOD, DAVID E. BRUNS. TIETZ TEXTBOOK OF CLINICAL CHEMISTRY AND MOLECULAR DIAGNOSTICS. CHAPTER 31.VITAMINS AND TRACE ELEMENTS. PAGE: 948-952.

Please correlate with clinical conditions.

Method:- 3,5-DIBR-PAESA

 Sample Collected on (SCT)
 : 05 Oct 2020 09:42

 Sample Received on (SRT)
 : 06 Oct 2020 00:36

 Report Released on (RRT)
 : 06 Oct 2020 07:59

 Sample Type
 : SERUM

 Labcode
 : 0510057841/A9992

Barcode : Q9429007

Practimen

Dr.Prachi Sinkar MD(Path)

Jan.

Dr.Caesar Senguta MD(Micro)

Page: 9 of 21







: ASHISH KEJRIWAL(47Y/M) NAME

: SELF REF. BY

TEST ASKED : ADV FULL BODY CHECKUP SAMPLE COLLECTED AT :

ADDRESS IS L703 PALM COURT COMPLEX LINK ROAD MALAD WEST MUMBAI , - 400064

TEST NAME TECHNOLOGY VALUE UNITS SERUM ZINC **PHOTOMETRY** 102.37 μg/dL Reference Range :-

52 - 286

CLINICAL SIGNIFICANCE

ZINC IS ONE OF THE ESSENTIAL TRACE ELEMENTS IN THE BODY. ITS METALLOENZYMES PLAY A KEY ROLE IN PROTEIN AND NUCLEIC ACID SYNTHESIS, GENE EXPRESSION, WOUND HEALING, AS AN ANTIOXIDANT, ETC.

DEFICIENCY CAN CAUSE - POOR WOUND HEALING, GASTROENTERITIS, IMPAIRED SPERMATOGENESIS, ALZHEIMER'S DISEASE, ETC. TOXICITY MAY BE MANIFESTED AS PANCREATITIS, GASTRIC ULCER, ANEMIA, PULMONARY FIBROSIS.

REFERENCE: CARL A. BURTIS, EDWARD R. ASHWOOD, DAVID E. BRUNS. TIETZ TEXTBOOK OF CLINICAL CHEMISTRY AND MOLECULAR DIAGNOSTICS. CHAPTER 31.VITAMINS AND TRACE ELEMENTS. PAGE:960-965.

Please correlate with clinical conditions.

Method:- NITRO - PAPS

Sample Collected on (SCT)

Sample Received on (SRT) Report Released on (RRT)

Sample Type

Labcode

Barcode

.30 Aug 2020 12:00 :31 Aug 2020 00:45 .31 Aug 2020 05:27

:SERUM

:3008037375/PP004 :Q3891620

Dr.Prachi Sinkar MD(Path)

Dr.Caesar Senguta MD(Micro) Page: 9 of 21



After





prope

NAME : ASHISSH KEJRIWAL(47Y/M)

REF. BY : SELF

TEST ASKED : AAROGYAM 1.3,BLOOD SUGAR (F),COMPLETE URINE

ANALYSIS

SAMPLE COLLECTED AT :

L703 TAMCOLD COMPLEX LINK ROAD MALAD

WEST MUMBAI , - ,

TEST NAME TECHNOLOGY VALUE UNITS

SERUM ZINC PHOTOMETRY 64.73 μg/dL

Reference Range:-

52 - 286

CLINICAL SIGNIFICANCE

ZINC IS ONE OF THE ESSENTIAL TRACE ELEMENTS IN THE BODY. ITS METALLOENZYMES PLAY A KEY ROLE IN PROTEIN AND NUCLEIC ACID SYNTHESIS, GENE EXPRESSION, WOUND HEALING, AS AN ANTIOXIDANT, ETC.

DEFICIENCY CAN CAUSE - POOR WOUND HEALING, GASTROENTERITIS, IMPAIRED SPERMATOGENESIS, ALZHEIMER□S DISEASE, ETC. TOXICITY MAY BE MANIFESTED AS PANCREATITIS, GASTRIC ULCER, ANEMIA, PULMONARY FIBROSIS.

REFERENCE: CARL A. BURTIS, EDWARD R. ASHWOOD, DAVID E. BRUNS. TIETZ TEXTBOOK OF CLINICAL CHEMISTRY AND MOLECULAR DIAGNOSTICS. CHAPTER 31.VITAMINS AND TRACE ELEMENTS. PAGE:960-965.

Please correlate with clinical conditions.

Method:- NITRO - PAPS

 Sample Collected on (SCT)
 : 05 Oct 2020 09:42

 Sample Received on (SRT)
 : 06 Oct 2020 00:36

 Report Released on (RRT)
 : 06 Oct 2020 07:59

Sample Type : SERUM

Labcode : 0510057841/A9992

Barcode : Q9429007

Practimen

Dr.Prachi Sinkar MD(Path)

(m

Dr.Caesar Senguta MD(Micro)

Page: 10 of 21







: ASHISH KEJRIWAL(47Y/M) NAME

REF. BY : SELF

TEST ASKED : ADV FULL BODY CHECKUP SAMPLE COLLECTED AT :

ADDRESS IS L703 PALM COURT COMPLEX LINK ROAD MALAD WEST MUMBAI , - 400064

TEST NAME TECHNOLOGY VALUE UNITS **TESTOSTERONE** C.L.I.A 301.21 ng/dL Reference Range :-

Adult Male

21 - 49 Yrs : 164.94 - 753.38 50 - 89 Yrs : 86.49 - 788.22 Adult Female

12.09 - 59.46 Pre-Menopause: Post-Menopause: < 7.00 - 48.93

Boys

2-10 Years : < 7.00 - 25.91 11 Years : < 7.00 - 341.53 12 Years : < 7.00 - 562.59 13 Years : 9.34 - 562.93 : 23.28 - 742.46 : 144.15 - 841.44 14 Years 15 Years 16-21 Years : 118.22 - 948.56 Girls

2-10 Years : < 7.00 - 108.30 11-15 Years : < 7.00 - 48.40 16-21 Years : 17.55 - 50.41

Clinical Significance:

Clinical evaluation of serum testosterone, along with serum LH, assists in evaluation of Hypogonadal males. Major causes of lowered testosterone in males include Hypogonadotropic hypogonadism, testicular failure Hyperprolactinema, Hypopituitarism some types of liver and kidney diseases and critical illness.

Specifications: Precision: Intra assay (%CV): 8.5 %, Inter assay (%CV): 12.6%; Sensitivity: 7 ng/dL.

External quality control program participation:

College of American pathologists: Ligand assay (special) survey; cap number: 7193855-01

Please correlate with clinical conditions.

Method:- FULLY AUTOMATED BIDIRECTIONALLY INTERFACED CHEMI LUMINESCENT IMMUNO ASSAY

Sample Collected on (SCT) .30 Aug 2020 12:00 :31 Aug 2020 00:45 Sample Received on (SRT) .31 Aug 2020 05:27 Report Released on (RRT)

:SERUM Sample Type : 3008037375/PP004 Labcode

:Q3891620 Barcode

Dr.Prachi Sinkar MD(Path)

Dr.Caesar Senguta MD(Micro)

Page: 10 of 21









: ASHISSH KEJRIWAL(47Y/M) NAME

REF. BY : SELF

TEST ASKED : AAROGYAM 1.3,BLOOD SUGAR (F),COMPLETE URINE

ANALYSIS

SAMPLE COLLECTED AT :

L703 TAMCOLD COMPLEX LINK ROAD MALAD

WEST MUMBAI , - ,

TECHNOLOGY TEST NAME VALUE UNITS TESTOSTERONE C.L.I.A 354.06 ng/dL

Reference Range :-

Adult Male

21 - 49 Yrs: 164.94 - 753.38 50 - 89 Yrs : 86.49 - 788.22 Adult Female

Pre-Menopause : 12.09 - 59.46 Post-Menopause: < 7.00 - 48.93

Boys

2-10 Years : < 7.00 - 25.91 11 Years : < 7.00 - 341.53 : < 7.00 - 562.59 12 Years : 9.34 - 562.93 13 Years : 23.28 - 742.46 14 Years : 144.15 - 841.44 15 Years 16-21 Years : 118.22 - 948.56 Girls

2-10 Years : < 7.00 - 108.30 11-15 Years : < 7.00 - 48.40 16-21 Years : 17.55 - 50.41

Clinical Significance:

Clinical evaluation of serum testosterone, along with serum LH, assists in evaluation of Hypogonadal males. Major causes of lowered testosterone in males include Hypogonadotropic hypogonadism, testicular failure Hyperprolactinema, Hypopituitarism some types of liver and kidney diseases and critical illness.

Specifications: Precision: Intra assay (%CV): 8.5 %, Inter assay (%CV): 12.6%; Sensitivity: 7 ng/dL.

External quality control program participation:

College of American pathologists: Ligand assay (special) survey; cap number: 7193855-01

Please correlate with clinical conditions.

Method:- FULLY AUTOMATED BIDIRECTIONALLY INTERFACED CHEMI LUMINESCENT IMMUNO ASSAY

Sample Collected on (SCT) : 05 Oct 2020 09:42 Sample Received on (SRT) :06 Oct 2020 00:36

Report Released on (RRT) : 06 Oct 2020 07:59

Sample Type

:0510057841/A9992

: SERUM

Labcode : Q9429007 Barcode

Dr.Prachi Sinkar MD(Path)

Dr.Caesar Senguta MD(Micro)

Page: 11 of 21







NAME : ASHISH KEJRIWAL(47Y/M)

REF. BY : SELF

TEST ASKED : ADV FULL BODY CHECKUP SAMPLE COLLECTED AT :

ADDRESS IS L703 PALM COURT COMPLEX LINK ROAD MALAD WEST MUMBAI , - 400064

TEST NAME TECHNOLOGY VALUE UNITS **PHOTOMETRY** 21.5 μg/dl **IRON** Reference Range: Male: 65 - 175 Female : 50 - 170 Method: FERROZINE METHOD WITHOUT DEPROTEINIZATION **PHOTOMETRY** 562 TOTAL IRON BINDING CAPACITY (TIBC) μg/dl Reference Range:
Male: 225 - 535 µg/dl Female: 215 - 535 µg/dl
Method: SPECTROPHOTOMETRIC ASSAY CALCULATED 3.83 % % TRANSFERRIN SATURATION Reference Range:

Method: DERIVED FROM IRON AND TIBC VALUES

Please correlate with clinical conditions.

30 Aug 2020 12:00 Sample Collected on (SCT) Sample Received on (SRT) .31 Aug 2020 00:45

.31 Aug 2020 05:27 Report Released on (RRT)

. SERUM Sample Type

:3008037375/PP004 Labcode

Barcode Q38**9**620

Dr.Prachi Sinkar MD(Path)

Dr.Caesar Senguta MD(Micro)

Page: 11 of 21









NAME : ASHISSH KEJRIWAL(47Y/M)

REF. BY : SELF

TEST ASKED : AAROGYAM 1.3,BLOOD SUGAR (F),COMPLETE URINE

ANALYSIS

SAMPLE COLLECTED AT :

L703 TAMCOLD COMPLEX LINK ROAD MALAD WEST MUMBAI , - ,

TEST NAME	TECHNOLOGY	VALUE	UNITS	
IRON	PHOTOMETRY	24.3	μg/dl	
Reference Range :				
Male : 65 - 175				
Female: 50 - 170				
Method: FERROZINE METHOD WITHOUT DEPROTEINIZA	TION			
TOTAL IRON BINDING CAPACITY (TIBC)	PHOTOMETRY	565	μg/dl	
Reference Range :				
Male: 225 - 535 μg/dl Female: 215 - 535 μg/dl				
Method: SPECTROPHOTOMETRIC ASSAY				
% TRANSFERRIN SATURATION	CALCULATED	4.3	%	
Reference Range :				
13 - 45				
Method: DERIVED FROM IRON AND TIBC VALUES				

Please correlate with clinical conditions.

Sample Collected on (SCT) :05 Oct 2020 09:42 Sample Received on (SRT) :06 Oct 2020 00:36 Report Released on (RRT) :06 Oct 2020 07:59

: SERUM Sample Type

Labcode

Barcode : Q9429007

: 0510057841/A9992 Dr.Prachi Sinkar MD(Path)

Dr.Caesar Senguta MD(Micro)

Page : 12 of 21







: ASHISH KEJRIWAL(47Y/M) NAME

REF. BY : SELF

TEST ASKED : ADV FULL BODY CHECKUP

SAMPLE COLLECTED AT :ADDRESS IS L703 PALM COURT COMPLEX LINK ROAD MALAD WEST MUMBAI , - 400064

TEST NAME	TECHNOLOGY	VALUE	UNITS	NORMAL RANGE
ALKALINE PHOSPHATASE	PHOTOMETRY	86.1	U/L	45 - 129
BILIRUBIN -DIRECT	PHOTOMETRY	0.08	mg/dl	< 0.3
BILIRUBIN - TOTAL	PHOTOMETRY	0.37	mg/dl	0.3-1.2
BILIRUBIN (INDIRECT)	CALCULATED	0.29	mg/dl	0-0.9
GAMMA GLUTAMYL TRANSFERASE (GGT)	PHOTOMETRY	56.4	U/I	< 55
ASPARTATE AMINOTRANSFERASE (SGOT)	PHOTOMETRY	39.52	U/I	< 35
ALANINE TRANSAMINASE (SGPT)	PHOTOMETRY	34.1	U/I	< 45
PROTEIN - TOTAL	PHOTOMETRY	7.49	gm/dl	5.7-8.2
ALBUMIN - SERUM	PHOTOMETRY	4.24	gm/dl	3.2-4.8
SERUM GLOBULIN	PHOTOMETRY	3.25	gm/dL	2.5-3.4
SERUM ALB/GLOBULIN RATIO	CALCULATED	1.3	Ratio	0.9 - 2

Please correlate with clinical conditions.

Method:

ALKP - Modified IFCC method

BILD - Vanadate Oxidation

BILT - Vanadate Oxidation

BILI - DERIVED FROM SERUM TOTAL AND DIRECT BILIRUBIN VALUES

GGT - Modified IFCC method

SGOT - IFCC* WITHOUT PYRIDOXAL PHOSPHATE ACTIVATION

SGPT - IFCC* WITHOUT PYRIDOXAL PHOSPHATE ACTIVATION

PROT - BIURET METHOD

SALB - ALBUMIN BCG¹METHOD (COLORIMETRIC ASSAY ENDPOINT)

SEGB - DERIVED FROM SERUM ALBUMIN AND PROTEIN VALUES

A/GR - DERIVED FROM SERUM ALBUMIN AND PROTEIN VALUES

. 30 Aug 2020 12:00 Sample Collected on (SCT) Sample Received on (SRT) . 31 Aug 2020 00:45

Report Released on (RRT) . 31 Aug 2020 05:27

Sample Type : SERUM

: 3008037375/PP004 Labcode

: Q3891620 Barcode

Dr.Prachi Sinkar MD(Path)

Dr.Caesar Senguta MD(Micro)

Page: 12 of 21









REF. BY

TEST ASKED : AAROGYAM 1.3,BLOOD SUGAR (F),COMPLETE URINE

ANALYSIS

SAMPLE COLLECTED AT :L703 TAMCOLD COMPLEX LINK ROAD MALAD WEST

TEST NAME	TECHNOLOGY	VALUE	UNITS	NORMAL RANGE
ALKALINE PHOSPHATASE	PHOTOMETRY	74.9	U/L	45 - 129
BILIRUBIN -DIRECT	PHOTOMETRY	0.14	mg/dl	< 0.3
BILIRUBIN - TOTAL	PHOTOMETRY	0.45	mg/dl	0.3-1.2
BILIRUBIN (INDIRECT)	CALCULATED	0.31	mg/dl	0-0.9
GAMMA GLUTAMYL TRANSFERASE (GGT)	PHOTOMETRY	47.6	U/I	< 55
ASPARTATE AMINOTRANSFERASE (SGOT)	PHOTOMETRY	44.35	U/I	< 35
ALANINE TRANSAMINASE (SGPT)	PHOTOMETRY	39	U/I	< 45
PROTEIN - TOTAL	PHOTOMETRY	8.07	gm/dl	5.7-8.2
ALBUMIN - SERUM	PHOTOMETRY	4.09	gm/dl	3.2-4.8
SERUM GLOBULIN	PHOTOMETRY	3.98	gm/dL	2.5-3.4
SERUM ALB/GLOBULIN RATIO	CALCULATED	1.03	Ratio	0.9 - 2

Please correlate with clinical conditions.

Method:

ALKP - Modified IFCC method

BILD - Vanadate Oxidation

BILT - Vanadate Oxidation

BILI - DERIVED FROM SERUM TOTAL AND DIRECT BILIRUBIN VALUES

GGT - Modified IFCC method

SGOT - IFCC* WITHOUT PYRIDOXAL PHOSPHATE ACTIVATION

SGPT - IFCC* WITHOUT PYRIDOXAL PHOSPHATE ACTIVATION

PROT - BIURET METHOD

SALB - ALBUMIN BCG¹METHOD (COLORIMETRIC ASSAY ENDPOINT)

SEGB - DERIVED FROM SERUM ALBUMIN AND PROTEIN VALUES

A/GR - DERIVED FROM SERUM ALBUMIN AND PROTEIN VALUES

Sample Collected on (SCT) : 05 Oct 2020 09:42 : 06 Oct 2020 00:36 Sample Received on (SRT) Report Released on (RRT) : 06 Oct 2020 07:59

: SERUM **Sample Type**

Labcode : 0510057841/A9992

Barcode : Q9429007

Dr.Prachi Sinkar MD(Path)

Dr.Caesar Senguta MD(Micro)

Page: 13 of 21









: ASHISH KEJRIWAL(47Y/M) NAME

REF. BY : SELF

TEST ASKED : ADV FULL BODY CHECKUP

SAMPLE COLLECTED AT :ADDRESS IS L703 PALM COURT COMPLEX LINK ROAD MALAD WEST MUMBAI , - 400064

TEST NAME	TECHNOLOGY	VALUE	UNITS	NORMAL RANGE
TOTAL CHOLESTEROL	PHOTOMETRY	163	mg/dl	125-200
HDL CHOLESTEROL - DIRECT	PHOTOMETRY	57	mg/dl	35-80
TRIGLYCERIDES	PHOTOMETRY	150	mg/dl	25-200
LDL CHOLESTEROL - DIRECT	PHOTOMETRY	93	mg/dl	85-130
TC/ HDL CHOLESTEROL RATIO	CALCULATED	2.9	Ratio	3 - 5
LDL / HDL RATIO	CALCULATED	1.6	Ratio	1.5-3.5
VLDL CHOLESTEROL	CALCULATED	30.06	mg/dl	5 - 40
NON-HDL CHOLESTEROL	CALCULATED	106.7	mg/dl	< 160

Please correlate with clinical conditions.

Method:

CHOL - CHOD POD METHOD

HCHO - ENZYME SELECTIVE PROTECTION METHOD

TRIG - ENZYMATIC COLORIMETRIC METHOD (GPO) [HIGHLY INFLUENCED BY LEVEL OF FASTING]

LDL - HOMOGENOUS ENZYMATIC COLORIMETRIC ASSAY

TC/H - DERIVED FROM SERUM CHOLESTEROL AND HDL VALUES

LDL/ - Derived from serum HDL and LDL Values

VLDL - DERIVED FROM SERUM TRIGLYCERIDE VALUES

NHDL - Derived from serum Cholesterol and HDL values

*REFERENCE RANGES AS PER NCEP ATP III GUIDELINES:

TOTAL CHOLESTEROL	(mg/dl)	HDL	(mg/dl)	LDL	(mg/dl)	TRIGLYCERIDES	(mg/dl)
DESIRABLE	<200	LOW	<40	OPTIMAL	<100	NORMAL	<150
BORDERLINE HIGH	200-239	HIGH	>60	NEAR OPTIMAL	100-129	BORDERLINE HIGH	150-199
HIGH	>240			BORDERLINE HIGH	130-159	HIGH	200-499
				HIGH	160-189	VERY HIGH	>500
				VERY HIGH	>190		

Alert !!! 10-12 hours fasting is mandatory for lipid parameters. If not, values might flutuate.

. 30 Aug 2020 12:00 Sample Collected on (SCT)

Sample Received on (SRT) . 31 Aug 2020 00:45 Report Released on (RRT) . 31 Aug 2020 05:27

Sample Type : SERUM

: 3008037375/PP004 Labcode

: Q3891620 Barcode

Dr.Prachi Sinkar MD(Path)

Dr.Caesar Senguta MD(Micro)

Page: 13 of 21







REF. BY

TEST ASKED : AAROGYAM 1.3,BLOOD SUGAR (F),COMPLETE URINE

ANALYSIS

SAMPLE COLLECTED AT : L703 TAMCOLD COMPLEX LINK ROAD MALAD WEST

TEST NAME	TECHNOLOGY	VALUE	UNITS	NORMAL RANGE
TOTAL CHOLESTEROL	PHOTOMETRY	177	mg/dl	125-200
HDL CHOLESTEROL - DIRECT	PHOTOMETRY	53	mg/dl	35-80
TRIGLYCERIDES	PHOTOMETRY	185	mg/dl	25-200
LDL CHOLESTEROL - DIRECT	PHOTOMETRY	102	mg/dl	85-130
TC/ HDL CHOLESTEROL RATIO	CALCULATED	3.4	Ratio	3 - 5
LDL / HDL RATIO	CALCULATED	1.9	Ratio	1.5-3.5
VLDL CHOLESTEROL	CALCULATED	36.9	mg/dl	5 - 40
NON-HDL CHOLESTEROL	CALCULATED	124.1	ma/dl	< 160

Please correlate with clinical conditions.

Method:

CHOL - CHOD POD METHOD

HCHO - ENZYME SELECTIVE PROTECTION METHOD

TRIG - ENZYMATIC COLORIMETRIC METHOD (GPO) [HIGHLY INFLUENCED BY LEVEL OF FASTING]

LDL - HOMOGENOUS ENZYMATIC COLORIMETRIC ASSAY

TC/H - DERIVED FROM SERUM CHOLESTEROL AND HDL VALUES

LDL/ - Derived from serum HDL and LDL Values

VLDL - DERIVED FROM SERUM TRIGLYCERIDE VALUES

NHDL - Derived from serum Cholesterol and HDL values

*REFERENCE RANGES AS PER NCEP ATP III GUIDELINES:

TOTAL CHOLESTEROL	(mg/dl)	HDL	(mg/dl)	LDL	(mg/dl)	TRIGLYCERIDES	(mg/dl)
DESIRABLE	<200	LOW	<40	OPTIMAL	<100	NORMAL	<150
BORDERLINE HIGH	200-239	HIGH	>60	NEAR OPTIMAL	100-129	BORDERLINE HIGH	150-199
HIGH	>240			BORDERLINE HIGH	130-159	HIGH	200-499
				HIGH	160-189	VERY HIGH	>500
				VERY HIGH	>190		

Alert !!! 10-12 hours fasting is mandatory for lipid parameters. If not, values might flutuate.

Sample Collected on (SCT) : 05 Oct 2020 09:42 : 06 Oct 2020 00:36 Sample Received on (SRT) Report Released on (RRT) : 06 Oct 2020 07:59

Sample Type

: SERUM

Labcode

: 0510057841/A9992

Barcode : Q9429007

Dr.Prachi Sinkar MD(Path)

Dr.Caesar Senguta MD(Micro)

Page: 14 of 21



Before





NAME : ASHISH KEJRIWAL(47Y/M)

REF. BY : SELF

TEST ASKED : ADV FULL BODY CHECKUP

SAMPLE COLLECTED AT : ADDRESS IS L703 PALM COURT COMPLEX LINK ROAD MALAD WEST MUMBAI , - 400064

TEST NAME	TECHNOLOGY	VALUE	UNITS	REFERENCE RANGE
TOTAL TRIIODOTHYRONINE (T3)	C.L.I.A	96	ng/dl	60-200
TOTAL THYROXINE (T4)	C.L.I.A	10.7	µg/dl	4.5-12
THYROID STIMULATING HORMONE (TSH)	C.L.I.A	1.17	μIU/ml	0.3-5.5

Comments: SUGGESTING THYRONORMALCY

Please correlate with clinical conditions.

Method:

T3 - COMPETITIVE CHEMI LUMINESCENT IMMUNO ASSAY

T4 - COMPETITIVE CHEMI LUMINESCENT IMMUNO ASSAY

TSH - SANDWICH CHEMI LUMINESCENT IMMUNO ASSAY

Sample Collected on (SCT)

Sample Received on (SRT)

Report Released on (RRT)

Sample Type

Labcode

Barcode

: 3008037375/PP004

: Q3891620

: SERUM

: 30 Aug 2020 12:00

: 31 Aug 2020 00:45

: 31 Aug 2020 05:27

Dr.Prachi Sinkar MD(Path)

Dr.Caesar Senguta MD(Micro)

Page: 14 of 21









REF. BY : SELF

TEST ASKED

: AAROGYAM 1.3,BLOOD SUGAR (F),COMPLETE URINE

ANALYSIS

SAMPLE COLLECTED AT : L703 TAMCOLD COMPLEX LINK ROAD MALAD WEST MUMBAI , - ,

TEST NAME	TECHNOLOGY	VALUE	UNITS RE	FERENCE RANGE
TOTAL TRIIODOTHYRONINE (T3)	C.L.I.A	97	ng/dl 60-	-200
TOTAL THYROXINE (T4)	C.L.I.A	9.7	µg/dl 4.5	-12
THYROID STIMULATING HORMONE (TSH)	C.L.I.A	1.94	μIU/ml 0.3	-5.5

Comments: SUGGESTING THYRONORMALCY

Please correlate with clinical conditions.

Method:

T3 - COMPETITIVE CHEMI LUMINESCENT IMMUNO ASSAY T4 - COMPETITIVE CHEMI LUMINESCENT IMMUNO ASSAY

TSH - SANDWICH CHEMI LUMINESCENT IMMUNO ASSAY

Sample Collected on (SCT) : 05 Oct 2020 09:42 Sample Received on (SRT) : 06 Oct 2020 00:36

Report Released on (RRT) : 06 Oct 2020 07:59 Sample Type : SERUM

Labcode : 0510057841/A9992 Barcode : Q9429007

Dr.Prachi Sinkar MD(Path)

Dr.Caesar Sengu**t**a MD(Micro)

Page : 15 of 21



Before





: ASHISH KEJRIWAL(47Y/M) NAME

REF. BY : SELF

TEST ASKED : ADV FULL BODY CHECKUP

SAMPLE COLLECTED AT :ADDRESS IS L703 PALM COURT COMPLEX LINK ROAD MALAD WEST MUMBAI , - 400064

TEST NAME	TECHNOLOGY	VALUE	UNITS	NORMAL RANGE
BLOOD UREA NITROGEN (BUN)	PHOTOMETRY	10.17	mg/dl	7 - 25
CREATININE - SERUM	PHOTOMETRY	0.76	mg/dl	0.6-1.1
URIC ACID	PHOTOMETRY	4.34	mg/dl	4.2 - 7.3
CALCIUM	PHOTOMETRY	9.56	mg/dl	8.8-10.6
BUN / SR.CREATININE RATIO	CALCULATED	13.38	Ratio	9:1-23:1

Please correlate with clinical conditions.

Method:

BUN - KINETIC UV ASSAY.

SCRE - CREATININE ENZYMATIC METHOD

URIC - Uricase / Peroxidase Method

CALC - ARSENAZO III METHOD, END POINT.

B/CR - DERIVED FROM SERUM BUN AND CREATININE VALUES

Sample Collected on (SCT)

Sample Received on (SRT)

Report Released on (RRT)

Sample Type

Labcode

: 3008037375/PP004

. SERUM

30 Aug 2020 12:00

. 31 Aug 2020 00:45

: Q3891620 Barcode

: 31 Aug 2020 05:27

Dr.Prachi Sinkar MD(Path)

Dr.Caesar Senguta MD(Micro)

Page: 15 of 21









REF. BY

TEST ASKED : AAROGYAM 1.3,BLOOD SUGAR (F),COMPLETE URINE

ANALYSIS

SAMPLE COLLECTED AT : L703 TAMCOLD COMPLEX LINK ROAD MALAD WEST

TEST NAME	TECHNOLOGY	VALUE	UNITS	NORMAL RANGE
BLOOD UREA NITROGEN (BUN)	PHOTOMETRY	10.92	mg/dl	7 - 25
CREATININE - SERUM	PHOTOMETRY	0.94	mg/dl	0.6-1.1
URIC ACID	PHOTOMETRY	4.86	mg/dl	4.2 - 7.3
CALCIUM	PHOTOMETRY	10.47	mg/dl	8.8-10.6
BUN / SR.CREATININE RATIO	CALCULATED	11.62	Ratio	9:1-23:1

Please correlate with clinical conditions.

Method:

BUN - KINETIC UV ASSAY.

SCRE - CREATININE ENZYMATIC METHOD

URIC - Uricase / Peroxidase Method

CALC - ARSENAZO III METHOD, END POINT.

B/CR - DERIVED FROM SERUM BUN AND CREATININE VALUES

Sample Collected on (SCT) : 05 Oct 2020 09:42 Sample Received on (SRT) : 06 Oct 2020 00:36 : 06 Oct 2020 07:59 Report Released on (RRT)

Sample Type : SERUM

Labcode : 0510057841/A9992

Barcode : Q9429007

Dr.Prachi Sinkar MD(Path)

Dr.Caesar Senguta MD(Micro)

Page: 16 of 21



Before





NAME : ASHISH KEJRIWAL(47Y/M)

REF. BY

TEST ASKED : ADV FULL BODY CHECKUP SAMPLE COLLECTED AT :

ADDRESS IS L703 PALM COURT COMPLEX LINK ROAD MALAD WEST MUMBAI, - 400064

TECHNOLOGY TEST NAME VALUE UNITS EST. GLOMERULAR FILTRATION RATE (eGFR) CALCULATED 109 mL/min/1.73 m2 Reference Range :-

> = 90 : Normal 60 - 89 : Mild Decrease

45 - 59 : Mild to Moderate Decrease : Moderate to Severe Decrease

15 - 29 : Severe Decrease

Clinical Significance

The normal serum creatinine reference interval does not necessarily reflect a normal GER for a patient. Because mild and moderate kidney injury is poorly inferred from serum creatinine alone. Thus, it is recommended for clinical laboratories to routinely estimate glomerular filtration rate (eGFR), a "gold standard" measurement for assessment of renal function, and report the value when serum creatinine is measured for patients 18 and older, when appropriate and feasible. It cannot be measured easily in clinical practice, instead, GFR is estimated from equations using serum creatinine, age, race and sex. This provides easy to interpret information for the doctor and patient on the degree of renal impairment since it approximately equates to the percentage of kidney function remaining. Application of CKD-EPI equation together with the other diagnostic tools in renal medicine will further improve the detection and management of patients with CKD.

Reference

Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-12.

Please correlate with clinical conditions. Method:- CKD-EPI Creatinine Equation

Sample Collected on (SCT) Sample Received on (SRT)

Report Released on (RRT)

Sample Type Labcode

Barcode

. 30 Aug 2020 12:00 .31 Aug 2020 00:45 .31 Aug 2020 05:27

:Q3891620

:SERUM :3008037375/PP004

Dr.Prachi Sinkar MD(Path)

Dr.Caesar Senguta MD(Micro)

Page: 16 of 21









DEPORT

NAME : ASHISSH KEJRIWAL(47Y/M)

REF. BY : SELF

TEST ASKED : AAROGYAM 1.3,BLOOD SUGAR (F),COMPLETE URINE

ANALYSIS

SAMPLE COLLECTED AT :

L703 TAMCOLD COMPLEX LINK ROAD MALAD

WEST MUMBAI, -,

TEST NAME	TECHNOLOGY	VALUE	UNITS
EST. GLOMERULAR FILTRATION RATE (eGFR)	CALCULATED	96	mL/min/1.73 m2
Reference Range :-			

> = 90 : Normal 60 - 89 : Mild Decrease

45 - 59 : Mild to Moderate Decrease 30 - 44 : Moderate to Severe Decrease

15 - 29 : Severe Decrease

Clinical Significance

The normal serum creatinine reference interval does not necessarily reflect a normal GFR for a patient. Because mild and moderate kidney injury is poorly inferred from serum creatinine alone. Thus, it is recommended for clinical laboratories to routinely estimate glomerular filtration rate (eGFR), a \square gold standard \square measurement for assessment of renal function, and report the value when serum creatinine is measured for patients 18 and older, when appropriate and feasible. It cannot be measured easily in clinical practice, instead, GFR is estimated from equations using serum creatinine, age, race and sex. This provides easy to interpret information for the doctor and patient on the degree of renal impairment since it approximately equates to the percentage of kidney function remaining. Application of CKD-EPI equation together with the other diagnostic tools in renal medicine will further improve the detection and management of patients with CKD.

Reference

Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-12.

Please correlate with clinical conditions.

Method:- CKD-EPI Creatinine Equation

 Sample Collected on (SCT)
 : 05 Oct 2020 09:42

 Sample Received on (SRT)
 : 06 Oct 2020 00:36

 Report Released on (RRT)
 : 06 Oct 2020 07:59

Sample Type : SERUM

Labcode : 0510057841/A9992

Barcode : Q9429007

Moode

Dr.Prachi Sinkar MD(Path)

Dr.Caesar Senguta MD(Micro)

Page : 17 of 21



Before





NAME : ASHISH KEJRIWAL(47Y/M)

REF. BY : SELF

TEST ASKED : ADV FULL BODY CHECKUP SAMPLE COLLECTED AT :

ADDRESS IS L703 PALM COURT COMPLEX LINK ROAD MALAD WEST MUMBAI , - 400064

TEST NAME TECHNOLOGY VALUE UNITS

HbA1c - (HPLC - NGSP Certified)

H.P.L.C

8.2

%

Reference Range:

Reference Range: As per ADA Guidelines

Below 5.7% : Normal 5.7% - 6.4% : Prediabetic >=6.5%

: Diabetic

Guidance For Known Diabetics

Below 6.5% : Good Control 6.5% - 7% : Fair Control

7.0% - 8%: Unsatisfactory Control >8% : Poor Control

Method: Fully Automated H.P.L.C. using Biorad Variant II Turbo, NGSP Certified. **AVERAGE BLOOD GLUCOSE (ABG) CALCULATED** 189 mg/dl

Reference Range:

90 - 120 mg/dl : Good Control 121 - 150 mg/dl : Fair Control

151 - 180 mg/dl : Unsatisfactory Control

> 180 mg/dl : Poor Control

Method: Derived from HBA1c values Please correlate with clinical conditions.

.30 Aug 2020 12:00 Sample Collected on (SCT) Sample Received on (SRT) . 30 Aug 2020 22:57

Report Released on (RRT) :31 Aug 2020 04:59

: EDTA **Sample Type**

Labcode :3008034726/PP004

Barcode :Q7171680

Dr.Prachi Sinkar MD(Path)

Dr.Caesar Senguta MD(Micro)

Page: 17 of 21









REF. BY : SELF

TEST ASKED : AAROGYAM 1.3,COMPLETE URINE ANALYSIS,FBS SAMPLE COLLECTED AT :

L703 TAMCOLD COMPLEX LINK ROAD MALAD WEST MUMBAI , - ,

TEST NAME TECHNOLOGY VALUE UNITS

HbA1c - (HPLC - NGSP Certified)

H.P.L.C

8.2

%

mg/dl

Reference Range:

Reference Range: As per ADA Guidelines

Below 5.7% : Normal 5.7% - 6.4% : Prediabetic

>=6.5% : Diabetic **Guidance For Known Diabetics**

Below 6.5%: Good Control 6.5% - 7% : Fair Control

7.0% - 8%: Unsatisfactory Control >8% : Poor Control

189

Method: Fully Automated H.P.L.C. using Biorad Variant II Turbo, NGSP Certified. **AVERAGE BLOOD GLUCOSE (ABG) CALCULATED**

Reference Range:

90 - 120 mg/dl : Good Control 121 - 150 mg/dl : Fair Control

151 - 180 mg/dl : Unsatisfactory Control

> 180 mg/dl : Poor Control Method: Derived from HBA1c values

Please correlate with clinical conditions.

Sample Collected on (SCT) :05 Oct 2020 09:42 Sample Received on (SRT) :06 Oct 2020 00:53 :06 Oct 2020 05:42 Report Released on (RRT)

Sample Type : EDTA

Labcode

Barcode :Q9429008

: 0510058717/A9992 Dr.Prachi Sinkar MD(Path)

Dr.Caesar Senguta MD(Micro)

Page: 18 of 21









REF. BY : SELF

TEST ASKED : AAROGYAM 1.3,COMPLETE URINE ANALYSIS,FBS

SAMPLE COLLECTED AT :

L703 PALMCAURT COMPLEX LINK ROAD MALAD WEST MUMBAI , - , - ,

TEST NAME TECHNOLOGY VALUE UNITS

HbA1c - (HPLC)

H.P.L.C

CALCULATED

8.6

%

mg/dl

Reference Range:

Reference Range: As per ADA Guidelines

Below 5.7% : Normal 5.7% - 6.4% : Prediabetic >=6.5%

: Diabetic

Guidance For Known Diabetics

Below 6.5% : Good Control 6.5% - 7% : Fair Control

7.0% - 8% : Unsatisfactory Control

200

: Poor Control >8%

Method: Fully Automated H.P.L.C. using Biorad Variant II Turbo

AVERAGE BLOOD GLUCOSE (ABG)

Reference Range:

90 - 120 mg/dl : Good Control 121 - 150 mg/dl : Fair Control

151 - 180 mg/dl : Unsatisfactory Control

> 180 mg/dl : Poor Control Method: Derived from HBA1c values

Please correlate with clinical conditions.

Sample Collected on (SCT)

Sample Received on (SRT) Report Released on (RRT)

Sample Type

Labcode

Barcode :R7114991

:01 Nov 2020 08:58

:02 Nov 2020 00:51 :02 Nov 2020 04:43

: EDTA

: 0111037594/A1681 Dr.Prachi Sinkar MD(Path)

Dr.Caesar Senguta MD(Micro)

Page: 2 of 21









REF. BY : SELF

TEST ASKED : ADV FULL BODY CHECKUP SAMPLE COLLECTED AT :

ADDRESS IS L703 PALM COURT COMPLEX LINK ROAD MALAD WEST MUMBAI , - 400064

TEST NAME	VALUE	UNITS	REFERENCE RANGE
TOTAL LEUCOCYTES COUNT	11.81	X 10 ³ / μL	4.0-10.0
NEUTROPHILS	62.3	%	40-80
LYMPHOCYTE PERCENTAGE	30.1	%	20-40
MONOCYTES	3.2	%	0-10
EOSINOPHILS	3.1	%	0.0-6.0
BASOPHILS	1	%	<2
IMMATURE GRANULOCYTE PERCENTAGE(IG%)	0.3	%	0-0.5
NEUTROPHILS - ABSOLUTE COUNT	7.36	X 10 ³ / μL	20-70
LYMPHOCYTES - ABSOLUTE COUNT	3.55	X 10 ³ / μL	1.0-30
MONOCYTES - ABSOLUTE COUNT	0.38	X 10 ³ / μL	0.2-1
BASOPHILS - ABSOLUTE COUNT	0.12	X 10 ³ / μL	0-0.1
EOSINOPHILS - ABSOLUTE COUNT	0.37	X 10 ³ / μL	0-0.5
IMMATURE GRANULOCYTES(IG)	0.04	X 10 ³ / μL	0-0.3
TOTAL RBC	5.45	X 10^6/μL	4.5-5.5
NUCLEATED RED BLOOD CELLS	Nil	X 10 ³ / μL	<0.01
NUCLEATED RED BLOOD CELLS %	Nil	%	<0.01
HEMOGLOBIN	11.4	g/dL	1317
HEMATOCRIT(PCV)	42	%	40-50
MEAN CORPUSCULAR VOLUME(MCV)	77.1	fL	8 101
MEAN CORPUSCULAR HEMOGLOBIN(MCH)	20.9	pq	22
MEAN CORP.HEMO.CONC(MCHC)	27.1	g/dL	3.6 8.5
RED CELL DISTRIBUTION WIDTH - SD(RDW-SD)	60.3	fL	94 6
RED CELL DISTRIBUTION WIDTH (RDW-CV)	22.1	%	11.614
PLATELET DISTRIBUTION WIDTH(PDW)	10.3	fL	9.6-15.2
MEAN PLATELET VOLUME(MPV)	9.4	fL	6.5-12
PLATELET COUNT	518	X 10³ / μL	1 6 -400
PLATELET TO LARGE CELL RATIO(PLCR)	20.4	%	19.7-42.4
PLATELETCRIT(PCT)	0.48	%	0.190.9

Remarks : ALERT !!! Hypochromia, Mild Leucocytosis

Please Correlate with clinical conditions.

Method : Fully automated bidirectional analyser (6 Part Differential SYSMEX XN-1000)

(This device performs hematology analyses according to the Hydrodynamic Focussing (DC method), Flow Cytometry Method (using a semiconductor laser), and SLS- hemoglobin method)

30 Aug 2020 12:00 Sample Collected on (SCT) :30 Aug 2020 22:57 Sample Received on (SRT) :31 Aug 2020 04:59 Report Released on (RRT)

: EDTA Sample Type

Labcode : 3008034726/PP004 . Q7171680 Barcode

Dr.Prachi Sinkar MD(Path)

Dr.Caesar Sengupta MD(Micro)

Page: 18 of 21







REF. BY

TEST ASKED : AAROGYAM 1.3,COMPLETE URINE ANALYSIS,FBS SAMPLE COLLECTED AT :

L703 TAMCOLD COMPLEX LINK ROAD MALAD WEST MUMBAI , - ,

TEST NAME	VALUE	UNITS	REFERENCE RANGE
TOTAL LEUCOCYTES COUNT	10.34	X 10 ³ / μL	4.0-10.0
NEUTROPHILS	71.7	%	40-80
LYMPHOCYTE PERCENTAGE	22.3	%	20-40
MONOCYTES	2.9	%	0-10
EOSINOPHILS	1.9	%	0.0-6.0
BASOPHILS	0.9	%	<2
IMMATURE GRANULOCYTE PERCENTAGE(IG%)	0.3	%	0-0.5
NEUTROPHILS - ABSOLUTE COUNT	7.41	X 10 ³ / μL	20-70
LYMPHOCYTES - ABSOLUTE COUNT	2.31	X 10 ³ / μL	1.0-3.0
MONOCYTES - ABSOLUTE COUNT	0.3	X 10 ³ / μL	0.2-1
BASOPHILS - ABSOLUTE COUNT	0.09	X 10 ³ / μL	0-0.1
EOSINOPHILS - ABSOLUTE COUNT	0.2	X 10 ³ / μL	0-0.5
IMMATURE GRANULOCYTES(IG)	0.03	X 10 ³ / μL	0-0.3
TOTAL RBC	5.01	X 10^6/µL	4.5-5.5
NUCLEATED RED BLOOD CELLS	Nil	X 10 ³ / μL	<0.01
NUCLEATED RED BLOOD CELLS %	Nil	%	<0.01
HEMOGLOBIN	10.7	g/dL	1317
HEMATOCRIT(PCV)	38.8	%	40-6
MEAN CORPUSCULAR VOLUME(MCV)	77.4	fL	81 01
MEAN CORPUSCULAR HEMOGLOBIN(MCH)	21.4	pq	22
MEAN CORP.HEMO.CONC(MCHC)	27.6	g/dL	3.63 .5
RED CELL DISTRIBUTION WIDTH - SD(RDW-SD)	63.2	fL	9 46
RED CELL DISTRIBUTION WIDTH (RDW-CV)	22.9	%	11.614
PLATELET DISTRIBUTION WIDTH(PDW)	11.6	fL	9.6-15.2
MEAN PLATELET VOLUME(MPV)	9.8	fL	6.5-12
PLATELET COUNT	482	X 10³ / μL	1 6-4 00
PLATELET TO LARGE CELL RATIO(PLCR)	24.4	%	19.7-42.4
PLATELETCRIT(PCT)	0.47	%	0.190.9

Remarks : ALERT !!! Hypochromia

Please Correlate with clinical conditions.

Method : Fully automated bidirectional analyser (6 Part Differential SYSMEX XN-1000)

(This device performs hematology analyses according to the Hydrodynamic Focussing (DC method), Flow Cytometry Method (using a semiconductor laser), and SLS- hemoglobin method)

Sample Collected on (SCT) :05 Oct 2020 09:42 Sample Received on (SRT) :06 Oct 2020 00:53 :06 Oct 2020 05:42 Report Released on (RRT)

Sample Type : EDTA

Labcode : 0510058717/A9992

Barcode : Q9429008

Dr.Prachi Sinkar MD(Path)

Dr.Caesar Sengupta MD(Micro)

Page: 19 of 21









DEPART

NAME : ASHISSH KEJRIWAL(48Y/M)

REF. BY : SELF

TEST ASKED : AAROGYAM 1.3,COMPLETE URINE ANALYSIS,FBS

SAMPLE COLLECTED AT :

L703 PALMCAURT COMPLEX LINK ROAD MALAD

WEST MUMBAI , - , - ,

TEST NAME	VALUE	UNITS	REFERENCE RANGE
TOTAL LEUCOCYTES COUNT	10.19	X 10 ³ / μL	4.0-10.0
NEUTROPHILS	63.5	%	40-80
LYMPHOCYTE PERCENTAGE	29.4	%	20-40
MONOCYTES	3	%	0-10
EOSINOPHILS	2.8	%	0.0-6.0
BASOPHILS	1	%	<2
IMMATURE GRANULOCYTE PERCENTAGE(IG%)	0.3	%	0-0.5
NEUTROPHILS - ABSOLUTE COUNT	6.47	X 10 ³ / μL	2.0-7.0
LYMPHOCYTES - ABSOLUTE COUNT	3	$X~10^3$ / μL	1.0-3.0
MONOCYTES - ABSOLUTE COUNT	0.31	X 10 ³ / μL	0.2-1
BASOPHILS - ABSOLUTE COUNT	0.1	X 10 ³ / μL	0-0.1
EOSINOPHILS - ABSOLUTE COUNT	0.29	X 10 ³ / μL	0-0.5
IMMATURE GRANULOCYTES(IG)	0.03	$X~10^3$ / μL	0-0.3
TOTAL RBC	5.11	X 10^6/µL	4.5-5.5
NUCLEATED RED BLOOD CELLS	Nil	$X~10^3$ / μL	<0.01
NUCLEATED RED BLOOD CELLS %	Nil	%	<0.01
HEMOGLOBIN	10.5	g/dL	1317
HEMATOCRIT(PCV)	38.5	%	40 -6
MEAN CORPUSCULAR VOLUME(MCV)	75.3	fL	8 101
MEAN CORPUSCULAR HEMOGLOBIN(MCH)	20.5	pq	22
MEAN CORP.HEMO.CONC(MCHC)	27.3	g/dL	3.63 .5
RED CELL DISTRIBUTION WIDTH - SD(RDW-SD)	57.4	fL	9 46
RED CELL DISTRIBUTION WIDTH (RDW-CV)	21.5	%	11.614
PLATELET DISTRIBUTION WIDTH(PDW)	10.5	fL	9.6-15.2
MEAN PLATELET VOLUME(MPV)	9.6	fL	6.5-12
PLATELET COUNT	465	X 10 ³ / μL	1 6 -400
PLATELET TO LARGE CELL RATIO(PLCR)	21.3	%	19.7-42.4
PLATELETCRIT(PCT)	0.45	%	0.190. 9

Remarks: ALERT !!! Hypochromia

Please Correlate with clinical conditions.

Method : Fully automated bidirectional analyser (6 Part Differential SYSMEX XN-1000)

(This device performs hematology analyses according to the Hydrodynamic Focussing (DC method), Flow

 $\textbf{Cytometry Method (using a semiconductor laser), and SLS-\ hemoglobin\ method) }$

 Sample Collected on (SCT)
 : 01 Nov 2020 08:58

 Sample Received on (SRT)
 : 02 Nov 2020 00:51

 Report Released on (RRT)
 : 02 Nov 2020 04:43

 Sample Type
 : EDTA

 Labcode
 : 0111037594/A1681

Barcode : R7114991

Worze

Dr.Prachi Sinkar MD(Path)

بريو

Dr.Caesar Sengupta MD(Micro)

Page : 3 of 21



Before





: ASHISH KEJRIWAL(47Y/M) NAME

REF. BY : SELF

TEST ASKED : ADV FULL BODY CHECKUP

SAMPLE COLLECTED AT :ADDRESS IS L703 PALM COURT COMPLEX LINK ROAD MALAD WEST MUMBAI , - 400064

TEST NAME	TECHNOLOGY	VALUE	UNITS	NORMAL RANGE
ARSENIC	ICP-MS	0.62	μg/l	< 5
CADMIUM	ICP-MS	0.22	μg/l	< 1.5
MERCURY	ICP-MS	0.82	μg/l	< 5
LEAD	ICP-MS	56.97	μg/l	< 150
CHROMIUM	ICP-MS	0.79	μg/l	< 30
BARIUM	ICP-MS	0.89	μg/l	< 30
COBALT	ICP-MS	0.31	μg/l	0.10 - 1.50
CAESIUM	ICP-MS	1.95	μg/l	< 5
THALLIUM	ICP-MS	0.03	μg/l	< 1
URANIUM	ICP-MS	0.05	μg/l	< 1
STRONTIUM	ICP-MS	16.91	μg/l	8 - 38
ANTIMONY	ICP-MS	4.8	μg/l	0.10 - 18
TIN	ICP-MS	0.21	μg/l	< 2
MOLYBDENUM	ICP-MS	0.58	μg/l	0.70 - 4.0
SILVER	ICP-MS	0.12	μg/l	< 4
VANADIUM	ICP-MS	0.72	μg/l	< 0.8
BERYLLIUM	ICP-MS	0.03	μg/l	0.10 - 0.80
BISMUTH	ICP-MS	0.21	μg/l	0.10 - 0.80
SELENIUM	ICP-MS	237.08	μg/l	60 - 340
ALUMINIUM	ICP-MS	4.79	μg/l	< 30
NICKEL	ICP-MS	1.9	μg/l	< 15
MANGANESE	ICP-MS	20.04	μg/l	7.10 - 20

Please correlate with clinical conditions.

Method:

ICP - MASS SPECTROMETRY

Note: Reference range has been obtained after considering 95% population as cutoff.

30 Aug 2020 12:00 Sample Collected on (SCT) 30 Aug 2020 22:57 Sample Received on (SRT)

: 31 Aug 2020 04:59 Report Released on (RRT)

Sample Type . EDTA

: 3008034726/PP004 Labcode

: Q7171680 Barcode

Dr.Prachi Sinkar MD(Path)

Dr.Caesar Senguta MD(Micro)

Page: 19 of 21









: ASHISSH KEJRIWAL(47Y/M) NAME

REF. BY : SELF

TEST ASKED : AAROGYAM 1.3,COMPLETE URINE ANALYSIS,FBS

SAMPLE COLLECTED AT :L703 TAMCOLD COMPLEX LINK ROAD MALAD WEST MUMBAI , - ,

TEST NAME	TECHNOLOGY	VALUE	UNITS	NORMAL RANGE
ARSENIC	ICP-MS	0.5	μg/l	< 5
CADMIUM	ICP-MS	0.32	μg/l	< 1.5
MERCURY	ICP-MS	0.85	μg/l	< 5
LEAD	ICP-MS	62.72	μg/l	< 150
CHROMIUM	ICP-MS	0.29	μg/l	< 30
BARIUM	ICP-MS	0.99	μg/l	< 30
COBALT	ICP-MS	0.38	μg/l	0.10 - 1.50
CAESIUM	ICP-MS	1.66	μg/l	< 5
THALLIUM	ICP-MS	0.02	μg/l	< 1
JRANIUM	ICP-MS	0.05	μg/l	< 1
STRONTIUM	ICP-MS	22.56	μg/l	8 - 38
ANTIMONY	ICP-MS	4.53	μg/l	0.10 - 18
ΓΙΝ	ICP-MS	0.23	μg/l	< 2
MOLYBDENUM	ICP-MS	0.47	μg/l	0.70 - 4.0
SILVER	ICP-MS	1.19	μg/l	< 4
VANADIUM	ICP-MS	0.19	μg/l	< 0.8
BERYLLIUM	ICP-MS	0.09	μg/l	0.10 - 0.80
BISMUTH	ICP-MS	0.18	μg/l	0.10 - 0.80
SELENIUM	ICP-MS	172.33	μg/l	60 - 340
ALUMINIUM	ICP-MS	10.42	μg/l	< 30
NICKEL	ICP-MS	1.69	μg/l	< 15
MANGANESE	ICP-MS	18.12	μg/l	7.10 - 20

Please correlate with clinical conditions.

Method:

ICP - MASS SPECTROMETRY

Note: Reference range has been obtained after considering 95% population as cutoff.

~~ End of report ~~

Sample Collected on (SCT)

Sample Received on (SRT)

Report Released on (RRT)

Sample Type

Labcode

Barcode

: 05 Oct 2020 09:42

: 06 Oct 2020 00:53

: 06 Oct 2020 05:42 : EDTA

: 0510058717/A9992

: Q9429008

Dr.Prachi Sinkar MD(Path)

Dr.Caesar Senguta MD(Micro)

Page: 20 of 21









REF. BY

TEST ASKED : AAROGYAM 1.3,COMPLETE URINE ANALYSIS,FBS

SAMPLE COLLECTED AT :L703 PALMCAURT COMPLEX LINK ROAD MALAD WEST MUMBAI , - , - ,

TEST NAME	TECHNOLOGY	VALUE	UNITS	NORMAL RANGE
ARSENIC	ICP-MS	0.43	µg/l	< 5
CADMIUM	ICP-MS	0.15	μg/l	< 1.5
MERCURY	ICP-MS	0.73	μg/l	< 5
LEAD	ICP-MS	55.25	μg/l	< 150
CHROMIUM	ICP-MS	0.39	μg/l	< 30
BARIUM	ICP-MS	0.93	μg/l	< 30
COBALT	ICP-MS	0.47	μg/l	0.10 - 1.50
CAESIUM	ICP-MS	1.96	μg/l	< 5
THALLIUM	ICP-MS	0.03	μg/l	< 1
URANIUM	ICP-MS	0.02	μg/l	< 1
STRONTIUM	ICP-MS	18.25	μg/l	8 - 38
ANTIMONY	ICP-MS	10.18	μg/l	0.10 - 18
TIN	ICP-MS	0.14	μg/l	< 2
MOLYBDENUM	ICP-MS	0.72	μg/l	0.70 - 4.0
SILVER	ICP-MS	0.33	μg/l	< 4
VANADIUM	ICP-MS	0.51	μg/l	< 0.8
BERYLLIUM	ICP-MS	0.09	μg/l	0.10 - 0.80
BISMUTH	ICP-MS	0.17	μg/l	0.10 - 0.80
SELENIUM	ICP-MS	166.97	μg/l	60 - 340
ALUMINIUM	ICP-MS	2.31	μg/l	< 30
NICKEL	ICP-MS	1.38	μg/l	< 15
MANGANESE	ICP-MS	18.04	μg/l	7.10 - 20

Please correlate with clinical conditions.

Method:

ICP - MASS SPECTROMETRY

Note:Reference range has been obtained after considering 95% population as cutoff.

Sample Collected on (SCT) : 01 Nov 2020 08:58 Sample Received on (SRT) : 02 Nov 2020 00:51 Report Released on (RRT) : 02 Nov 2020 04:43

Sample Type : EDTA

: 0111037594/A1681 Labcode

Barcode : R7114991

Dr.Prachi Sinkar MD(Path)

Dr.Caesar Senguta MD(Micro)

Page: 4 of 21



Before





NAME : ASHISH KEJRIWAL(47Y/M)

REF. BY

TEST ASKED : ADV FULL BODY CHECKUP

SAMPLE COLLECTED AT :
ADDRESS IS L703 PALM COURT COMPLEX LINK ROAD MALAD WEST MUMBAI , - 400064

TEST NAME TECHNOLOGY VALUE UNITS FASTING BLOOD SUGAR PHOTOMETRY 213.3 mg/dL Reference Range :-

Please correlate with clinical conditions.

Method:- GOD-PAP METHOD

~~ End of report ~~

Sample Collected on (SCT) Sample Received on (SRT)

Report Released on (RRT) Sample Type

Barcode

Labcode

30 Aug 2020 12:00

.30 Aug 2020 23:20

:31 Aug 2020 01:31

. FLUORIDE

:300803**7**69/PP004

. Q7226877

Dr.Prachi Sinkar MD(Path)



Dr.Caesar Senguta MD(Micro)

Page : 20 of 21



After





: ASHISSH KEJRIWAL(48Y/M) NAME

REF. BY : SELF

TEST ASKED : AAROGYAM 1.3,BLOOD SUGAR (F),COMPLETE URINE

ANALYSIS

SAMPLE COLLECTED AT :

L703 PALMCAURT COMPLEX LINK ROAD MALAD

WEST MUMBAI , - , - ,

TECHNOLOGY TEST NAME VALUE UNITS FASTING BLOOD SUGAR PHOTOMETRY 151 mg/dL Reference Range :-

70-99

Please correlate with clinical conditions.

Method:- GOD-PAP METHOD

Sample Collected on (SCT)

Sample Received on (SRT)

Report Released on (RRT)

Sample Type Labcode

Barcode

:01 Nov 2020 08:58

:02 Nov 2020 00:41

:02 Nov 2020 01:52

: FLUORIDE

:Q5717593

: 0111037154/A1681 Dr.Prachi Sinkar MD(Path)

Dr.Caesar Senguta MD(Micro)

Page: 1 of 21



After





NAME : ASHISSH KEJRIWAL(47Y/M)

REF. BY : SELF

TEST ASKED : AAROGYAM 1.3,BLOOD SUGAR (F),COMPLETE URINE

ANALYSIS

SAMPLE COLLECTED AT :

L703 TAMCOLD COMPLEX LINK ROAD MALAD WEST MUMBAI , - ,

TEST NAME TECHNOLOGY VALUE UNITS FASTING BLOOD SUGAR **PHOTOMETRY** 182.3 mg/dL Reference Range :-

Please correlate with clinical conditions.

Method:- GOD-PAP METHOD

Sample Collected on (SCT) :05 Oct 2020 09:42 Sample Received on (SRT) : 06 Oct 2020 00:46 Report Released on (RRT) :06 Oct 2020 02:28

Sample Type : FLUORIDE Labcode : 0510058343/A9992

:Q9429006 Barcode

Dr.Prachi Sinkar MD(Path)

Dr.Caesar Senguta MD(Micro)

Page: 2 of 21



ilts are for information and interpretation of the referring doctor only.
that the tests performed on the specimen belong to the patient; named or identified.

cests may vary from laboratory to laboratory and also in some parameters from time to time for the

- Should the results indicate an unexpected abnormality, the same should be reconfirmed.
- Only such medical professionals who understand reporting units, reference ranges and limitations of technologies should interpret results.
- This report is not valid for medico-legal purpose.
- Neither Thyrocare, nor its employees/representatives assume any liability, responsibility for any loss or damage that may be incurred by any person as a result of presuming the meaning or contents of the report.
- Thyrocare Discovery video link :- https://youtu.be/nbdYeRgYyQc
- For clinical support please contact @8450950851,8450950852,8450950853,8450950854 between 10:00 to 18:00

EXPLANATIONS

- Majority of the specimen processed in the laboratory are collected by Pathologists and Hospitals we call them as "Clients"
- Name The name is as declared by the client and recored by the personnel who collected the specimen.
- * Ref.Dr The name of the doctor who has recommended testing as declared by the client.
- ❖ Labcode This is the accession number in our laboratory and it helps us in archiving and retrieving the data.
- **& Barcode** This is the specimen identity number and it states that the results are for the specimen bearing the barcode (irrespective of the name).
- SCP Specimen Collection Point This is the location where the blood or specimen was collected as declared by the client.
- ❖ SCT Specimen Collection Time The time when specimen was collected as declared by the client.
- **SRT** Specimen Receiving Time This time when the specimen reached our laboratory.
- RRT Report Releasing Time The time when our pathologist has released the values for Reporting.
- * Reference Range Means the range of values in which 95% of the normal population would fall.

SUGGESTIONS

- Values out of reference range requires reconfirmation before starting any medical treatment.
- Retesting is needed if you suspect any quality shortcomings.
- Testing or retesting should be done in accredited laboratories.
- For suggestions, complaints or feedback, write to us at info@thyrocare.com or call us on 022-3090 0000 / 42525
- ❖ SMS:<Labcode No.≯to 98633
 </p>





CONDITIONS OF REPORTING

- The reported results are for information and interpretation of the referring doctor only.
- It is presumed that the tests performed on the specimen belong to the patient; named or identified.
- Results of tests may vary from laboratory to laboratory and also in some parameters from time to time for the same patient.
- Should the results indicate an unexpected abnormality, the same should be reconfirmed.
- Only such medical professionals who understand reporting units, reference ranges and limitations of technologies should interpret results.
- This report is not valid for medico-legal purpose.
- Neither Thyrocare, nor its employees/representatives assume any liability, responsibility for any loss or damage that may be incurred by any person as a result of presuming the meaning or contents of the report.
- ❖ Thyrocare Discovery video link :- https://youtu.be/nbdYeRgYyQc
- For clinical support please contact @8450950851,8450950852,8450950853,8450950854 between 10:00 to 18:00

EXPLANATIONS

- Majority of the specimen processed in the laboratory are collected by Pathologists and Hospitals we call them as "Clients".
- Name The name is as declared by the client and recored by the personnel who collected the specimen.
- Ref.Dr The name of the doctor who has recommended testing as declared by the client.
- * Labcode This is the accession number in our laboratory and it helps us in archiving and retrieving the data.
- Barcode This is the specimen identity number and it states that the results are for the specimen bearing the barcode (irrespective of the name).
- SCP Specimen Collection Point This is the location where the blood or specimen was collected as declared by the client.
- SCT Specimen Collection Time The time when specimen was collected as declared by the client.
- SRT Specimen Receiving Time This time when the specimen reached our laboratory.
- RRT Report Releasing Time The time when our pathologist has released the values for Reporting.
- Reference Range Means the range of values in which 95% of the normal population would fall.

SUGGESTIONS

- Values out of reference range requires reconfirmation before starting any medical treatment.
- Retesting is needed if you suspect any quality shortcomings.
- Testing or retesting should be done in accredited laboratories.
- For suggestions, complaints or feedback, write to us at info@thyrocare.com or call us on 022-3090 0000 / 42525
- ❖ SMS:<Labcode No.≯to 99633
 </p>











DEBART

NAME : ASHISSH KEJRIWAL(48Y/M)

REF. BY : SELF

TEST ASKED : AAROGYAM 1.3,BLOOD SUGAR (F),COMPLETE URINE

ANALYSIS

SAMPLE COLLECTED AT :

L703 PALMCAURT COMPLEX LINK ROAD MALAD

WEST MUMBAI , - , - ,

TEST NAME	TECHNOLOGY	VALUE	UNITS
HOMOCYSTEINE	PHOTOMETRY	41.1	μmol/L
Reference Range :-			

< 30

CLINICAL SIGNIFICANCE:

HOMOCYSTEINE IS LINKED TO INCREASED RISK OF PREMATURE CORONARY ARTERY DISEASE, STROKE AND THROMBOEMBOLISM. MOREOVER, ALZHEIMER□S DISEASE, OSTEOPOROSIS, VENOUS THROMBOSIS, SCHIZOPHRENIA, COGNITIVE DEFICIENCY AND PREGNANCY COMPLICATIONS ALSO ELEVATES HOMOCYSTEINE LEVELS.

HIGH VALUES:

ELEVATED HOMOCYSTEINE LEVELS MIGHT BE DUE TO INCREASING AGE, GENETIC TRAITS, DRUGS, RENAL DYSFUNCTION AND DIETARY DEFICIENCY OF VITAMINS OR SMOKING. TO LOWER YOUR HOMOCYSTEINE, EAT MORE GREEN VEGETABLES, STOP SMOKING, ALCOHOL. FOLIC ACID HELPS LOWERING ELEVATED LEVELS.

Please correlate with clinical conditions.

Method:- ENZYMATIC ASSAY

 Sample Collected on (SCT)
 : 01 Nov 2020 08:58

 Sample Received on (SRT)
 : 02 Nov 2020 00:42

 Report Released on (RRT)
 : 02 Nov 2020 05:58

Sample Type : SERUM

Labcode : 0111037185/A161
Barcode : R736810

Dr.Prachi Sinkar MD(Path)

Dr.Caesar Senguta MD(Micro)

Page : 5 of 21









DEBART

NAME : ASHISSH KEJRIWAL(48Y/M)

REF. BY : SELF

TEST ASKED : AAROGYAM 1.3,BLOOD SUGAR (F),COMPLETE URINE

ANALYSIS

SAMPLE COLLECTED AT :

L703 PALMCAURT COMPLEX LINK ROAD MALAD

WEST MUMBAI , - , - ,

TEST NAME	TECHNOLOGY	VALUE	UNITS
LIPOPROTEIN (A) [LP(A)]	IMMUNOTURBIDIMETRY	17.1	mg/dl
Reference Range :-			

ADULTS: < 30.0 MG/DL

INTERPRETATION:

DETERMINATION OF LPA MAY BE USEFUL TO GUIDE MANAGEMENT OF INDIVIDUALS WITH A FAMILY HISTORY OF CHD OR WITH EXISTING DISEASE. THE LEVELS OF LPA IN THE BLOOD DEPENDS ON GENETIC FACTORS; THE RANGE OF VARIATION IN A POPULATION IS RELATIVELY LARGE AND HENCE FOR DIAGNOSTIC PURPOSE, RESULTS SHOULD ALWAYS BE ASSESSED IN CONJUNCTION WITH THE PATIENT SMEDICAL HISTORY, CLINICAL EXAMINATION AND OTHER FINDINGS.

SPECIFICATIONS:

PRECISION: INTRA ASSAY (%CV): 3.4 %, INTER ASSAY (%CV): 2.0 %; SENSITIVITY: 0.002 GM/L

EXTERNAL QUALITY CONTROL PROGRAM PARTICIPATION:

COLLEGE OF AMERICAN PATHOLOGISTS: GENERAL CHEMISTRY AND TDM; CAP NUMBER: 7193855-01

KIT VALIDATION REFERENCES:

KOSCHINSKY ML, MARCOVINA SM. LIPOPROTEIN A: STRUCTURAL IMPLICATION FOR PATHOPHYSIOLOGY. INT J CLIN LAB RES, 1997; 27: 14-23.

Please correlate with clinical conditions.

Method:- LATEX ENHANCED IMMUNOTURBIDIMETRY

 Sample Collected on (SCT)
 : 01 Nov 2020 08:58

 Sample Received on (SRT)
 : 02 Nov 2020 00:42

 Report Released on (RRT)
 : 02 Nov 2020 05:58

Sample Type : SERUM

Labcode : 011103718 **Barcode** : R7364810

: SERUM : 0111037185/A1681 Dr.Prachi Sinkar MD(Path)

Dr.Caesar Senguta MD(Micro)

Page : 6 of 21









REF. BY

: SELF

: AAROGYAM 1.3,BLOOD SUGAR (F),COMPLETE URINE ANALYSIS TEST ASKED

SAMPLE COLLECTED AT :

L703 PALMCAURT COMPLEX LINK ROAD MALAD WEST MUMBAI , - , - ,

TEST NAME	TECHNOLOGY	VALUE	UNITS
APOLIPOPROTEIN - A1 (APO-A1)	IMMUNOTURBIDIMETRY	134	mg/dL
Reference Range :			
MALE : 86 - 152			
FEMALE : 94 - 162			
Method: FULLY AUTOMATED RATE IMMUNOTURBIDI	METRY BECKMAN COULTER		
APOLIPOPROTEIN - B (APO-B)	IMMUNOTURBIDIMETRY	87	mg/dL
Reference Range :			
MALE : 56 - 145			
EMALE : 53 - 138			
1ethod: FULLY AUTOMATED RATE IMMUNOTURBIDI	METRY □ BECKMAN COULTER		
APO B / APO A1 RATIO (APO B/A1)	CALCULATED	0.6	Ratio
Reference Range :			
MALE : 0.40 - 1.26			
FEMALE : 0.38 - 1.14			
Method: DERIVED FROM SERUM APO A1 AND APO B	VALUES		

Please correlate with clinical conditions.

Sample Collected on (SCT) :01 Nov 2020 08:58 :02 Nov 2020 00:42 Sample Received on (SRT) Report Released on (RRT) :02 Nov 2020 05:58

: SERUM Sample Type

Labcode : 0111037185/A1681 Dr.Prachi Sinkar MD(Path)

Barcode :R7364810

Dr.Caesar Senguta MD(Micro)

Page : 7 of 21









REF. BY : SELF TEST ASKED

: AAROGYAM 1.3,BLOOD SUGAR (F),COMPLETE URINE

ANALYSIS

SAMPLE COLLECTED AT :

L703 PALMCAURT COMPLEX LINK ROAD MALAD

WEST MUMBAI , - , - ,

TEST NAME	TECHNOLOGY	VALUE	UNITS
HIGH SENSITIVITY C-REACTIVE PROTEIN (HS-CRP) Reference Range :-	IMMUNOTURBIDIMETRY	1.6	mg/L

ADULT: <=3.0 MG/L

INTERPRETATION:

HIGH SENSITIVITY C-REACTIVE PROTEIN, WHEN USED IN CONJUNCTION WITH OTHER CLINICAL LABORATORY EVALUATION OF ACUTE CORONARY SYNDROMES, MAY BE USEFUL AS AN INDEPENDENT MARKER OF PROGNOSIS FOR RECURRENT EVENTS, IN PATIENTS WITH STABLE CORONARY DISEASE OR ACUTE CORONARY SYNDROMES. HSCRP LEVELS SHOULD NOT BE SUBSTITUTED FOR ASSESSMENT OF TRADITIONAL CARDIOVASCULAR RISK FACTORS, PATIENTS WITH PERSISTENTLY UNEXPLAINED, MARKED EVALUATION OF HSCRP AFTER REPEATED TESTING SHOULD BE EVALUATED FOR NON - CARDIOVASCULAR ETIOLOGIES

CLINICAL SIGNIFICANCE:

HSCRP MEASUREMENTS MAY BE USED AS AN INDEPENDENT RISK MARKER FOR THE IDENTIFICATION OF INDIVIDUALS AT RISK FOR FUTURE CARDIOVASCULAR DISEASE. ELEVATED CRP VALUES MAY BE INDICATIVE OF PROGNOSIS OF INDIVIDUALS WITH ACUTE CORONARY SYNDROMES, AND MAY BE USEFUL IN THE MANAGEMENT OF SUCH INDIVIDUALS.

SPECIFICATIONS: PRECISION: WITHIN RUN %CV HAS BEEN RECORDED <=5%.

1. CHENILLOT O, HENNY J, STEINMEZ J, ET AL. HIGH SENSITIVITY C-REACTIVE PROTEIN: BIOLOGICAL VARIATIONS AND REFERENCE LIMITS, CLIN CHEM LAB MED 2000;38:1003-11.

2. HIND CRH, PEPYS MB. THE ROLE OF SERUM C-REACTIVE PROTEIN MEASUREMENTS IN CLINICAL PRACTICE. INT MED 1984;5:112-51.

Please correlate with clinical conditions.

Method:- FULLY AUTOMATED LATEX AGGLUTINATION ☐ BECKMAN COULTER

Sample Collected on (SCT) :01 Nov 2020 08:58 Sample Received on (SRT) :02 Nov 2020 00:42 Report Released on (RRT) :02 Nov 2020 05:58

Sample Type : SERUM

Labcode Barcode :R7364810

: 0111037185/A1681 Dr.Prachi Sinkar MD(Path)

Dr.Caesar Senguta MD(Micro)

Page: 8 of 21









DEGNOT

NAME : ASHISSH KEJRIWAL(48Y/M)

REF. BY : SELF

TEST ASKED : AAROGYAM 1.3,BLOOD SUGAR (F),COMPLETE URINE

ANALYSIS

SAMPLE COLLECTED AT :

L703 PALMCAURT COMPLEX LINK ROAD MALAD

WEST MUMBAI , - , - ,

TEST NAME	TECHNOLOGY	VALUE	UNITS
SERUM COPPER	PHOTOMETRY	117.36	µg/dL
Reference Range :-			

nordrande namge

MALE : 63.5 - 150 FEMALE : 80 - 155

CLINICAL SIGNIFICANCE

COPPER IS AN IMPORTANT TRACE ELEMENT AND A COMPONENT OF NUMEROUS ENZYMES AND PROTEINS INVOLVED IN ENERGY PRODUCTION, CONNECTIVE TISSUE FORMATION, MELANIN SYNTHESIS, IRON METABOLISM, DEVELOPMENT OF CENTRAL NERVOUS SYSTEM, ANGIOGENESIS AS WELL AS AN ANTIOXIDANT.

DEFICIENCY CAN CAUSE - MALNOURISHMENT, CARDIOVASCULAR DISEASE, ANEMIA & NEUROPATHY. TOXICITY MAY BE MANIFESTED AS ACUTE RENAL FAILURE, GASTROENTERITIS & CHRONIC LIVER DISEASE.

REFERENCE: CARL A. BURTIS, EDWARD R. ASHWOOD, DAVID E. BRUNS. TIETZ TEXTBOOK OF CLINICAL CHEMISTRY AND MOLECULAR DIAGNOSTICS. CHAPTER 31.VITAMINS AND TRACE ELEMENTS. PAGE: 948-952.

Please correlate with clinical conditions.

Method:- 3,5-DIBR-PAESA

 Sample Collected on (SCT)
 : 01 Nov 2020 08:58

 Sample Received on (SRT)
 : 02 Nov 2020 00:42

 Report Released on (RRT)
 : 02 Nov 2020 05:58

Sample Type : SERUM

Labcode : 011103718 **Barcode** : R7364810

: SERUM : 0111037185/A1681 Dr.Prachi Sinkar MD(Path)

Dr.Caesar Senguta MD(Micro)

Page : 9 of 21









REF. BY : SELF

TEST ASKED : AAROGYAM 1.3,BLOOD SUGAR (F),COMPLETE URINE

ANALYSIS

SAMPLE COLLECTED AT :

L703 PALMCAURT COMPLEX LINK ROAD MALAD WEST MUMBAI , - , - ,

TEST NAME	TECHNOLOGY	VALUE	UNITS
SERUM ZINC	PHOTOMETRY	235.49	μg/dL
Reference Range :-			

52 - 286

CLINICAL SIGNIFICANCE

ZINC IS ONE OF THE ESSENTIAL TRACE ELEMENTS IN THE BODY. ITS METALLOENZYMES PLAY A KEY ROLE IN PROTEIN AND NUCLEIC ACID SYNTHESIS, GENE EXPRESSION, WOUND HEALING, AS AN ANTIOXIDANT, ETC.

DEFICIENCY CAN CAUSE - POOR WOUND HEALING, GASTROENTERITIS, IMPAIRED SPERMATOGENESIS, ALZHEIMER S DISEASE, ETC. TOXICITY MAY BE MANIFESTED AS PANCREATITIS, GASTRIC ULCER, ANEMIA, PULMONARY FIBROSIS.

REFERENCE: CARL A. BURTIS, EDWARD R. ASHWOOD, DAVID E. BRUNS. TIETZ TEXTBOOK OF CLINICAL CHEMISTRY AND MOLECULAR DIAGNOSTICS. CHAPTER 31.VITAMINS AND TRACE ELEMENTS. PAGE:960-965.

Please correlate with clinical conditions.

Method:- NITRO - PAPS

Sample Collected on (SCT) :01 Nov 2020 08:58 Sample Received on (SRT) :02 Nov 2020 00:42 Report Released on (RRT) :02 Nov 2020 05:58

Sample Type : SERUM

Labcode Barcode :R7364810

: 0111037185/A1681 Dr.Prachi Sinkar MD(Path)

Dr.Caesar Senguta MD(Micro)

Page: 10 of 21









DEGNOT

NAME : ASHISSH KEJRIWAL(48Y/M)

REF. BY : SELF

TEST ASKED : AAROGYAM 1.3,BLOOD SUGAR (F),COMPLETE URINE

ANALYSIS

SAMPLE COLLECTED AT :

L703 PALMCAURT COMPLEX LINK ROAD MALAD

WEST MUMBAI , - , - ,

TEST NAME TECHNOLOGY VALUE UNITS
TESTOSTERONE C.L.I.A 278.24 ng/dL
Reference Range:-

Adult Male

21 - 49 Yrs : 164.94 - 753.38 50 - 89 Yrs : 86.49 - 788.22 Adult Female Pre-Menopause : 12.09 - 59.46 Post-Menopause: < 7.00 - 48.93

Boys

2-10 Years : < 7.00 - 25.91 11 Years : < 7.00 - 341.53 12 Years : < 7.00 - 562.59 13 Years : 9.34 - 562.93 14 Years : 23.28 - 742.46 15 Years : 144.15 - 841.44 16-21 Years : 118.22 - 948.56

Girls

Clinical Significance:

Clinical evaluation of serum testosterone, along with serum LH, assists in evaluation of Hypogonadal males. Major causes of lowered testosterone in males include Hypogonadotropic hypogonadism, testicular failure Hyperprolactinema, Hypopituitarism some types of liver and kidney diseases and critical illness.

Specifications: Precision: Intra assay (%CV): 8.5 %, Inter assay (%CV): 12.6%; Sensitivity: 7 ng/dL.

External quality control program participation:

College of American pathologists: Ligand assay (special) survey; cap number: 7193855-01

Please correlate with clinical conditions.

Method:- FULLY AUTOMATED BIDIRECTIONALLY INTERFACED CHEMI LUMINESCENT IMMUNO ASSAY

 Sample Collected on (SCT)
 : 01 Nov 2020 08:58

 Sample Received on (SRT)
 : 02 Nov 2020 00:42

 Report Released on (RRT)
 : 02 Nov 2020 05:58

Sample Type : SERUM

Labcode : 011103718 **Barcode** : R7364810

: 0111037185/A1681 Dr.Prachi Sinkar MD(Path)

Dr.Caesar Senguta MD(Micro)

Page : 11 of 21









REF. BY : SELF

TEST ASKED : AAROGYAM 1.3,BLOOD SUGAR (F),COMPLETE URINE

ANALYSIS

SAMPLE COLLECTED AT :

L703 PALMCAURT COMPLEX LINK ROAD MALAD

ng/ml

WEST MUMBAI, -, -,

19.79

TEST NAME TECHNOLOGY UNITS VALUE C.L.I.A

25-OH VITAMIN D (TOTAL)

Reference Range:
DEFICIENCY: <20 ng/ml
INSUFFICIENCY: 20-<30 ng/ml SUFFICIENCY : 30-100 ng/ml TOXICITY : >100 ng/ml

Vitamin D Total test is analyzed on Siemens ADVIA Centaur, standardized against ID-LC/MS/MS, as per Vitamin D Standardization

Specifications: Intra assay (%CV):5.3%, Inter assay (%CV):11.9%; Sensitivity:3.2 ng/ml

Method: FULLY AUTOMATED CHEMI LUMINESCENT IMMUNO ASSAY

C.L.I.A VITAMIN B-12 pg/ml

Reference Range: Normal: 211 - 911 pg/ml

Clinical significance :

 $\ \ \, \text{Vitamin B12} \ \, \text{or cyanocobalamin, is a complex corrinoid compound found exclusively from animal dietary sources, such as meat, eggs}$ and milk. It is critical in normal DNA synthesis, which in turn affects erythrocyte maturation and in the formation of myelin sheath. Vitamin-B12 is used to find out neurological abnormalities and impaired DNA synthesis associated with macrocytic anemias. For diagnostic purpose, results should always be assessed in conjunction with the patients medical history, clinical examination and

Specifications: Intra assay (%CV):5.0%, Inter assay (%CV):9.2 %; Sensitivity:45 pg/ml

External quality control program participation:

College of American pathologists: ligand assay (general) survey; CAP number: 7193855-01

Kit validation references:

Chen IW, Sperling MI, Heminger IA. Vitamin B12. In: Pesce AJ, Kalpan LA, editors. Methods in clinical chemistry. St. Louis: CV Mosby,1987.P.569-73.

Method: FULLY AUTOMATED BIDIRECTIONALLY INTERFACED CHEMI LUMINESCENT IMMUNO ASSAY

Please correlate with clinical conditions.

:01 Nov 2020 08:58 Sample Collected on (SCT) Sample Received on (SRT) :02 Nov 2020 00:42 :02 Nov 2020 05:58 Report Released on (RRT)

Sample Type : SERUM

Labcode

Barcode :R7364810

:0111037185/A1681 Dr.Prachi Sinkar MD(Path)

Dr.Caesar Senguta MD(Micro)

Page: 12 of 21









DEGNOT

NAME : ASHISSH KEJRIWAL(48Y/M)

REF. BY : SELF

TEST ASKED : AAROGYAM 1.3,BLOOD SUGAR (F),COMPLETE URINE

ANALYSIS

SAMPLE COLLECTED AT :

L703 PALMCAURT COMPLEX LINK ROAD MALAD

WEST MUMBAI , - , - ,

TEST NAME TECHNOLOGY VALUE UNITS

CYSTATIN C IMMUNOTURBIDIMETRY 1.06 mg/L

Reference Range :-

<= 60 years: <= 1.03 mg/L > 60 years : < 1.50 mg/L

Clinical significance

Cystatin c, is a small 13-kda protein and is a member of the cysteine proteinase inhibitor family, it is produced at a constant rate by all nucleated cells. Due to its small size it is freely filtered by the glomerulus and is not secreted but is fully reabsorbed and broken down by the renal tubules. This means that the primary determinate of blood Cystatin c levels is the rate at which it is filtered at the glomerulus making it an excellent gfr marker. Cystatin c is also a marker of inflammation and like many other markers of inflammation; its serum concentration may be higher in patients with decreased renal clearance. There is mounting evidence, however, that Cystatin c may be a predictor of adverse outcomes independent of renal function with its higher sensitivity to detect a reduced GFR than Creatinine determination, also in the so-called Creatinine-blind range. Thus, Cystatin c is suggested to be a better marker for GFR than the ubiquitous serum Creatinine.

Reference

1. Barrett aj, Davies me, Grubb a. the place of human gamma-trace (Cystatin c) among the cysteine proteinase inhibitors. Biochem biophys res common 1984; 12: 631-6.

2 Grubb a. diagnostic value of analysis of Cystatin c and protein HC in biological fluids. Clin Nephrol 1992 38: S2-7.

Please correlate with clinical conditions.

Method:- LATEX ENHANCED IMMUNOTURBIDIMETRY

 Sample Collected on (SCT)
 : 01 Nov 20 08:58

 Sample Received on (SRT)
 : 02Nov 20 00:42

 Report Released on (RRT)
 : 02Nov 20 05:58

Sample Type : SERUM

Labcode : 011103718 **Barcode** : R7364810

: 0111037185/A1681 Dr.Prachi Sinkar MD(Path)

Dr.Caesar Senguta MD(Micro)

Page : 13 of 21









REF. BY : SELF

TEST ASKED : AAROGYAM 1.3,BLOOD SUGAR (F),COMPLETE URINE ANALYSIS

SAMPLE COLLECTED AT :

L703 PALMCAURT COMPLEX LINK ROAD MALAD WEST MUMBAI , - , - ,

TEST NAME	TECHNOLOGY	VALUE	UNITS
TEST NAME	TECHNOLOGY	VALUE	UNITS
IRON	PHOTOMETRY	23.1	μg/dl
Reference Range : Male : 65 - 175			
Female: 50 - 170			
Method: FERROZINE METHOD WITHOUT DEPROTEINIZA	ATION		
TOTAL IRON BINDING CAPACITY (TIBC)	PHOTOMETRY	517	μg/dl
Reference Range : Male: 225 - 535 µg/dl Female: 215 - 535 µg/dl Method : SPECTROPHOTOMETRIC ASSAY			
% TRANSFERRIN SATURATION	CALCULATED	4.47	%
Reference Range: 13 - 45			

Method: DERIVED FROM IRON AND TIBC VALUES

Please correlate with clinical conditions.

Sample Collected on (SCT) :01 Nov 2020 08:58 :02 Nov 2020 00:42 Sample Received on (SRT) Report Released on (RRT) :02 Nov 2020 05:58

: SERUM Sample Type

Labcode

Barcode :R7364810

: 0111037185/A1681 Dr.Prachi Sinkar MD(Path)

Dr.Caesar Senguta MD(Micro)

Page : 14 of 21









: ASHISSH KEJRIWAL(48Y/M) NAME

REF. BY

TEST ASKED : AAROGYAM 1.3,BLOOD SUGAR (F),COMPLETE URINE

ANALYSIS

SAMPLE COLLECTED AT : L703 PALMCAURT COMPLEX LINK ROAD MALAD WEST

MUMBAI , - , - ,

TEST NAME	TECHNOLOGY	VALUE	UNITS	NORMAL RANGE
ALKALINE PHOSPHATASE	PHOTOMETRY	61.3	U/L	45 - 129
BILIRUBIN -DIRECT	PHOTOMETRY	0.11	mg/dl	< 0.3
BILIRUBIN - TOTAL	PHOTOMETRY	0.34	mg/dl	0.3-1.2
BILIRUBIN (INDIRECT)	CALCULATED	0.24	mg/dl	0-0.9
GAMMA GLUTAMYL TRANSFERASE (GGT)	PHOTOMETRY	43.9	U/I	< 55
ASPARTATE AMINOTRANSFERASE (SGOT)	PHOTOMETRY	22.79	U/I	< 35
ALANINE TRANSAMINASE (SGPT)	PHOTOMETRY	21.62	U/I	< 45
PROTEIN - TOTAL	PHOTOMETRY	7.18	gm/dl	5.7-8.2
ALBUMIN - SERUM	PHOTOMETRY	3.78	gm/dl	3.2-4.8
SERUM GLOBULIN	PHOTOMETRY	3.4	gm/dL	2.5-3.4
SERUM ALB/GLOBULIN RATIO	CALCULATED	1.11	Ratio	0.9 - 2

Please correlate with clinical conditions.

Method:

ALKP - Modified IFCC method

BILD - Vanadate Oxidation

BILT - Vanadate Oxidation

BILI - DERIVED FROM SERUM TOTAL AND DIRECT BILIRUBIN VALUES

GGT - Modified IFCC method

SGOT - IFCC* WITHOUT PYRIDOXAL PHOSPHATE ACTIVATION

SGPT - IFCC* WITHOUT PYRIDOXAL PHOSPHATE ACTIVATION

PROT - BIURET METHOD

SALB - ALBUMIN BCG¹METHOD (COLORIMETRIC ASSAY ENDPOINT)

SEGB - DERIVED FROM SERUM ALBUMIN AND PROTEIN VALUES

A/GR - DERIVED FROM SERUM ALBUMIN AND PROTEIN VALUES

Sample Collected on (SCT) : 01 Nov 2020 08:58 : 02 Nov 2020 00:42 Sample Received on (SRT) : 02 Nov 2020 05:58 Report Released on (RRT)

: SERUM **Sample Type**

Labcode : 0111037185/A1681

Barcode : R7364810

Dr.Prachi Sinkar MD(Path)

Dr.Caesar Senguta MD(Micro)

Page: 15 of 21









REF. BY

TEST ASKED : AAROGYAM 1.3,BLOOD SUGAR (F),COMPLETE URINE

ANALYSIS

SAMPLE COLLECTED AT : L703 PALMCAURT COMPLEX LINK ROAD MALAD WEST

MUMBAI,-,-,

TEST NAME	TECHNOLOGY	VALUE	UNITS	NORMAL RANGE
TOTAL CHOLESTEROL	PHOTOMETRY	178	mg/dl	125-200
HDL CHOLESTEROL - DIRECT	PHOTOMETRY	51	mg/dl	35-80
TRIGLYCERIDES	PHOTOMETRY	143	mg/dl	25-200
LDL CHOLESTEROL - DIRECT	PHOTOMETRY	114	mg/dl	85-130
TC/ HDL CHOLESTEROL RATIO	CALCULATED	3.5	Ratio	3 - 5
LDL / HDL RATIO	CALCULATED	2.3	Ratio	1.5-3.5
VLDL CHOLESTEROL	CALCULATED	28.51	mg/dl	5 - 40
NON-HDL CHOLESTEROL	CALCULATED	127.5	ma/dl	< 160

Please correlate with clinical conditions.

Method:

CHOL - CHOD POD METHOD

HCHO - ENZYME SELECTIVE PROTECTION METHOD

TRIG - ENZYMATIC COLORIMETRIC METHOD (GPO) [HIGHLY INFLUENCED BY LEVEL OF FASTING]

LDL - HOMOGENOUS ENZYMATIC COLORIMETRIC ASSAY

TC/H - DERIVED FROM SERUM CHOLESTEROL AND HDL VALUES

LDL/ - Derived from serum HDL and LDL Values

VLDL - DERIVED FROM SERUM TRIGLYCERIDE VALUES

NHDL - Derived from serum Cholesterol and HDL values

*REFERENCE RANGES AS PER NCEP ATP III GUIDELINES:

TOTAL CHOLESTEROL	(mg/dl)	HDL	(mg/dl)	LDL	(mg/dl)	TRIGLYCERIDES	(mg/dl)
DESIRABLE	<200	LOW	<40	OPTIMAL	<100	NORMAL	<150
BORDERLINE HIGH	200-239	HIGH	>60	NEAR OPTIMAL	100-129	BORDERLINE HIGH	150-199
HIGH	>240			BORDERLINE HIGH	130-159	HIGH	200-499
				HIGH	160-189	VERY HIGH	>500
				VERY HIGH	>190		

Alert !!! 10-12 hours fasting is mandatory for lipid parameters. If not, values might flutuate.

Sample Collected on (SCT) : 01 Nov 2020 08:58 : 02 Nov 2020 00:42 Sample Received on (SRT) Report Released on (RRT) : 02 Nov 2020 05:58

Sample Type

: SERUM

Labcode Barcode

: 0111037185/A1681

: R7364810

Dr.Prachi Sinkar MD(Path)

Dr.Caesar Senguta MD(Micro)

Page: 16 of 21







SAMPLE COLLECTED AT :
L703 PALMCAURT COMPLEX LINK ROAD MALAD WEST
MUMBAI , - , - ,



NAME : ASHISSH KEJRIWAL(48Y/M)

REF. BY : SELF

TEST ASKED

: AAROGYAM 1.3,BLOOD SUGAR (F),COMPLETE URINE

ANALYSIS

TEST NAME	TECHNOLOGY	VALUE	UNITS	REFERENCE RANGE
TOTAL TRIIODOTHYRONINE (T3)	C.L.I.A	86	ng/dl	60-200
TOTAL THYROXINE (T4)	C.L.I.A	10.3	µg/dl	4.5-12
THYROID STIMULATING HORMONE (TSH)	C.L.I.A	1.56	μIU/ml	0.3-5.5

Comments: SUGGESTING THYRONORMALCY

Please correlate with clinical conditions.

Method:

T3 - COMPETITIVE CHEMI LUMINESCENT IMMUNO ASSAY T4 - COMPETITIVE CHEMI LUMINESCENT IMMUNO ASSAY TSH - SANDWICH CHEMI LUMINESCENT IMMUNO ASSAY

Sample Collected on (SCT) : 01 Nov 2020 08:58 Sample Received on (SRT) : 02 Nov 2020 00:42 : 02 Nov 2020 05:58

Report Released on (RRT) Sample Type : SERUM

Labcode : 0111037185/A1681

Barcode : R7364810 Dr.Prachi Sinkar MD(Path)

Dr.Caesar Senguta MD(Micro)

Page : 17 of 21









NAME : ASHISSH KEJRIWAL(48Y/M)

REF. BY

TEST ASKED

: AAROGYAM 1.3,BLOOD SUGAR (F),COMPLETE URINE

ANALYSIS

SAMPLE COLLECTED AT : L703 PALMCAURT COMPLEX LINK ROAD MALAD WEST

MUMBAI , - , - ,

TEST NAME	TECHNOLOGY	VALUE	UNITS	NORMAL RANGE
BLOOD UREA NITROGEN (BUN)	PHOTOMETRY	7.88	mg/dl	7 - 25
CREATININE - SERUM	PHOTOMETRY	0.77	mg/dl	0.6-1.1
URIC ACID	PHOTOMETRY	4.69	mg/dl	4.2 - 7.3
CALCIUM	PHOTOMETRY	9.23	mg/dl	8.8-10.6
BUN / SR.CREATININE RATIO	CALCULATED	10.23	Ratio	9:1-23:1

Please correlate with clinical conditions.

Method:

BUN - KINETIC UV ASSAY.

SCRE - CREATININE ENZYMATIC METHOD

URIC - Uricase / Peroxidase Method

CALC - ARSENAZO III METHOD, END POINT.

B/CR - DERIVED FROM SERUM BUN AND CREATININE VALUES

Sample Collected on (SCT) : 01 Nov 2020 08:58 Sample Received on (SRT) : 02 Nov 2020 00:42 Report Released on (RRT) : 02 Nov 2020 05:58

Sample Type : SERUM

Labcode : 0111037185/A1681

Barcode : R7364810

Dr.Prachi Sinkar MD(Path)

NO IMAGE

Dr.Caesar Senguta MD(Micro)

Page: 18 of 21









DEGNOT

NAME : ASHISSH KEJRIWAL(48Y/M)

REF. BY : SELF

TEST ASKED : AAROGYAM 1.3,BLOOD SUGAR (F),COMPLETE URINE

ANALYSIS

SAMPLE COLLECTED AT :

L703 PALMCAURT COMPLEX LINK ROAD MALAD

WEST MUMBAI , - , - ,

TEST NAME	TECHNOLOGY	VALUE	UNITS
EST. GLOMERULAR FILTRATION RATE (eGFR)	CALCULATED	107	mL/min/1.73 m2
Reference Range :-			

> = 90 : Normal 60 - 89 : Mild Decrease

45 - 59 : Mild to Moderate Decrease 30 - 44 : Moderate to Severe Decrease

15 - 29 : Severe Decrease

Clinical Significance

The normal serum creatinine reference interval does not necessarily reflect a normal GFR for a patient. Because mild and moderate kidney injury is poorly inferred from serum creatinine alone. Thus, it is recommended for clinical laboratories to routinely estimate glomerular filtration rate (eGFR), a \square gold standard \square measurement for assessment of renal function, and report the value when serum creatinine is measured for patients 18 and older, when appropriate and feasible. It cannot be measured easily in clinical practice, instead, GFR is estimated from equations using serum creatinine, age, race and sex. This provides easy to interpret information for the doctor and patient on the degree of renal impairment since it approximately equates to the percentage of kidney function remaining. Application of CKD-EPI equation together with the other diagnostic tools in renal medicine will further improve the detection and management of patients with CKD.

Reference

Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-12.

Please correlate with clinical conditions.

Method:- CKD-EPI Creatinine Equation

 Sample Collected on (SCT)
 : 01 Nov 2020 08:58

 Sample Received on (SRT)
 : 02 Nov 2020 00:42

 Report Released on (RRT)
 : 02 Nov 2020 05:58

Sample Type : SERUM

Labcode : 0111037189 **Barcode** : R7364810

: SERUM : 0111037185/A1681 Dr.Prachi Sinkar MD(Path)

Dr.Caesar Senguta MD(Micro)

Page : 19 of 21









DEDMOT

NAME :ASHISSH KEJRIWAL(48Y/M)

REF. BY :SELF

TEST ASKED : COMPLETE URINE ANALYSIS

SAMPLE COLLECTED AT : L703 PALMCAURT COMPLEX LINK ROAD MALAD WEST MUMBAI , - , - ,

TEST NAME	OBSERVATION	UNITS	REFERENCE RANGE
COMPLETE URINOGRAM			
URINARY GLUCOSE	NEGATIVE	mg/dl	Negative
URINARY BILIRUBIN	NEGATIVE	mg/dl	Negative
JRINE KETONE	NEGATIVE	mg/dl	Negative
PECIFIC GRAVITY	1.01	-	1.003-1.030
RINE BLOOD	NEGATIVE	Cells/ul*	Negative
-1	5.5	-	5 - 8
RINARY PROTEIN	NEGATIVE	mg/dl	Negative
ROBILINOGEN	0.2	mg/dl	<=0.2
TRITE	NEGATIVE	-	Negative
INARY LEUCOCYTES	NEGATIVE	Cells/ul*	Negative
LOUR	PALE YELLOW	-	Pale Yellow
PEARANCE	CLEAR	-	Clear
LE SALT	NEGATIVE	-	Negative
ILE PIGMENT	NEGATIVE	-	Negative
PITHELIAL CELLS	1-2	-	2-3
STS	ABSENT	-	Absent
RYSTALS	ABSENT	-	Absent
ACTERIA	ABSENT	-	Absent

* To Obtain Counts in Cells / HPF Divide the Cells / ul by 5

Please correlate with clinical conditions.

Method: Manual Dipstick Method

Remarks :Alert!!!

Yeast cells are present.

~~ End of report ~~

Sample Collected on (SCT)
Sample Received on (SRT)

Report Released on (RRT)

Sample Type

Labcode Barcode :01 Nov 2020 08:58

:02 Nov 2020 00:53

:02 Nov 2020 03:33

: URINE

:0111037701/A1681

:R8374821

(nachukar

Dr.Prachi Sinkar MD(Path)

(gar

Dr.Caesar Senguta MD(Micro)

Page: 20 of 21



CONDITIONS OF REPORTING

- The reported results are for information and interpretation of the referring doctor only.
- It is presumed that the tests performed on the specimen belong to the patient; named or identified.
- Results of tests may vary from laboratory to laboratory and also in some parameters from time to time for the same patient.
- Should the results indicate an unexpected abnormality, the same should be reconfirmed.
- Only such medical professionals who understand reporting units, reference ranges and limitations of technologies should interpret results.
- This report is not valid for medico-legal purpose.
- Neither Thyrocare, nor its employees/representatives assume any liability, responsibility for any loss or damage that may be incurred by any person as a result of presuming the meaning or contents of the report.
- Thyrocare Discovery video link :- https://youtu.be/nbdYeRgYyQc
- ❖ For clinical support please contact @8450950851,8450950852,8450950853,8450950854 between 10:00 to 18:00

EXPLANATIONS

- Majority of the specimen processed in the laboratory are collected by Pathologists and Hospitals we call them as "Clients".
- ❖ Name The name is as declared by the client and recored by the personnel who collected the specimen.
- Ref.Dr The name of the doctor who has recommended testing as declared by the client.
- ❖ Labcode This is the accession number in our laboratory and it helps us in archiving and retrieving the data.
- Barcode This is the specimen identity number and it states that the results are for the specimen bearing the barcode (irrespective of the name).
- SCP Specimen Collection Point This is the location where the blood or specimen was collected as declared by the client.
- * SCT Specimen Collection Time The time when specimen was collected as declared by the client.
- SRT Specimen Receiving Time This time when the specimen reached our laboratory.
- RRT Report Releasing Time The time when our pathologist has released the values for Reporting.
- Reference Range Means the range of values in which 95% of the normal population would fall.

SUGGESTIONS

- Values out of reference range requires reconfirmation before starting any medical treatment.
- Retesting is needed if you suspect any quality shortcomings.
- Testing or retesting should be done in accredited laboratories.
- For suggestions, complaints or feedback, write to us at info@thyrocare.com or call us on 022-3090 0000 / 42525
- ❖ SMS:<Labcode No.≯to 98633</p>





BEFORE

DR. AMRISH MEHTA'S,
APPLE DIAGNOSTIC

PATHOLOGY,X-RAY,SONOGRAPHY,E.C.G. AND STRESS TEST Prabhu Krupa, 2Nd Floor, Tilak Road, Near Lions Garden Ghatkopar (E) Mumbai- 400077 Phone - 7208066884, 7208066885, 7208066886, 9819151819

PATIENT NAME : MRS BALWINDER KAUR

REFERRED BY DR. : AXELIA SEX / AGE: FEMALE / 64 Y VISIT CODE : 10211920210



REGISTRATION : 12/07/2021 6:28 PM COLLECTED ON : 12/07/2021 6:28 PM REPORTED ON : 12/07/2021 8:52 PM

Test	Result	Units	Biological Reference Interval
HB A1C (GLYCO HB)	9.4	%	Non-diabetic: 4.0 - 6.0 Objective: 6.0 - 6.5 Good Control: 6.5 - 8.0 Poor Control: > 8.0
MEAN BLOOD GLUCOSE	227	mg/dl.	

(Mean Blood Glucose is a calculated value.)

Method: HPLC done on Bio-Rad D10.







DR. AMRISH MEHTA'S, APPLE DIAGNOSTIC

PATHOLOGY, X-RAY, SONOGRAPHY, E.C.G. AND STRESS TEST Prabhu Krupa, 2Nd Floor, Tilak Road, Near Lions Garden Ghatkopar (E) Mumbai- 400077 Phone - 7208066884, 7208066885, 7208066886, 9819151819

REGISTRATION : 12/07/2021 6:28 PM PATIENT NAME: MRS BALWINDER KAUR REFERRED BY DR.: AXELIA COLLECTED ON : 12/07/2021 6:28 PM SEX / AGE: FEMALE / 64 Y REPORTED ON : 12/07/2021 8:52 PM

VISIT CODE: 10211920210



LIPID PROFILE

Test SERUM TRIGLYCERIDES Enzymatic method	Result *1778.7	Units mg/dl.	Biological Reference Interval DESIRABLE: 10 - 150 BORDERLINE: 150 - 190
Enzymatic method			
SERUM CHOLESTROL(TOTAL)	*467	mg/dl.	DESIRABLE CHOL: < 200 BORDERLINE CHOL: 200-239 HIGH CHOL :> 240
Enzymatic method			
SERUM HDL CHOLESTROL	47.7	mg/dl.	< 40 - Major Risk 40-60 - Normal > 60 - Negative Risk
Enzymatic method			
TOTAL CHOL/HDL RATIO	9.8		LOW RISK : 3.3 TO 4.4 AVERAGE RISK : 4.4 TO 7.1 MODERATE RISK : 7.1 TO 11.0 HIGH RISK : >11.0
NON - HDL CHOLESTEROL	419.3	mg/dl	Optimal :<130 Desirable : 130-159 Borderline high: 159-189 High : 189-220 Very High :>=220

Remark: *RECHECKED SAMPLE IS GROSSLY LIPAEMIC KINDLY CORRELATE WITH CLINICAL CONDITIONS

Tests done on Fully Automated AU680 Biochemistry Analyzer.

Note:- Reference Interval as per National Cholestrol Education Program(NCEP) Adult Treatment Panel III Report.VLDL, CHOL/HDL Ratio, LDL/HDL Ratio, LDL Cholestrol, Non HDL Cholestrol are calculated parameters.

DR. AMRISH K. MEHTA M.D., D.P.B.



BEFORE

DR. AMRISH MEHTA'S,
APPLE DIAGNOSTIC

PATHOLOGY,X-RAY,SONOGRAPHY,E.C.G. AND STRESS TEST Prabhu Krupa, 2Nd Floor, Tilak Road, Near Lions Garden Ghatkopar (E) Mumbai- 400077 Phone - 7208066884, 7208066885, 7208066886, 9819151819

 ${\tt PATIENT\ NAME: MRS\ BALWINDER\ KAUR}$

REFERRED BY DR. : AXELIA SEX / AGE: FEMALE / 64 Y VISIT CODE : 10211920210



COLLECTED ON : 12/07/2021 6:28 PM REPORTED ON : 12/07/2021 8:52 PM

REGISTRATION : 12/07/2021 6:28 PM

Test Result Units Biological Reference Interval

FASTING BLOOD SUGAR(PLASMA) *214.2 mg/dl Normal : < 100

Normal: < 100 Impaired fasting glucose: 100 - 125 Diabetes mellitus: > 126 (On more than one occasion) (American diabetes association guidlines 2016)

GOD/POD method

All Biochemical tests done on Fully Automated Beckman Coulter Au 680 Biochemistry Analyzer.

S. CREATININE 0.5 mg/dl 0.5-1.3

Jaffe-s Kinetic method

All Biochemical tests done on Fully Automated Beckman Coulter Au 680 Biochemistry Analyzer.

DR. AMRISH K. MEHTA M.D., D.P.B.





DR. AMRISH MEHTA'S,

APPLE DIAGNOSTIC

VISIT CODE: 10211920210

PATHOLOGY,X-RAY,SONOGRAPHY,E.C.G. AND STRESS TEST Prabhu Krupa, 2Nd Floor, Tilak Road, Near Lions Garden Ghatkopar (E) Mumbai- 400077 Phone - 7208066884, 7208066885, 7208066886, 9819151819

PATIENT NAME : MRS BALWINDER KAUR
REFERRED BY DR. : AXELIA
COLLECTED ON : 12/07/2021 6:28 PM
SEX / AGE: FEMALE / 64 Y
REPORTED ON : 12/07/2021 8:52 PM



EXAMINATION OF URINE

Test	Result	Units	Biological Reference Interval
PHYSICAL EXAMINATION			=
QUANTITY	30	ml	
DEPOSIT	ABSENT		ABSENT
COLOUR	PALE YELLOW	/	Pale Yellow
SP.GRAVITY	1.010		1.000 - 1.030
APPEARANCE	SLIGHTLY HAZ	ZY	CLEAR
CHEMICAL EXAMINATION			
ALBUMIN	TRACE		ABSENT
SUGAR	PRESENT(++)		ABSENT
REACTION	ACIDIC		ACIDIC/ALKALIN
OCCULT BLOOD	NEGATIVE		NEGATIVE
BILE PIGMENTS	ABSENT		
ACETONE	ABSENT		
MICROSCOPIC EXAMINATION			
RED BLOOD CELLS	ABSENT		Absent
PUS CELLS	PRESENT (35-4	0/hpf)	0 - 5
EPITHELIAL CELLS	PRESENT (6-8/I	npf)	0 - 5
AMORPHOUS DEPOSITS	ABSENT		ABSENT
CASTS	ABSENT		ABSENT
YEAST CELLS	ABSENT		ABSENT
CRYSTALS	ABSENT		ABSENT

Test Method: DIPSTICK / MICROSCOPY

DR. AMRISH K. MEHTA M.D., D.P.B.



AFTER

PROCESSED AT:

Thyrocare

103, Kanakia - B. Zillion building,

lbs marg, kurla (w), Mumbai - 400 070

The Trust. The Truth.



Corporate office : Thyrocare Technologies Limited, ♥ D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400 703

NAME : BALWINDER KAUR MADAN (64Y/F)

: SELF REF. BY

TEST ASKED : BLOOD SUGAR (F) SAMPLE COLLECTED AT :

(4001028782),GENERAL DIAGNOSTIC,G-12,SECTOR 4,BMC COLONY,ANAND NAGAR,OPP.MEGA MALL,OSHIWARA,JOGESHWARI WEST,400102

TEST NAME	TECHNOLOGY	VALUE	UNITS
FASTING BLOOD SUGAR	PHOTOMETRY	295.2	mg/dL
Reference Range :-			

70-99

Please correlate with clinical conditions.

Method:- GOD-PAP METHOD

Sample Collected on (SCT) Sample Received on (SRT) Report Released on (RRT)

Sample Type Labcode Barcode

: 12 Aug 2021 11:15

: 12 Aug 2021 20:09

: 12 Aug 2021 22:33

: FLUORIDE

: 1208089343/PU137 Dr.Prachi Sinkar MD(Path)

: V2905917

Dr.Caesar Sengupta MD(Micro)

Page: 1 of 4



PROCESSED AT : Thyrocare

103, Kanakia - B. Zillion building, lbs marg, kurla (w), Mumbai - 400 070





Corporate office: Thyrocare Technologies Limited, ♥ D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400 703
© 022 - 3090 0000 / 6712 3400 © 9870666333 ■ wellness@thyrocare.com ⊕ www.thyrocare.com

REPORT

NAME : BALWINDER KAUR MADAN (64Y/F)

REF. BY : SELF

TEST ASKED : LIPID PROFILE

SAMPLE COLLECTED AT:

(4001028782),GENERAL DIAGNOSTIC,G-12,SECTOR 4,BMC COLONY,ANAND NAGAR,OPP.MEGA MALL,OSHIWARA,JOGESHWARI WEST,400102

TEST NAME	TECHNOLOGY	VALUE	UNITS	NORMAL RANGE
TOTAL CHOLESTEROL	PHOTOMETRY	269	mg/dl	< 200
HDL CHOLESTEROL - DIRECT	PHOTOMETRY	42	mg/dl	40-60
TRIGLYCERIDES	PHOTOMETRY	542	mg/dl	< 150
LDL CHOLESTEROL - DIRECT	PHOTOMETRY	147	mg/dl	< 100
VLDL CHOLESTEROL	CALCULATED	108.4	mg/dl	5 - 40
TC/ HDL CHOLESTEROL RATIO	CALCULATED	6.5	Ratio	3 - 5
LDL / HDL RATIO	CALCULATED	3.5	Ratio	1.5-3.5
NON-HDL CHOLESTEROL	CALCULATED	227.5	mg/dl	< 160

Please correlate with clinical conditions.

Method

CHOL - Cholesterol Oxidase, Esterase, Peroxidase

HCHO - Direct Enzymatic Colorimetric

TRIG - Enzymatic, End Point

LDL - Direct Measure

VLDL - Derived from serum Triglyceride values

TC/H - Derived from serum Cholesterol and Hdl values

LDL/ - Derived from serum HDL and LDL Values

NHDL - Derived from serum Cholesterol and HDL values

*REFERENCE RANGES AS PER NCEP ATP III GUIDELINES:

TOTAL CHOLESTEROL	(mg/dl)	HDL	(mg/dl)	LDL	(mg/dl)	TRIGLYCERIDES	(mg/dl)
DESIRABLE	<200	LOW	<40	OPTIMAL	<100	NORMAL	<150
BORDERLINE HIGH	200-239	HIGH	>60	NEAR OPTIMAL	100-129	BORDERLINE HIGH	150-199
HIGH	>240			BORDERLINE HIGH	130-159	HIGH	200-499
				HIGH	160-189	VERY HIGH	>500
				VERY HIGH	>190		

Alert !!! 10-12 hours fasting is mandatory for lipid parameters. If not, values might fluctuate.

Sample Collected on (SCT) : 12 Aug 2021 11:15 Sample Received on (SRT) : 12 Aug 2021 19:55

Report Released on (RRT) : 12 Aug 2021 21:47

Sample Type : SERUM

Labcode : 1208088912/PU137

Barcode : V3106364

Chachentar

Dr.Prachi Sinkar MD(Path)

Dr.Caesar Sengupta MD(Micro)

Page: 2 of 4





PROCESSED AT :

Thyrocare

103, Kanakia - B. Zillion building,

lbs marg, kurla (w), Mumbai - 400 070

> Corporate office: Thyrocare Technologies Limited, ♥ D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400 703

The Trust. The Truth.

Thyrocare*

REPORT

: BALWINDER KAUR MADAN (64Y/F) NAME

: SELF REF. BY TEST ASKED : HbA1c SAMPLE COLLECTED AT:

(4001028782),GENERAL DIAGNOSTIC,G-12,SECTOR 4,BMC

COLONY,ANAND NAGAR,OPP.MEGA MALL,OSHIWARA,JOGESHWARI WEST,400102

TEST NAME	TECHNOLOGY	VALUE	UNITS
HbA1c - (HPLC)			
	H.P.L.C	8.9	%

Reference Range:

Reference Range: As per ADA Guidelines

Below 5.7% : Normal 5.7% - 6.4% : Prediabetic >=6.5% : Diabetic

Guidance For Known Diabetics

Below 6.5%: Good Control 6.5% - 7% : Fair Control

7.0% - 8% : Unsatisfactory Control >8% : Poor Control

Method: Fully Automated H.P.L.C. using Biorad Variant II Turbo

AVERAGE BLOOD GLUCOSE (ABG) CALCULATED 209 mg/dl

Reference Range :

90 - 120 mg/dl : Good Control 121 - 150 mg/dl : Fair Control

151 - 180 mg/dl : Unsatisfactory Control

> 180 mg/dl : Poor Control Method: Derived from HBA1c values

Please correlate with clinical conditions.

--- End of report ---

Sample Collected on (SCT)

Sample Received on (SRT) Report Released on (RRT)

Sample Type

Labcode Barcode

:12 Aug 2021 11:15

: 12 Aug 2021 20:04

: 12 Aug 2021 21:14

: V3106365

: 1208089161/PU137 Dr.Prachi Sinkar MD(Path)

Dr.Caesar Sengupta MD(Micro)

Page: 3 of 4



CONDITIONS OF REPORTING


- The reported results are for information and interpretation of the referring doctor only.
- It is presumed that the tests performed on the specimen belong to the patient; named or identified.
- Results of tests may vary from laboratory to laboratory and also in some parameters from time to time for the
- Should the results indicate an unexpected abnormality, the same should be reconfirmed.
- Only such medical professionals who understand reporting units, reference ranges and limitations of technologies should interpret results.
- v This report is not valid for medico-legal purpose.
- Neither Thyrocare, nor its employees/representatives assume any liability, responsibility for any loss or damage that may be incurred by any person as a result of presuming the meaning or contents of the report.
- v Thyrocare Discovery video link :- https://youtu.be/nbdYeRgYyQc
- v For clinical support please contact @8450950851,8450950852,8450950853,8450950854 between 10:00 to 18:00

EXPLANATIONS

- Majority of the specimen processed in the laboratory are collected by Pathologists and Hospitals we call them as "Clients".
- Name The name is as declared by the client and recored by the personnel who collected the specimen.
- Ref.Dr The name of the doctor who has recommended testing as declared by the client.
- Labcode This is the accession number in our laboratory and it helps us in archiving and retrieving the data.
- Barcode This is the specimen identity number and it states that the results are for the specimen bearing the barcode (irrespective of the name).
- SCP Specimen Collection Point This is the location where the blood or specimen was collected as declared by the client.
- SCT Specimen Collection Time The time when specimen was collected as declared by the client.
- SRT Specimen Receiving Time This time when the specimen reached our laboratory.
- RRT Report Releasing Time The time when our pathologist has released the values for Reporting.
- Reference Range Means the range of values in which 95% of the normal population would fall.

SUGGESTIONS

- Values out of reference range requires reconfirmation before starting any medical treatment.
- Retesting is needed if you suspect any quality shortcomings.
- Testing or retesting should be done in accredited laboratories.
- For suggestions, complaints or feedback, write to us at info@thyrocare.com or call us on 022-3090 0000 / 6712 3400
- SMS: < Labcode No. > to 9870666333





BOOK A TEST

Give a Call - 022 4128 2828
WhatsApp TGS to 9870666333
Email to tgs@focustb.com



Before

aematology | Clinical Chemistry | Immunoassays | ELISA | Microbiology | Cancer Markers | Bone Marrow | Histopathology | FNAC



1st Floor, Chandigarh - Kharar N.H.21, Adj. Easyday, Opposite HDFC Bank, New Sunny Enclave, Kharar (Mohali)

Ph.: 9056177788, 0160-5000169

Dr. Bharti Ahuja

MD (Pathology) Previously at CMC and DMC Ludhiana and Silver Oaks

Hospital, Mohali Reg. No. 32109

Reg No : 202101031180020 / OPD Sex / Age : Male / 41Y

Name : Mr. PUNEET GABA Reg Date : 04/01/2021 11:08 AM

Referred Dr : SELF Report Date : 04/01/2021 11:09 AM

Action suggested: > 8.0

BIOCHEMISTRY					
Test Name Result Unit Reference Range					
Blood Sugar (Random)					
Blood Sugar Random	3778	mg/dl	up to-140		
НЬА1С					
HbA1C *NGSP Certified (US FTSR:CAPA POCTORNINGS*PERMINISTRATIVE ST	15	%	Non-diabetic: 5.7 Pre-diabetics: 5.7 - 6.4		
Performed on ABBORT AFINION			Diabetics: > or = 6.5		
			ADA Target: 7.0		

Interpretation:

Glycosylated Haemoglobin is acurate and true index of the "Mean Blood Glucose Level in the body for the previous 2-3 months. HbA1c is an indicator of glycemic control. HbA1c represent average glycemia over the past six to eight weeks. Glycation of hemoglobin occurs the entire 120 dayslife span of the red blood cell, but with in this 120 days.

Recent glycemia has the largest influence on the HbA1c value.

Clinical studies suggest that a patient in stable control will have 50% of their HbA1c formed in the mouth before sampling, 25% in the month before that, and the remaining 25% in months 2-4.

Dr.Bharti Khera Ahuja M.D.(Pathology)







Smart Report

HEALTH ANALYSIS

Personalized Summary & Vital Parameters

Puneet Kumar Gaba Booking ID: 3270912105

Puneet Kumar Gaba,

Congratulations, We have successfully completed your health diagnosis. This is a big step towards staying on top of your health and identify potential to improve!

10 Vital Health Parameters of a Human Body Ecosystem

Below are the health parameters which require routine checkups for primary healthcare. The view also includes $\ensuremath{\textit{personalised information}}$ depending on the tests you have taken.

Comorbidities: Yes





Thyroid Function

Thyroid Stimulating Hormone (TSH)-Ultrasensit: 3.83 µIU/ml



Cholesterol Total

215 mg/dl



Kidney Function Serum Creatinine : 0.97 mg/dl

Everything looks good



Vitamin D

12.54 ng/ml



HbAlc 9.70 %



Vitamin B12 213 pg/ml



Liver Function

Alanine Aminotransfe (ALT/SGPT) : 74.0 U/I



Calcium Total

9.4 mg/dl



Iron studies

Serum Iron : 68.0 ug/dl



Complete Hemogram

Haemoglobin (HB): 13.7 g/dl



After



Smart Report

Puneet Kumar Gaba

Booking ID: 3270912105

HEALTH ANALYSIS

Critical Parameters

We have observed that the below given critical parameters have shown out of range results, which can have negative impact on your health.

Blood Glucose Fasting

This test measures the blood sugar level in the fasting state. It is done as a part of routine health tests, for diabetes screening and to monitor diabetic treatment. This test helps to detect prediabetes, type 1 and type 2 diabetes and gestational diabetes.

Impact on overall health?

This test can assess your risk of diabetes and evaluate the effectiveness of any ongoing diabetes treatment.

How to improve health conditions?

For high or low blood glucose levels, consult a physician for further investigations. Follow a healthy diet, Be active and practice stress management techniques.

Your Result Value

↑304 mg/dl

Concern

Normal Value

70-100 mg/dl



BEFORE

PROCESSED AT :

Thyrocare, Sohrabh Hall, 112, A Wing, 1st Floor, Sangamwadi, Pune - 411 001 Thyrocare The Trust. The Truth.

Corporate Office: Thyrocare Technologies Limited ♥ D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400703 © 022 - 3090 0000 / 4125 2525 🗷 8691866066 🖾 wellingss@thyrocare.com @www.thyrocare.com

NAME

: RAJKUMARI HEMDEV(78Y/F)

REF. BY

: SELF

: AAROGYAM B **TEST ASKED**

SAMPLE COLLECTED AT :

FA 2 YUTOPIA COMPLEX OPPOSITE RAHEJA

GARDEN WANWORI PUNE,

TEST NAME

TECHNOLOGY

VALUE

UNITS

mg/di

HbA1c - (HPLC - NGSP Certified)

H.P.L.C

€ 8.4

Guidance For Known Diabetics

194

0/0

Reference Range:

Reference Range: As per ADA Guidelines

Below 6.5%: Good Control 6.5% - 7% : Fair Control

Below 5.7% : Normal

5.7% - 6.4% : Prediabetic

>=6.5% : Diabetic

7.0% - 8% : Unsatisfactory Control >8% : Poor Control

Method: Fully Automated H.P.L.C. using Biorad Variant II Turbo, NGSP Certified. CALCULATED

AVERAGE BLOOD GLUCOSE (ABG)

Reference Range:

90 - 120 mg/dl : Good Control 121 - 150 mg/dl : Fair Control

151 - 180 mg/dl : Unsatisfactory Control

> 180 mg/dl : Poor Control

Method: Derived from HBA1c values

Please correlate with clinical conditions.

Sample Collected on (SCT)

Sample Received on (SRT)

Report Released on (RRT)

Sample Type

Labcode

Barcode

.06 Oct 2020 07:56

. 06 Oct 2020 17:25

. 06 Oct 2020 18:28

. EDTA

:0610043989/AE847

Dr. Prachi Sinkar MD(Path)

:Q8129684





0

Shri Anandpur Trust Charitable Diagnostic Centre, Pune

Sr. No. 18, Hissa 3/2 + 4 B/2, Off. NIBM Road, Kondhwa Khurd, Pune - 411 048.

• Tel.: 2683 5266, 2683 5666 • Fax: 91 - 020 - 2683 1635

E-mail : satcdc@yahoo.co.in

Department of Pathology

 Patient Name
 : Mrs.. RAJKUMARI HEMDEV
 Registration Time:
 23/08/2021
 3:22PM

 MR No.
 : 569935
 Collection Time
 : 25/08/2021
 8:36AM

 Sex
 : Female
 Age: 78
 Year
 Print Time
 : 25/08/2021
 4:13PM

Ref. Doctor : Dr.K E M HOSPITAL Sample No : 40166

REPORT

	REPORT	
Description	RESULT	Normal Range
	BIO-CHEMISTRY	
Glycosylated Haemoglobin (HbA1c)		
HbA1C	7.7 %	Non diabetic: 4.0 - 6.0 Target of therapy: < 7.0 Change of therapy: > 8.0 %
Creatinine - Serum		
Creatinine, Serum Alkaline Phosphatase - Serum	0.69 mg/dl	0.5 - 1.0 mg/dl
Alkaline Phosphatase - Serum Liver function Test	101.4 IU/L	30 - 140 IU/L
Total Bilirubin, Serum	0.86 mg/dl	0.1 - 1.2 mg/dl
Direct Bilirubin, Serum	0.44 mg/dl	0.0 - 0.3 mg/dl
Indirect Bilirubin, Serum	0.42 mg/dl	0.0 - 0.9 mg/dl
AST (SGOT), Serum	17.7 IU/ml	0 - 35 IU/ml
ALT (SGPT), Serum	25.8 IU/ml	0 - 35 IU/ml
Alkaline Phosphatase - Serum LIPID PROFILE	101.4 IU/L	30 - 140 IU/L
Total Cholesterol, Serum	157.3 mg/dl	140 - 200 mg/dl
Triglycerides, Serum	225.3 mg/dl	0 - 150 mg/dl
HDL Cholesterol, Serum	44.7 mg/dl	35 - 65 mg/dl
LDL Cholesterol, Serum	67.54 mg/dl	60 - 130 mg/dl
VLDL Cholesterol, Serum	45.06 mg/dl	7 - 35 mg/dl
Total Cholesterol/HDL Ratio	3.52	3 - 5
LDL/HDL Ratio SERUM SGPT (ALT)	1.51	0.5 - 3.0
ALT (SGPT), Serum SERUM BILIRUBIN	25.8 IU/ml	0 - 35 IU/ml
Total Bilirubin, Serum	0.86 mg/dl	0.1 - 1.2 mg/dl
Direct Bilirubin, Serum	0.44 mg/dl	0.0 - 0.3 mg/dl
		AT MARKET PROGRAM AND MARKET

Foot Note Test performed on fully automated biochemistry analyzer

*** End Of Report ***





Before

PROCESSED AT :

Thyrocare, Sohrabh Hall, 112, A Wing, 1st Floor, Sangamwadi, Pune - 411 001 Thyrocare

The Trust. The Truth.

Corporate Office : Thyrocare Technologies Limited ♥ D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400703

NAME

: RAJKUMAR HEMDEV(79Y/M)

: SELF REF. BY

: AAROGYAM B

SAMPLE COLLECTED AT :

FA 2 YUTOPIA COMPLEX OPPOSITE RAHEJA

GARDEN WANWORI PUNE ,

TEST NAME

TEST ASKED

VALUE TECHNOLOGY

HbA1c - (HPLC - NGSP Certified)

H.P.L.C

10.2

UNITS

Reference Range:

Reference Range: As per ADA Guidelines

Below 5.7% : Normal 5.7% - 6.4% : Prediabetic

: Diabetic >=6.5%

Guidance For Known Diabetics

Below 6.5%: Good Control 6.5% - 7% : Fair Control

7.0% - 8% : Unsatisfactory Control

: Poor Control

Method: Fully Automated H.P.L.C. using Biorad Variant II Turbo, NGSP Certified

AVERAGE BLOOD GLUCOSE (ABG)

CALCULATED

246

mg/dl

Reference Range:

90 - 120 mg/dl : Good Control 121 - 150 mg/dl : Fair Control

151 - 180 mg/dl : Unsatisfactory Control

: Poor Control > 180 mg/dl

Method: Derived from HBA1c values

Please correlate with clinical conditions.

Sample Collected on (SCT)

.06 Oct 2020 07:56

Sample Received on (SRT)

.06 Oct 2020 17:23 :06 Oct 2020 18:43

Report Released on (RRT)

:EDTA

Sample Type Labcode

:0610043934/AE847

Dr. Prachi Sinkar MD(Path)

Barcode

:R1402709

Page: 7 of 9







K.E.M. HOSPITAL, PUNE - 11.

489, Rasta Peth, Sardar Moodliar Road. TEL.:020-66037300, E-mail : diagnosticsmanager@kemhospital.org



Certificate No.: M0362
NABL Accredited Laboratory

Patient

: Mr. RAJKUMAR LALCHAND HEMDEV

PRN

: 780262 IP

IP No.

Date : 01/06/2021

Age/Sex

: 79 Yrs/Male

Visit No.

: OP-7 Date : 01/06/2021 12:43

. 01/00/202

Referred By Location

: Dr. Smita Dhadge

:0032115221

Sample Collected

: 01/06/2021 12:43

Sponsor :-

: OPD

GLYCOSYLATED HB (HB A1C)

Sample Recvd in Lab Reported On

: 02/06/2021 12:43

Specimen : Blood

Control of Control

Lab No.

Status

: Final

DEPARTMENT OF ENDOCRINOLOGY

Result Bio. Ref. Interval

Investigations

7.900 %

NON DIABETES LESS THAN 5.7 %

PRE DIABETES: 5.7 - 6.4 % DIABETES: 6.5 % OR HIGHER

Method:

HPLC

-----End Of Report-----

Checked By Technician

2.9

DR. SADANAND NAIK
M.Sc.Ph.D.(Med.Biochemistry)
HOD-Clinical Biochemistry

Entered By:thp9686

